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ABSTRACT OF THE DISSERTATION
Abstract
A mechanistic and genomic analysis of molluscum contagiosum virus immune evasion
by
Ian B. Harvey
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry, Bioinformatics, and Structural Biology
Washington University in St. Louis, 2020
Professor David Wang, Chair
Professor Daved Fremont, Mentor
Molluscum contagiosum virus (MCV) is a common human-specific poxvirus with a proclivity for
infecting children and the immune-compromised. A characteristic MCV infection is restricted to
the epidermal layers of the skin and can persist for weeks to years in an otherwise healthy
individual. The high clinical burden of MCV is at odds with our limited knowledge regarding how
it successfully evades the human immune response, which is in part due to the lack of an animal
model or cell line to propagate the virus. Through this dissertation, we have uncovered and
characterized a novel mechanism by which MC80, a protein encoded by MCV, downregulates
host MHC-I surface expression in human and murine cell lines to evade T cell killing.
Additionally, by sequencing clinically-derived MCV lesions, we have been able to assemble
multiple novel MCV genomes and identified that three key regions of the MCV genome, encoding
immune-evasive proteins, appear to be undergoing both homologous recombination and accordion
expansion.
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Preface
How can MCV persist on human skin for so long? This question has been the main driving force
of my dissertation, as this tenacity distinguishes MCV from the acute-nature of other poxviral
infections. When I began my graduate studies, some MCV-encoded proteins had been found to be
involved in immune evasion strategies. Many of these proteins functioned by inhibiting apoptosis
or NFkB signaling within the MCV-infected cells, which would be undoubted important for
effective viral propagation (Shisler, 2015). However, MCV would not only have to concern itself
with targeting intracellular innate pathways to persist on the skin, but would also have to encode
mechanisms to account for resident lymphocyte surveillance as well as adaptive immune
responses.

Toward that goal, MC54 and MC148 had been found to antagonize human IL18 proinflammatory
signaling and CC/CXC-mediated chemotaxis, respectively (Damon, Murphy, & Moss, 1998; Y
Xiang & Moss, 1999). Both of these proteins serve the purpose of de-escalating an inflammatory
signal, as the presence of extracellular IL18 or inflammatory chemokines suggests that an upstream
host pathway was able to trigger. This lead us to the question of how MCV is able to evade random
tissue surveillance by T lymphocytes. For if a CD8 T cell were activated by a viral epitope, this
would likely prove cytotoxic, even in the absence of IL18 or chemokine signaling. We tackle this
question in Chapter 2, describing a novel mechanism by which MCV prevents MHC-I from
displaying peptides on the surface of infected cells.

Of course, the T cell response is not the only external pressure influencing MCV infections. Given
the protective effects of the antibody response against other poxviruses such as smallpox, and the

xviii

fact that MCV could re-infect a previously infected patient, we posited that MCV may encode
means of evading antibody-mediated protective mechanisms and/or select for variation in
antigenic epitopes to subvert previous memory responses. However, at the beginning of my
graduate studies, only a single strain of MCV had been sequenced (T G Senkevich et al., 1996).
So in Chapter 3, I sought to sequence and assemble multiple novel MCV genomes to define the
phylogenetic variations that distinguish strains which may be under increased selective pressure.
This analysis not only highlighted highly polymorphic regions of the genomes, but provided
evidence that MCV may undergo homologous recombination and accordion expansion within
these regions to achieve this high variance.
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Epigraph
Plus une maladie est rare, plus on doit saisir avec empressement l'occasion de
l'étudier et de la décrire quand elle se présente à notre observation.

The rarer a disease, the more eagerly we must grasp the opportunity to study and
describe it when it presents itself for our observation.

M. Jacobovics
Du Molluscum, 1840

1

Chapter 1: Introduction to MCV
1.1 A Brief History: 1629-1919
1.1.1 Identification by James Bontius
The first account of a case resembling MC pathology was reported to have occurred on the
Molucca islands in 1629, and was referred to as the “Amboyna pimple”1 in a Latin publication
which was later translated to English (Bontius, 1769). This disease seemed to occur without
“venereal embrace”, producing numerous hard skin tumors on the arms, legs, and face which could
discharge a viscid substance if ulcerated. This pathology is today characteristic of molluscum
contagiosum infections2. The author also remarked on the
disease’s high prevalence in Amboyna (Southeast Asia), now
known for an unusually high rate of MC disease (Sturt, Muller,
& Francis, 1971). Few publications have been found to expand
upon this disease until the turn of the 19th century.

1.1.2 Classification by Thomas Bateman
There is a general consensus among those studying MCV that
the disease’s name,

molluscum contagiosum (MC), was

originally coined by Thomas Bateman in his 1814 publication,

Figure 5-1: A patient with severe molluscum
contagiosum by Thomas Bateman, 1814

1

Controversially, the “Amboyna pimple” has been referred to as syphilis (Lancereaux, 1868). Indeed, even today
there are cases where syphilitic ulcers resemble MC lesions to the point of mistaken diagnosis (Brown, Koren, Cassler,
& Turiansky, 2019). However Bontius explicitly remarks on the dissimilarity between the “Amboyna pimple” and
lues venerea (syphilis). He states that the former does not seem to occur through venereal embrace nor cause much
pain. He goes on to say that it does not affect the patient’s bones as easily as syphilis. Furthermore, Bontius states that
the described disease is relatively easy to treat if recently identified, but difficult if chronic. Given the lack of germ
theory/modern medicine in 1629, “treatment” is likely through damage-induced regression or self-resolution of
disease. The ease of treatment and arguable lack of a pre-antibiotic cure for syphilis suggest that the disease described
by Bontius is not likely to be syphilis.
2

Likely due to inflammation or infection of the lesion, viscid substance is likely the MCV viral core.

2

“A Practical Synopsis of Cutaneous Diseases” (Bateman, 1814) (Figure 1-1). While no direct
rationale was cited for Bateman’s choice of nomenclature, ‘molluscum’ is thought to derive from
the Latin word for soft, mollusca, as MCV specifically infects soft tissue (Jacobovics, 1840).
However, the name molluscum may also be an homage to the geographic location of its discovery,
the Molucca islands.

Either way, the section of Bateman’s book which addresses molluscum outlines a set of
characteristics which distinguish this disease from other cutaneous diseases, as observed by
himself and other physicians. While emphasizing that the molluscum lesions contain a small
aperture and can vary considerably in shape and size, he remarked that “they show no tendency to
inflammation or ulceration, but continue through life.” Later in the text, he references a particular
patient, indicating that some of their lesions “had recently become inflamed, and were proceeding
to a slow and curdly suppuration.” As suggested by Bateman, the link between inflammation and
regression of molluscum would be reaffirmed by other physicians (Henderson, 1845; Vermi et al.,
2011).

Indeed, many of the aspects of Bateman’s description of molluscum have become known as
hallmarks of the disease today. As germ-theory had become well established by the 19th century,
Bateman described the infection as one “which appears to be communicable by contact.” Of note,
the majority of cases which he describes involved a child either as the origin of disease or patient
(See Section 1.4.1).

3

1.1.3 MCV lesion progression by Wile and Kingery
Without a model animal to study MCV, our understanding of its dermal progression largely stems
from late 19th century and early 20th century studies in which healthy volunteers were infected with
the disease (Wile & Kingery, 1919). These studies histologically defined MC lesions by the
presence of enlarged keratinocytes that formed a cup-like structure in the epidermis and contained
multiple eosinophilic cytoplasmic granules, or “molluscum bodies.”

Prior to the 1919 study, others reported that the incubation period prior to lesion development
could range from five weeks to six months following scarification or rubbing with MC material.
Instead, Wile and Kingery were one of the first to filter MC lesions to demonstrate, in the age of
germ theory, that MC was caused by a filterable virus. They injected the filtrate subcutaneously
into two subjects and reported that MC lesions began to emerge at 14 and 25 days, respectively.
Far faster than what was reported by scarification or rubbing. Additionally, Wile and Kingery were
able to biopsy MC lesions at various timepoints during the course of an infection for histological
comparison. By this, they were also able to conclude that the overall structural morphology of an
MC lesion occurs prior to the development of molluscum bodies within the lesion.

1.2 The search for a model system
Since its early characterization on humans, many studies have been able to demonstrate
cytopathogenic effects of clinical isolates on cell lines or specific-animal models. However, no
model has been identified which can effectively propagate MCV. This is particularly unfortunate,
as there is still no FDA-approved treatment for this disease (See Section 1.5). Whether animal or
cell-based, a model system would provide a means of rapidly understanding the disease and
screening for inhibitors of its pathogenicity. While no model has yet been identified, multiple have
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been attempted. Below is a brief summary of the work that has been published with regards to
modelling MCV infections.

1.2.1 Attempts with animal models
It is difficult to devise exactly how many animal models have been attempted with MCV, as
negative data is rarely publishable. However, studies from the 1930s indicate that MCV does not
propagate in wild-type monkeys, apes, sheep, ferrets, rabbits, fowl, pigeons, chickens, guinea pigs,
and mice (Horsfall & Tamm, 1965; van Rooyen & Rhodes, 1940). Remarkably, given the long
incubation periods demonstrated in earlier human studies, some of this animal work was conducted
over the course of 6 months post infection. However, no lesions were observed in any of these
studies.

In 1995 and 1996, two studies conducted an heroic set of experiments with human foreskins grafted
onto athymic nude mice to attempt to develop a model to study MCV. In 1995, Buller et al
demonstrated that approximately 50% of the athymic nude mice grafted with a human foreskin
(which did not reject the foreskin) developed an MCV-like lesion (Buller, Burnett, Chen, &
Kreider, 1995). These lesions contained MCV DNA and demonstrated morphologically similar
epidermal characteristics to the canonical human infection. However, this study did not attempt to
propagate the virus generated from this model. The following year, Fife et al confirmed that the
athymic mouse xenograft model could be used to infect human skin using patient-derived MCV
samples (Fife et al., 1996). However, this group remarked that the MCV generated by the mouse
model did not appear to propagate to other keratinocytes in the tissue, nor could murine-generated
MCV particles be passaged. Therefore, Fife et al concluded that this model produced noninfectious
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MCV particles. Since the 1996 manuscript, no studies have been published using the athymic
mouse model for MCV infection.

1.2.2 Attempts with cell-lines
Similarly to the athymic mouse model, studies have demonstrated that inoculation of clinical MCV
samples into cultured human cells induces dramatic cytopathic changes. However, these “infected”
cells do not in-turn produce infectious MCV particles. Indeed, over the course of 2 to 6 passages,
the cytopathogenic effects dissipate to undetectable levels (Chang & Weinstein, 1961; Neva,
1962). While the cytopathic effects of MCV infection were found to be likely due to the viral
genome, there was no clear rationale for why MCV cannot produce infectious progeny in vitro (La
Placa, 1966).

Following additional studies demonstrating that MCV is replication-deficient in numerous cell
lines, Bugert et al used RT-PCR to identify a time-course for the transcription of specific MCV
mRNA molecules in tissue culture (J. J. Bugert, Melquiot, & Kehm, 2001). They found that ORFs
characterized as being transcribed early (based on orthopoxvirus orthologs) were detectably
transcribed 1-2 hours post-infection. Additionally, the group found that late transcripts could be
detected around five days post-infection (J. J. Bugert et al., 2001). The induction of late poxvirus
mRNA transcription typically leads to the maturation and egress of other poxviruses. However,
like the aforementioned studies, no infectious MCV was detectable in the supernatant of this
infected fibroblasts model.

To provide a more comprehensive comparison of in vitro abortive replication and primary human
infections, Mendez-Rios et al conducted a set of RNAseq experiments comparing MCV RNA
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transcription in multiple cell lines and primary human infections (Mendez-Rios et al., 2016).
Through this unbiased approach, they found that MCV is skewed to transcribing early mRNA in
vitro, while primary human infections were found to generate early, intermediate, and late ORF
mRNA. In vitro MCV infections were also found to be able to generate intermediate mRNA
transcripts through a reporter plasmid. However, this was confounded by the fact that few
intermediate transcription factor mRNA were detected, which in turn would lead to a lack of late
gene transcription and a lack of viral egress. The authors conclude that abortive replication may
be due to a lack of viral DNA synthesis and/or the activation of an innate immune pathway which
MCV does not properly evade, but the evidence for such a theory is currently lacking.

1.2.3 The MCV-like equine poxvirus
Aside from replication of canonical MCV, multiple studies have reported an equine poxvirus that
phenocopies and is phylogenetically related to MCV (Ehmann et al., 2020; Moens & Kombe,
1988; Rahaley & Mueller, 1983; Van Rensburg, Collett, Ronen, & Gerdes, 1991). Similar to MCV,
this equine molluscum contagiosum-like virus (EMCLV) has a much higher GC content than the
orthopoxvirus clade. Additionally, when comparing the 139 EMCLV ORFs with orthologs in other
poxviruses, MCV is the closest hit in almost all cases. This includes many of the MCV
immunomodulators which have been characterized to date. Given their genetic similarity, EMCLV
may provide a model system to better understand MCV pathogenicity through studies that would
be otherwise unfeasible through human studies. However, EMCLV is missing 24 ORFs encoded
by MCV, including NFkB inhibitors and chemokine receptor antagonists (Ehmann et al., 2020).
These points must be taken into account in the design of any further studies which seek to utilize
EMCLV as a model of MCV infection.
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1.3 MCV Epidemiology
1.3.1 Geographic phyloepidemiology of MCV
Table 1-1: Molluscum contagiosum virus strain distribution of patient populations by geographic location. MCV-1 is the most
prevalent strain in all studies. The number of individuals in each study is indicated by N = # for each column. Nakamura et al
described the MCV-3 strain, stating that previous papers had misidentified this strain as “MCV-2v.” Multiple studies diagnosed
MCV through morphology and histology and included a “multi” (multiple tandem infections of a single lesion) and “neg”
(negative) sections to indicate that these were false positive diagnoses or that there is no longer any MCV DNA in the lesion.
Germany England
N = 14

N = 41

Scotland

England

N = 147

N = 93

Australia Australia

Japan

Japan

Spain

Turkey

NJ, USA

Slovenia

Iran

N = 34

N = 43

N = 114

qPCR

qPCR

N = 75

N = 85

N = 477

N = 191

N = 149

N = 61

RFLP

RFLP

RFLP

RFLP

Hybrid

Hybrid

RFLP

RFLP

RFLP

RFLP

Darai et al,
1986

Porter et
al, 1987

Scholz et
al, 1988

Porter et
al, 1989

MCV-1

92.9%

70.7%

96.6%

76.3%

58.7%

52.9%

91.4%

83.2%

98.6%

100.0%

73.5%

55.8%

71.1%

MCV-2

7.1%

29.3%

2.0%

23.7%

29.3%

37.7%

2.7%

1.6%

0.7%

0.0%

26.5%

34.9%

28.9%

MCV-3

-

-

1.4%

-

2.7%

-

5.0%

4.7%

-

-

-

-

-

MCV-4

-

-

-

-

-

-

0.9%

-

-

-

-

-

-

Multi

-

-

-

-

4.0%

5.9%

-

-

-

-

-

-

-

Neg

-

-

-

-

5.3%

3.5%

-

10.5%

0.7%

-

-

9.3%

-

Thompson Thompson Nakamura Yamashita Agromayor Saral et al,
et al, 1990 et al, 1992 et al, 1995 et al, 1996 et al, 2002
2006

qPCR
Trama et
al, 2007

Hošnjak et Ghobadi et
al, 2013
al, 2018

In 1986, Darai et al were the first to demonstrate that different MCV strains existed through
restriction enzyme digest maps and Southern blotting (Darai, Reisner, Scholz, Schnitzler, & de
Ruiz, 1986). This work led to multiple geographic surveys of MCV strain distributions, each
finding a high prevalence of MCV-1 strains/variants compared to other strains, followed by MCV2 in most cases (Table 1-1)(Agromayor et al., 2002; Hosnjak, Kocjan, Kusar, Seme, & Poljak,
2013; Nakamura, Muraki, Yamada, Hatano, & Nii, 1995; Porter & Archard, 1987; Porter et al.,
1989; Saral, Kalkan, Ozdarendeli, Bulut, & Doymaz, 2006; Scholz et al., 1988; Taghinezhad-S,
Mohseni, Keyvani, & Ghobadi, 2018; Thompson, De Zwart-Steffe, & Biggs, 1990; Thompson, de
Zwart-Steffe, & Donovan, 1992; Trama, Adelson, & Mordechai, 2007; Yamashita, Uemura, &
Kawashima, 1996). Nakamura et al made the case that previous MCV studies had mislabeled
MCV-3 as a MCV-2v, arguing that MCV-3 appeared too phylogenetically distant (by restriction
mapping) from MCV-2 to be a sub-variant (Nakamura et al., 1995). Regardless, MCV-3 infections
have been rarely detected in epidemiological surveys.
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Following the whole genome sequencing of MCV-1p in 1996, methods for typing MCV have
involved polymerase chain reaction (PCR) due to the increased sensitivity. At first, groups used a
hybrid technique involving restriction digestion of a PCR amplified region of the MCV genome
to distinguish type 1 and type 2 infections (Agromayor et al., 2002; Saral et al., 2006). This has
been replaced by quantitative RT-PCR (qPCR) using probes specific for type 1 or type 2 MCV
DNA in recent studies. While these PCR and qPCR methods simplify MCV typing protocols and
allow for amplification of minute samples, these methods constrict the typing to only distinguish
MCV-1 strains from MCV-2 strains. Not only would these methods mischaracterize an MCV-3 or
MCV-4 strain, but they do not provide a means to distinguish between the subvariants (e.g. MCV1p vs MCV-1va).

To alleviate this issue, genomic sequences of all known (sub)variants of MCV would be required.
Even then, qPCR may not be an ideal method for subvariant identification, given how many
variants of MCV may exist. Next-generation sequencing, while expensive, may provide a
promising alternative in the future to enhance the accuracy of phylo-epidemiological surveys, as
this would provide increased sensitivity over RFLP analysis, while also identifying MCV
substrains and whether a lesion has a tandem MCV infection.

1.3.2 Sero-epidemiology of MCV
Multiple studies have been conducted to assess the antigenicity of MC lesions during infection. In
1977, Shirodaria and Matthews demonstrated that 69% of MCV patients’ sera (from a cohort of
67 patients) reacted with viral antigen in MCV lesions (Shirodaria & Matthews, 1977). While the
IgG response dominated this signal, the authors also found IgM-specific and IgA-specific
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responses against virally-infected cells by immunofluorescent staining. This work additionally
highlighted the lack of clearance of MCV following an antibody response, which has since been
reaffirmed by others (Konya & Thompson, 1999).

Shirodaria and Matthews also demonstrated that sera derived from vaccinia, rabbit-pox or
ectromelia infections did not cross-react with MCV lesions, providing early evidence for the
phylogenetic divergence of MCV from the orthopoxvirus genus. However, evidence suggested
that MCV-1 and MCV-2 viral particles, the two most common strains of MCV, cross-react to
human sera from patients infected with the reciprocal variant (Konya, Thompson, & De ZwartSteffe, 1992). To discern which specific viral proteins were responsible for this antigenicity,
Watanabe et al conducted a set of western blot experiments to assess patient sera reactivity to
MCV lesions and recombinant cowpox viruses with MCV DNA inserted. They found that patient
sera predominantly associates with two MCV proteins3, MC084L and MC133L (Watanabe et al.,
1998). This group went on to recombinantly express both proteins (variant unknown), finding that
their MC084 protein did not react with patient sera but MC133 appeared to provide a detectable
ELISA signal. Using this as a diagnostic, they found that 6% of healthy patients (no infection)
contained antibodies against MC133. They also found that 2% of HIV+ patients (see Section 1.4.2)
and 9% of patients with atopic dermatitis (see Section 1.4.3) had anti-MC133 seroresponses
(Watanabe et al., 2000).

The reported 6% sero-prevalence is considerably lower than the general MCV seroprevalence
reported by other studies. A 1999 Australian study, which used whole MCV virions as antigen,

3

It should be noted that these studies were conducted on SDS/BME-treated samples, and therefore would have
primarily identified linear epitopes as opposed to tertiary/quaternary viral epitopes.
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found that 23% of the general population were sero-positive for MCV (Konya & Thompson,
1999). More recently, Sherwani et al used a recombinant peptide derived from MC84 (variant
unknown) to assess a German and U.K. serum cohort, finding that 14.8% of patients’ sera reacted
with the antigen (Sherwani et al., 2014). The discrepancy between these studies raises the question
of whether MCV pathogenesis varies by geography or whether strain-specific antibody responses
are not being adequately captured by a single recombinant antigen.

1.4 MCV Patient Demographics
1.4.1 MCV infections of adolescents
Molluscum contagiosum cases per year
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Figure 1-3: Age distribution of molluscum contagiosum cases [ICD-9-CM code: 078.0] presenting at clinics in the U.S. per year,
as per the National Ambulatory Medical Center Survey (1995-2015)

While it is not yet well understood why children are more likely to contract molluscum
contagiosum, this phenomena has been repeatedly identified in epidemiological studies (Figure 12) (Olsen, Gallacher, Piguet, & Francis, 2018). Considering the diseases documented by the
National Ambulatory Medical Center Survey (NAMCS), the age distribution of MCV is most
similar to other contagious infections such as hypertrophy of tonsils and adenoids [code: 474.10]
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(Pearson 95% CI 0.90 to 0.95; p-value < 0.0001), streptococcal sore throat [code: 034.0] (Pearson
95% CI: 0.86 to 0.94; p-value <0.0001), dermatophytosis of head and scalp [code: 110.0] (Pearson
95% CI: 0.84 to 0.92; p-value <0.0001), and impetigo [code: 684] (Pearson 95% CI: 0.82 to 0.91;
p-value < 0.0001) (Figure S1-1).

Without the ability to control for environmental influence, it is unclear whether the proclivity of
MCV and other pathogens for infecting children has an intrinsic basis, such as a lack of host
memory response, or is more due to extrinsic variables such as higher rates of physical contact
between children than that of adults. Remarkably, two of the four diseases with the most similar
age distributions to MCV are a fungal and a bacterial skin infection. This may suggest a role for
the immune response of the adolescent human skin in providing a niche for certain pathogenic
infections. However, further studies are warranted to determine what immunologic and
environmental factors distinguish the adolescent skin niche from the adult skin niche.

1.4.2 MCV infections of HIV+ patients
The presence of multiple MC lesions on an adult has been used as an indicator for potential HIV
infection for decades (Berger, Obuch, & Goldschmidt, 1990; Leahey, Shane, Listhaus, &
Trachtman, 1997; Staughton, 1990). In this opportunistic setting, MC lesions tend to be
exacerbated in number and size (Basu & Kumar, 2013; Nair, Desai, & Gopinathan, 2016; Yin &
Li, 2017) and often persist until antiretroviral therapy (ART) has re-established
immunocompetence (Hicks, Myers, & Giner, 1997; Horn, Scott, & Benton, 1998).

While maintenance of ART limits susceptibility to MC, initiation of ART has been reported to
cause molluscum contagiosum immune reconstitution inflammatory syndrome (IRIS) in 10% to
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25% of patients (Carvalho, Cruz, Lima, Parolin, & Noronha, 2009; Drain et al., 2013; Sung, Lee,
Choi, Seo, & Yoon, 2012; Yang et al., 2016). While the mechanism underlying IRIS is unclear,
this syndrome generally occurs during the initial decrease in HIV viral burden. During the
subsequent rebound of CD4 T cells, MCV pathology counterintuitively becomes more severe. This
often presents as an increased number and/or size of MC lesions, which clear once CD4 T cell
counts have risen higher.

One theory for the basis of MC-IRIS suggests that the lack of a memory response to MCV antigens,
along with a severe innate immune response that was not effectively responded to in the absence
of CD4 T cells, could be causing a noncanonical immune response that eventually clears the MCV
lesions once proper affinity maturation/generation of memory can occur after CD4 rebound.
Regardless of the mechanism underpinning MC-IRIS, a more complete understanding of MCV
replication and immune evasion strategies will likely provide insight into this complex
phenomenon.

1.4.3 MCV infections and Th2-skewed immune responses
Immunodeficiencies which correlate with MCV infections may provide hints as to the immune
evasive mechanisms employed by the virus, and which aspects of the immune response are critical
to mounting an effective defense. Most profound of which are Th2-skewed immune responses,
including hyper-IgE diseases and atopic dermatitis, which appear to correlate with MCV infection.

The earliest identified report of a link between hyper-IgE/atopic dermatitis and MCV described a
case involving a patient with elevated serum IgE coinciding with decreased cell-mediated
immunity (i.e. cutaneous anergy) (Pauly, Artis, & Jones, 1978). They concluded that this lack of a
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cell-mediated immune response was likely involved in the persistence of the patient’s MCV
infection. Indeed, given the lack of observed clearance of MCV following seroconversion (Konya
& Thompson, 1999; Shirodaria & Matthews, 1977) along with the known role of inflammation in
regression of MCV (Vermi et al., 2011), immune protection against MCV is likely cell-mediated.

Further studies have reinforced the correlation between hyper-IgE syndromes and MCV with
considerable focus on patients with a DOCK8-deficiency (W.-I. Lee et al., 2011; Moin et al., 2006;
Q. Zhang et al., 2009). Along with hyper-IgE levels, the CD4 T cells of DOCK8-deficient patients
are known to have an intrinsic Th2-skew. This would limit the induction of Th1 mediated
responses, which are known to be a necessary component of the anti-poxviral response (Stanford
& McFadden, 2005; Tangye et al., 2017).

Similar to hyper-IgE syndromes, the correlation between atopic dermatitis (AD) and MCV likely
stems from an overactive cutaneous Th2 response which dampens the Th1 cell-mediated antiviral
response (David Boothe, Tarbox, & Tarbox, 2017; Olsen, Piguet, Gallacher, & Francis, 2016; Ren
& Silverberg, 2020). Indeed clinicians have recently found that dampening the Th2 skew of atopic
dermatitis patients with dupilumab (an interleukin-4 receptor alpha antagonist) can result in
tandem clearance of MCV infections (Storan, Woolf, Smith, & Pink, 2019). However, paradoxical
findings indicate that MCV can either trigger AD disease flares (Silverberg, 2018) or locally
suppress AD inflammation (Pauly et al., 1978; Solomon & Telner, 1966), depending on the case
study4. This disparity may be due to genetic differences between patients, functionally divergent

4

Locally suppressed inflammation at the MCV lesional site has also been reported in non-AD patients (Charley &
Sontheimer, 1982; Le Treut et al., 2015). The underlying mechanism likely is related to the local immune-evasive
mechanisms employed by MCV, but remains unclear.
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viral subtypes, or distinct phases of the viral infection. Clearly addition studies are needed to
provide a more complete understanding of the relationship between the human immune system,
MCV and AD.

1.5 Medical interventions to treat MC disease
Many dermatologists opt to forgo treatment of MCV altogether, sometimes referred to as benign
neglect, instead relying on the immune system to eventually recognize the pathogen and clear the
infection. However, due to either the severity of disease or patient/clinician discretion, intervention
may be warranted. While there is currently no FDA-approved treatment for MCV infections,
clinicians have documented many attempts through case studies and small trials with limited
success (van der Wouden et al., 2017).

In this section, I seek to outline some of the major therapeutics which have been successfully used
to treat MC as well as therapies that have exacerbated disease. This section is by no means
exhaustive of the treatments which have been documented in the literature. It instead serves to
highlight how the current strategies to treat MC relate to our understanding of the human immune
response and MCV immune evasion strategies.

1.5.1 Surgical/mechanical disruption
There are six major methods of mechanical disruption of MCV lesions that have been reportedly
effective at clearing disease in the literature. This includes curettage, excision/biopsy, cryotherapy,
laser therapy, electrodesiccation and extrusion. The basic idea in all cases is to overcome the
infection by removing infectious material while also introducing damage-associated molecular
patterns at the site of infection to initiate an immune response.
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Curettage is the most common method of mechanically disrupting MCV lesions. It involves the
use of a sharp instrument applied to the lesion to scrape infectious material off while
simultaneously agitating the surrounding tissue. This method is purported to have the highest rate
of success (approximately 70%) of all current treatment strategies (Harel, Kutz, Hadj-Rabia, &
Mashiah, 2016). However, few studies have been performed in a controlled manner to assess
surgical treatment of MC compared to placebo.

1.5.2 DAMP-inducing topical small-molecules
As in the surgical treatment method, a majority of the small molecule therapeutics that are used to
treat MCV infections function by damaging the lesional skin and surrounding tissue, inducing a
damage-associated molecular pattern response by the immune system. This leads to temporally
increased immune surveillance of the tissue, which provides an increased likelihood of the immune
system recognizing foreign antigens/epitopes and instigating an appropriate response. This
includes, but is not limited to, cantharidin (Cathcart, Coloe, & Morrell, 2009; Silverberg, Sidbury,
& Mancini, 2000), ingenol mebutate (Shin et al., 2020), tricholoroacetic acid (Audisio et al., 2009),
glycolic acid (Dave & Abdelmaksoud, 2018; Song, Kang, Kim, Park, & Kim, 2004), hydrogen
peroxide (Schianchi, Nazzaro, & Veraldi, 2018), and potassium hydroxide (Giner-Soriano et al.,
2019; Qureshi et al., 2016; Teixidó et al., 2018). The tissue damage required to elicit an immune
response that may lead to viral clearance by these chemicals intrinsically mandates nonideal patient
discomfort. Additionally, MCV may be actively subverting these treatment strategies (e.g. MC066
encodes a glutathione peroxidase that provides intrinsic protection against hydrogen peroxide
(Shisler, Senkevich, Berry, & Moss, 1998)). Given the limited pathogenicity of MCV, the
application of a painful therapy is difficult to justify as a standard treatment strategy. Trials of
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DAMP-inducers have reported minimal to moderate levels of success, but given the rate of MC
spontaneous regression, few studies were adequately placebo-controlled (Dosal & Morrell, 2015).

1.5.3 Imiquimod
Imiquimod is generally described as an activator of a proinflammatory type-1 immune response.
Indeed, imiquimod has been found to be an agonist of TLR-7 and TLR-8, inducing NFκB and the
subsequent expression of IFN⍺, TNF⍺, and other cytokines (Gibson et al., 1995; Megyeri et al.,
1995; Weeks & Gibson, 1994). Given the central role of NFκB in many immune responses to
disease, topical imiquimod has become an option in the treatment of many skin diseases, both
FDA-approved and off-label.

However, the off-label use of imiquimod has not always been successful (Hanna, Abadi, & Abbas,
2016). Contrary to the pervasive use of imiquimod to treat MC lesions, there is mounting evidence
that imiquimod has little to no positive effect above placebo (Katz, Williams, & van der Wouden,
2018). This is likely due to the fact that MCV encodes at least 4 distinct ORFs that antagonize the
NFκB signaling pathway, which is central to the imiquimod mechanism of action (Biswas &
Shisler, 2017; Brady, Haas, Farrell, Pichlmair, & Bowie, 2017; Nichols & Shisler, 2009). This
suggests that, without local NFκB signaling, the proinflammatory effects of imiquimod would be
severely dampened by an MCV infection. As more research is conducted to understand the
pathways targeted by this well-adapted virus, we may be able to derive more elegant strategies to
overcome the persistent immune evasion of MCV.
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1.5.4 Interferon biologics
In recent years, the explosion in immune-targeting biologics has been advantageous for certain
diseases. For particularly aggressive, widespread MCV infections, a clinician may find the use of
such powerful immunomodulators to be warranted, especially when other viable options have been
exhausted. This has been particularly true for the use of interferon-alpha2b, which has been used
to treat disseminated MC in a patient with HIV, hyper-IgE syndrome (See Section 1.4.3),
folliculotropic mycosis fungoides, or unknown combined immunodeficiencies (Böhm, Luger, &
Bonsmann, 2008; Hourihane et al., 1999; Kilic & Kilicbay, 2006; Melchers et al., 2019). Limited
success has also been reported with interferon beta or interferon gamma treatment of a patient with
AIDS or severe atopic dermatitis, respectively (Gross, Roussaki, & Brzoska, 1998; Hein, Anegg,
& Volc-Platzer, 2005).

1.5.5 Cidofovir
Cidofovir is an antiviral nucleoside analog that is FDA-approved for the treatment of
cytomegalovirus (CMV) infections of HIV+ patients. However, its antiviral properties have been
reported to extend to other dsDNA viruses such as vaccinia virus and MCV by inhibition of the
viral DNA polymerase (Magee, Hostetler, & Evans, 2005; Watanabe & Tamaki, 2008). This has
led to its utilization in multiple case reports for the treatment of severe MCV infections (Davies,
Thrasher, Lacey, & Harper, 1999; Guérin et al., 2012; Toro, Wood, Patel, & Turner, 2000).
However, clearance of MCV disease in the presence of cidofovir therapy can take many months.
When considering the viral life cycle of MCV, by the stage at which a lesion has manifest,
infectious virions have likely already been produced en masse. As MC lesions are not known to
grow indefinitely, it is unclear whether DNA replication is necessary for viral persistence/spread
after lesion development.
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1.6 Medical interventions can exacerbate MC disease
Medical intervention does not always lead to a decrease in disease burden. As in the case of HIV
infections, MCV has been repeatedly found to opportunistically proliferate in patients undergoing
an immunomodulatory treatment, often for an unrelated illness.

1.6.1 Immunosuppression for solid organ transplantation
Organ transplant, and more specifically the accompanying immunosuppressive therapies, have
long been known to elicit higher rates/exacerbation of infections. Remarkably, many of the
diseases which organ-transplant recipient children are at increased risk of are diseases that are
already child-specific (Euvrard, Kanitakis, Cochat, Cambazard, & Claudy, 2001). This includes
MC, but also impetigo and dermatophytosis (See Appendix 1.1.2). It is therefore likely that these
patients are at equivalent risk of exposure to a given pathogen, but their diminished immune
response leads to exacerbated symptoms. There have been successful cases of treating systemically
immunosuppressed organ transplant recipients with local immune-modulators or virus inhibitors
to clear MC lesions (L. S. Gardner & Ormond, 2006). However, as stated above, the efficacy of
these therapeutic immune-modulators is now coming into question and the clearance of these
anecdotal cases may have been instead due to spontaneous regression of MC lesions.

1.6.2 Tacrolimus/Pimecrolimus treatment of atopic dermatitis
Tacrolimus has been used, not only in organ transplantation, but also as a non-steroid option to
reduce inflammation in atopic dermatitis patients. Tacrolimus/Pimecrolimus each modulate the
immune response by inhibiting calcineurin phosphatase which in turn suppresses multiple
immune-related pathways such as IL-2/TNF⍺/IFNɣ production and Th1 polarization (Gupta &
Chow, 2003; Sehgal, Srivastava, & Dogra, 2008). Combining this with the preexisting Th2-skew
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of AD hyperpolarizes the patient’s immune response away from a Th1 antiviral response (See
Section 1.4.3). This has repeatedly led to increased MC disease in AD patients treated with
tacrolimus or pimecrolimus (Fery-Blanco, Pelletier, Humbert, & Aubin, 2007; Goksugur,
Ozbostanci, & Goksugur, 2007; Lerbæk & Agner, 2004; Wetzel & Wollenberg, 2004; Wilson &
Reid, 2004). Due to the lack of high morbidity in MC disease, these infections may be viewed as
an worthwhile side-effect of treatment, and often clear at the conclusion of treatment.

1.6.3 Chemotherapy
While therapeutics for solid organ transplantation and atopic dermatitis are fully intentioned to
downregulate immune responses, this is also an unfortunate side-effect of chemotherapeutics due
to the proliferative nature of hematopoietic lineage cells (R. V. Gardner, 1999). Given the central
role of the immune response in the mechanism of action of most MC therapeutic options,
chemotherapy introduces a particularly difficult challenge for identifying effective interventions.
Particularly in the case of chemotherapy to treat acute lymphoid leukemia, MC has been found to
be resistant to surgical excision, DAMP-inducing strategies, and imiquimod (Ajithkumar et al.,
2017; Özyürek et al., 2011). However, antivirals which do not rely on the host immune response
have had varying levels of success, but require at least multiple months to achieve clearance
(Guérin et al., 2012; Özyürek et al., 2011).

Clearly, the majority of current medical interventions to alleviate MC disease rely on the host
immune response, as these modalities have minimal-to-no efficacy in immune-compromised
patients. Novel strategies to treat this disease will likely need to either target the virus itself or
activate host immune pathways which the virus does not intrinsically inhibit.
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1.7 MCV immune evasion mechanisms
MCV clearly elicits a strong immune-evasive profile that allows it to remain largely undetected by
the immune system for months. Clinical observations have been instrumental in defining what
immune responses MCV is evading (Vermi et al., 2011). But without a model system of infection,
to identify the molecular basis of each of these immune-evasive strategies employed by MCV,
researchers have been limited to studying isolated recombinant MCV proteins biochemically
and/or through tissue culture. While MCV additionally encodes ORFs with orthologs of known
function in other poxviruses, this section is limited to MCV ORFs which have explicitly been
studied.
Table 1-2: Functional characterization of MCV ORFs conducted independently of this thesis work.

ORF
MC005
MC007

Function
Inhibit NFκB

MC054

Inhibit pRb
(tumorigenesis)
IL18 antagonist

MC066

Inhibit apoptosis

MC080

Binds β2m

MC132

Inhibit NFκB

MC148

MC160

Chemokine receptor
antagonist
Inhibit
NFκB/apoptosis/IRF3
Inhibit NFκB

MC163

Inhibit TNFR apoptosis

MC159

Primary Source
Brady G, et al. Molluscum Contagiosum Virus Protein MC005 Inhibits NF-κB Activation by
Targeting NEMO-Regulated IκB Kinase Activation. Journal of Virology. 2017 August
Mohr S, et al. Targeting the Retinoblastoma Protein by MC007L, Gene Product of the
Molluscum Contagiosum Virus: Detection of a Novel Virus-Cell Interaction by a Member of the
Poxviruses. Journal of Virology. 2008 November
Xiang Y, Moss B. Correspondence of the Functional Epitopes of Poxvirus and Human
Interleukin-18-Binding Proteins. Journal of Virology. 2001 October
Shisler JL, Senkevich TG, Berry MJ, Moss B. Ultraviolet-induced Cell Death Blocked by a
Selenoprotein from a Human Dermatotropic Poxvirus. Science. 1998 January
Senkevich T, Moss B. Domain Structure, Intracellular Trafficking, and β2-Microglobulin
Binding of a Major Histocompatibility Complex Class I Homolog Encoded by Molluscum
Contagiosum Virus. Virology. 1998 August
Brady G, Haas DA, Farrell PJ, Pichlmair A, Bowie AG. Poxvirus Protein MC132 from
Molluscum Contagiosum Virus Inhibits NF-κB Activation by Targeting p65 for Degradation.
Journal of Virology. 2015 August
Damon I, Murphy PM, Moss B. Broad spectrum chemokine antagonistic activity of a human
poxvirus chemokine homolog. Proceedings of the National Academy of Science. 1998 May
Biswas S, Shisler JL. Molluscum Contagiosum Virus MC159 Abrogates cIAP1-NEMO
Interactions and Inhibits NEMO Polyubiquitination. Journal of Virology. 2017 August
Nichols DB, Shisler JL. Poxvirus MC160 Protein Utilizes Multiple Mechanisms To Inhibit NFκB Activation Mediated via Components of the Tumor Necrosis Factor Receptor 1 Signal
Transduction Pathway. Journal of Virology. 2009 April
Coutua J, Ryerson MR, Bugert J, Nichols DB. The Molluscum Contagiosum Virus protein
MC163 localizes to the mitochondria and dampens mitochondrial mediated apoptotic responses.
Virology. 2017 May
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1.7.1 MC005 inhibits NF-κB through association with NEMO to prevent IKK
complex activation
MC005 has recently been found to associate with NEMO in order to prevent signal propagation
through the IKK complex, which canonically leads to subsequent IκB degradation/p65
phosphorylation (Brady et al., 2017). As a demonstrable bottleneck of NF-κB signaling, the IKK
complex is a prime target for inhibition of NF-κB. MC005 appears to be enforcing an inhibitory
conformation of the IKK complex, even in otherwise constitutively active IKK complexes, to
prevent activation. Further work is likely warranted to determine the structural basis of this
inhibition.

1.7.2 MC007 antagonizes pRb through mitrochondrial-retention
The retinoblastoma protein pRb plays a central role in controlling cell proliferation through
association with E2F transcription factors to prevent transcription of genes related to cell cycle
progression/apoptosis. MC007 has been found to antagonize pRb function by sequestering pRb at
the mitochondrial membrane to constitutively active E2F transcription factors (Mohr et al., 2008).
Therefore, MC007 likely plays a role in the tumorigenic potential of MCV.

1.7.3 MC054 antagonizes IL-18 through direct association
Interleukin 18, also known as interferon-gamma inducing factor, has long been known as a potent
pro-inflammatory cytokine (Dinarello, Novick, Kim, & Kaplanski, 2013). In order to rapidly
overcome these proinflammatory signaling following clearance of disease, host species have
evolved a high affinity antagonist of IL-18, termed IL-18 binding protein (IL-18bp).
Unfortunately, poxviruses have since sequestered this protein from the host species, secreting them
to continually block IL-18/IFN signaling within the site of infection (Born et al., 2000; Esteban,
Nuara, & Buller, 2004; V. P. Smith, Bryant, & Alcamí, 2000; Y Xiang & Moss, 1999). These
poxviral IL-18bp appear to uniformly maintain a high affinity interaction to the host IL-18
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molecule. Additionally, crystal structures have been solved of the ectromelia virus and yaba-like
disease virus variants bound to IL-18 (Krumm, Meng, Li, Xiang, & Deng, 2008; Krumm, Meng,
Wang, Xiang, & Deng, 2012). Remarkably, the MCV genome contains three distinct ORFs with
sequence-similarity to the human IL-18bp, but only MC54 was found to associate with IL-18. The
functional relevance of MC51 and MC53 remain unknown.

1.7.4 MC066 protects cells from UV/peroxidase damage
Upon sequencing the MCV genome, MC066 was found to be sequence-similar to a known human
glutathione peroxidase selenoprotein (T G Senkevich et al., 1996). Following recombination of a
vaccinia virus with the MC066 ORF, follow-up experiments demonstrated that this ORF did
indeed encode the first identified viral selenoprotein (Shisler et al., 1998). This protein was also
found to protect infected cells from UV damage and peroxide damage, which presumably would
be important to persist in the skin niche without succumbing to sun-exposure or innate immune
responses, respectively.

1.7.5 MC080 binds β2m and is retained in the ER
Prior to this thesis work, the MC080 ORF had been partially characterized. The early interest in
MC080 stemmed from its sequence-similarity to the human MHC-I molecule (T G Senkevich et
al., 1996; Tatiana G. Senkevich, Koonin, Bugert, Darai, & Moss, 1997). To further assess the
function of MC80, the researchers recombined the MC080 ORF into a vaccinia virus. The previous
study was able to verify that MC80 associated with β2m, like classical MHC-I. Given the NKinhibitory effects previously observed with other viral MHC-I orthologs, the authors found it
difficult to reconcile the fact that MC80 appeared to localize in the endoplasmic reticulum (Tatiana
G Senkevich & Moss, 1998). Unfortunately, this preliminary study was unable to identify an
immunological role for MC80 (See Chapter 2).
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1.7.6 MC132 inhibits NFκB by mediating the degradation of p65
MC132 was identified through a screen of MCV ORFs for TNF⍺-based activation of NFκB
(Brady, Haas, Farrell, Pichlmair, & Bowie, 2015). Follow-up experiments were able to
determine that MC132 associates with and leads to the degradation of p65. MC132 appears
to coopt the Cullin-5/Elongin B/Elongin C complex to target p65 for ubiquitination and
degradation. This in turn prevents the IKK complex from phosphorylating p65, inhibiting
NFκB activation (Brady et al., 2015).

1.7.7 MC148 antagonizes chemokine receptors
MC148 shares sequence-similarity with host CC chemokines and has been shown to limit
chemotaxis of immune cell subsets. However, the precise chemokine receptors antagonized by
MC148 remains somewhat controversial. The earliest work found that MC148 antagonized
multiple CC and CXC chemokine receptors, interfering with the chemotaxis of monocytes,
lymphocytes, and neutrophils (Damon et al., 1998). However, follow-up work by another group
found that MC148 selectively antagonized human CCR8 (H. R. Lüttichau, Gerstoft, & Schwartz,
2001; Hans R. Lüttichau et al., 2000). CCR8 is involved in the chemotaxis of multiple
haematopoetic cell types, one of the most striking being the importance in tissue-resident memory
T cell skin responses (McCully et al., 2018). More recent work has since defined a role for MC148
in interfering with the CXCL12⍺:CXCR4 interaction (Jin, Altenburg, Hossain, & Alkhatib,
2011). But regardless of the breadth of targets, MC148 is likely evolutionarily conserved by
MCV to prevent recruitment of immune cells into the infection site.
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1.7.8 MC159 prevents NFκB through competitive inhibition of the
NEMO:cIAP1 interaction
The IκB kinase (IKK) complex is necessary for the phosphorylation of NFκB prior to nuclear
trafficking and signaling. This complex is mainly comprised of IKK⍺, IKKβ, and IKKɣ (NEMO).
MC159 has been found to associate specifically with the IKKɣ subunit, blocking the cellular
inhibitor of apoptosis protein 1 (cIAP1), an E3 ubiquitin ligase, from polyubiquitinating IKKɣ
(Biswas & Shisler, 2017; Randall, Jokela, & Shisler, 2012). The lack of an IKKɣ polyubiquitin
modification likewise inhibits NFκB activation.

1.7.9 MC160 inhibits NFκB activation through association with Hsp90 and
procaspase-8
IKK⍺ requires Hsp90 for stabilization and function as a component of the IKK complex (G. Chen,
Cao, & Goeddel, 2002). However, previous work has demonstrated that the C-terminal domain of
MC160 is sufficient to block the Hsp90:IKK interaction, which in turn inhibits NFκB signaling
(Nichols & Shisler, 2009). Additionally, this study suggests that the N-terminal domain of MC160
associates with procaspase-8, which may further decrease the level of NFκB activation.

1.7.10 MC163 inhibits apoptosis by preventing mitochondrial membrane
permeabilization
While the molecular basis remains unclear, MC163 was recently found to prevent TNF⍺/CHXmediated and carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-mediated apoptosis by
stabilizing the mitochondrial membrane (Coutu, Ryerson, Bugert, & Brian Nichols, 2017).
Without permeabilization of the mitochondrial membrane, downstream caspases remain
inactivated, which weakens the apoptotic cascade. Further studies are warranted to determine
whether the membrane stabilization is mediated by specific interaction, whether MC163 modifies
the general physical properties of the mitochondrial membrane, or uses an unforeseen strategy.
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Chapter 2: A mechanism of MC80-mediated
downregulation of MHC-I
This work was published in-part in PLoS Pathogens (Harvey, Wang, & Fremont, 2019).

2.1 Introduction to MHC-I peptide-loading and viral
mechanisms of pathway antagonism
Good stuff

Bad stuff
Acquire Information

Present Information

Observe and act
according to
information

Figure 6-1: Security cameras arbitrarily detect light and transmit the information to be presented to a security guard. The
security guard subsequently determines whether something is wrong.

The conceptual basis of MHC class I (MHC-I) function can be effectively described as a cellular
security camera system. Security cameras do not, in and of themselves, know whether the scene
they are detecting is depicting normal activity or whether something is wrong (Figure 2-1). The
camera merely transmits light through wires to a central computer. That computer then presents
the information to a secondary individual, often a security guard, whose job it is to determine
whether something is awry and act accordingly.
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Figure 2-2: The cellular processes of canonical peptide trafficking into the ER, peptide loading onto MHC-I, MHC-I
maturation, and T cell surveillance as compared to a security camera system. If a TCR recognizes a presented peptide:MHC-I
complex, the T cell initiates a signalling cascade that often results in killing the “infected” cell.

In the canonical MHC class I (MHC-I) peptide loading pathway, the “light” is replaced with short
peptides derived from cytosolic proteins degraded by the proteasome. Like a security camera’s
ability to arbitrarily transmit light, MHC-I molecules have a remarkable ability to associate with a
large range of peptide sequences (whether derived from host proteins or pathogens). However, no
one MHC-I variant can associate with all peptides equally. Therefore, many MHC-I alleles have
evolved and differentiated over time, providing every individual with a somewhat distinct set of
peptides that they can present on their cell surfaces5.

5

This would metaphorically equivocate to having multiple cameras that each detect somewhat different wavelengths
of light (e.g. night vision), to provide a more complete overview of the environment.
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Nascent MHC-I molecules are translated into the endoplasmic reticulum (ER), where they first
associate with chaperones (e.g. calnexin) and are stabilized through heterodimerization with the
protein β2-microglobulin (β2m) (Nößner & Parham, 1995). However, high affinity peptide
association is necessary for full stabilization of an MHC-I molecule (Wearsch et al., 2004).

In order for cytosolic peptides to bind MHC-I, the peptides must traffic from the cytosol to the ER.
This is accomplished by the transporter associated with antigen processing (TAP), a heterodimer
comprised of the two transmembrane proteins TAP1 and TAP2 (Carreno et al., 1995; Ortmann,
Androlewicz, & Cresswell, 1994). Following entry into the ER, peptides immediately encounter
nascent MHC-I molecules associated with the protein tapasin (Figure 2-2), which bridges the
MHC-I:TAP interaction and stabilizes nascent MHC-I in a peptide-receptive conformation
(Fleischmann et al., 2015; Ortmann et al., 1997). Along with the accessory proteins ERp57 and
calreticulin, MHC-I, tapasin, and TAP make up the core of the peptide-loading complex (PLC),
which is the metaphorical security camera itself .

Following stabilization of the MHC-I molecule by a high affinity peptide, the MHC-I/β2m/peptide
trimer dissociates from the PLC and is able to traffic from the ER through the Golgi apparatus to
the cell surface6. At the cell surface, each peptide associated with an MHC-I molecule is presented
to provide an indication of the protein-repertoire that is being expressed within the cell. Like a
computer monitor, these MHC-I complexes do not provide any indication, in and of themselves,
whether something is wrong in the cell or not.

6

Conversely, any MHC-I molecules that are not associated with the PLC or peptide would be bound by chaperones
such as calreticulin in the Golgi and trafficked back into the ER.
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To determine whether the peptide loaded on an MHC-I molecule is derived from a pathogen/
pathogenic cell (i.e. cancer), the host immune system employed T cells. These cells express a
membrane-bound cellular receptor called the T cell receptor (TCR) which can recognize the
peptide:MHC-I complex on somatic cells and antigen-presenting cells (APCs). However, through
somatic recombination and positive/negative selection in the thymus, the host immune system is
comprised of a repertoire of T cells; each expressing a distinct TCR which preferentially associates
with a distinct subset of non-self peptide:MHC-I complexes (Murphy & Weaver, 2017). These T
cells act as the metaphorical security guard who checks the security camera (peptide:MHC-I).

However, just as technologically-savvy criminals can devise methods of bypassing security
cameras, multiple pathogens have evolved mechanisms to evade the peptide:MHC-I axis (Hansen
& Bouvier, 2009). These viral immune-evasion mechanisms can be generally characterized by two
sets of characteristics: (1) whether they target MHC-I directly or target a component(s) of the
peptide loading complex; and (2) whether they actively block peptide-loading/MHC-I maturation
or lead to the degradation of MHC-I/a component of the peptide-loading complex. For example,
some viruses employ proteins which directly association and retain classical MHC-I molecules in
the endoplasmic reticulum (ER), Golgi apparatus, or lysosomal compartments (McCoy IV, Wang,
Yokoyama, Hansen, & Fremont, 2013; Ramnarayan et al., 2018). Remarkably, multiple of these
viral proteins (m145, m152, and m155) are sequence-similar to the classical MHC-I fold. Other
viral mechanisms target MHC-I, but in concert with degradation machinery (often ubiquitination)
to lead to its degradation (Boname, de Lima, Lehner, & Stevenson, 2004; Herr, Wang, Loh, Virgin,
& Hansen, 2012; Hewitt et al., 2002). Still other viral mechanisms associate with TAP or tapasin
in specific conformations to block peptide trafficking or loading, respectively.
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Figure 2-7: A tech-savvy criminal turning off the security cameras would be synonymous to a virus preventing MHC-I from
presenting peptides on the cell surface. The lack of peptide:MHC-I on the cell surface prevents T cell-mediated recognition of a
pathogenic state, but simultaneously leads to NK-mediated activation and killing of infected cells.

Indeed, the diversification and independence of viral immune evasion strategies is an attempt to
prevent the host from evolving a generalized means of inhibiting MHC-I downregulation. But,
similar to a security guard noticing a malfunctioning security camera, the lack of a peptide:MHCI complexes signal on the cell surface is itself a signal. This signal is recognized by the host
immune system through a distinct immune cell, the natural killer (NK) cell (Figure 2-3). NK cells
accomplish this by expressing activating and inhibitory NK receptors on the cell surface which
associate with various proteins on other cells. The likelihood of NK cell cytotoxic activation is
based on the overall balance of local activating and inhibitory signals. Classical and non-classical7
MHC-I molecules are a potent inhibitory signal for NK cells. Therefore, the loss of peptide:MHC-

7

Non-classical MHC-I molecules share the MHC-I fold, but do not present a repertoire of cytosolic peptides to T
cells.
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I from the surface of an infected cell would be recognized as a loss of inhibitory signals by the NK
cell, leading to activation and cytotoxic clearance of the infection (Ljunggren & Kärre, 1990).
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Figure 2-8: Viruses have developed mechanisms to overcome NK killing. One mechanism involves the expression of a viral
protein which mimics the MHC-I fold to associate with inhibitory NK receptors.

However, multiple viruses have overcome this host adaptation through expression of viral proteins
that associate with NK receptors to either enhance inhibitory signals or block activating signals.
Metaphorically, this is equivalent to replacing a security camera feed with a fake replica of the
scene so that the security guard does not notice anything amiss. One strategy employed by multiple
cytomegaloviruses is to express a protein that structurally mimics MHC-I without concomitantly
presenting cytosolic peptides (HCMV UL18, MCMV m157) (Margulies et al., 2011). Therefore,
TCRs would not recognize non-self peptides and NK cells would be provided with a replacement
MHC-I inhibitory signal (Figure 2-4). Additionally, a secreted viral MHC-I-like protein, CPXV
OMCP, acts as a competitive antagonist of the activating NK receptor NKG2D, hindering NK-
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mediated activation (Campbell, Trossman, Yokoyama, & Carayannopoulos, 2007; Lazear,
Peterson, Nelson, & Fremont, 2013).

2.2 Prior work on MCV MC80
The characterization of the first complete MCV genome included the identification of an MHC-Ilike protein, MC80, encoded by the virus (T G Senkevich et al., 1996). Given the central role of
classical MHC-I in multiple immune cell responses, this initial work suggested that this ORF may
have a role in either MHC-I downregulation or NK inhibition. Therefore, Moss group followed up
their sequencing work by attempting to characterize the functional role of MC80 (Tatiana G
Senkevich & Moss, 1998).

In the absence of a model system to study wild-type MCV infections, the group utilized
recombinant vaccinia viruses to express the ORF in cells. While the work was able to show that
MC80 associates with β2m similar to classical MHC-I, the protein did not appear to traffic out of
the ER in cultured cells. Additionally, the group claimed that MHC-I levels were not
downregulated following infection of cells with an MC80-expressing vaccinia virus, but did not
present the data justifying this claim in the final manuscript (Tatiana G Senkevich & Moss, 1998).
Therefore, the physiological role of MC80 during viral infections was not identified through this
study and would remain unknown for nearly 2 decades.
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2.3 MC80 downregulates peptide-binding MHC-I molecules
2.3.1 MC80 downregulates classical MHC-I surface expression

Figure 2-9: MC80 downregulates MHC-I surface expression. (A) The four MCV-specific ORFs which are predicted to encode
a type-1 transmembrane protein were cloned into the pMXsIG vector and transiently transfected into HEK 293T cells 2-4 days
prior to analysis of MHC-I (W6/32) surface expression by flow cytometry (three independent experiments of two replicates each).
(B) The top panel is a schematic of MC80 constructs used in A and B, where diagonal lines indicate the signal peptide derived
from mouse β2m, followed by dotted regions indicating N-terminal Flag peptide, and finally the MC80 ORF 18-395 (F-MC80S)
or 72-395 (F-MC80L), as described in the Materials and Methods. HEK 293T cells were transiently transfected with a vector
control or Flag-tagged MC80 constructs. Cells were stained for MHC-I surface expression (middle panel) and intracellular Flag
expression (bottom panel) 12 hours post-transfection (hpt), 24hpt, 72hpt, and 144hpt. Error bars represent the standard deviation
from three independent replicates. Statistical analyses were performed on the effect of each MC80 construct individually, with
equivalent significance found for both.

While MCV does not encode an ORF with sequence-similarity to any viral protein known to
downregulate MHC-I, previous studies have suggested that MCV may be downregulating MHC-I
and β2m in human lesions (Vermi et al., 2011; Viac & Chardonnet, 1990). Given that some
poxviruses do not appear to subvert MHC-I antigen presentation (Chisholm & Reyburn, 2006;
Esposito & Fenner, 2001), we hypothesized that the MCV ORF(s) responsible for MHC-I
downregulation may be unique to MCV. Additionally, as MHC-I traffics through the ER/Golgi to
the plasma membrane, we limited our initial screen to the four MCV-specific ORFs which are
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predicted to encode type-1 transmembrane proteins (MC003, MC033, MC080, and MC157). We
cloned the respective MCV-1 variants into an IRES-GFP retroviral vector (pMXsIG), replacing
each predicted signal peptide with the mouse β2m signal peptide and an N-terminal Flag tag.
Following transient transfection of human embryonic kidney (HEK-293T) cells with these
constructs or vector control, we found that MC80 dramatically decreased the level of cell surface
MHC-I by 2-4 days post-transfection (Figure 2-5A).

Figure 2-10: MC80 encodes an ER-retained MHC-I-like protein. (A) A structure-informed sequence alignment of MC80
variants and HLA-A2 was performed using ESPRESSO, followed by minor manual adjustments. The start residue of the MC80LF and MC80S-F constructs used in this work are labelled, as indicated by triangles. Constructs for F-MC80L and F-MC80S start
with a β2m signal peptide and N-terminal Flag tag, and the start MC80 residues of these constructs are also labeled. Finally, the
terminal residue of the soluble form of MC80 is also labeled. Regions of HLA-A2 with known functional roles are highlighted as:
β2m-binding residues in blue, PLC-binding residues in yellow, peptide-backbone-associated residues in red, and multi-componentassociated residues are shown in respective secondary colors. Solid colors indicate identical residues to the HLA-A2 sequence, and
light colors indicate divergence. The HLA-A2 secondary structure is shown in gray above the sequences (⍺-helix: cylinder, β-sheet:
arrow, transmembrane: box with lines). Conserved disulfide bonds are indicated with dashed lines. (B) Surface and intracellular
2D flow cytometry of HEK 293T cells transduced with vector control or N-terminally Flag-tagged MC80 constructs. While the
bicistronically-expressed GFP serves as an indicator for retrovirally transduced cells, anti-Flag antibody specifically detects the
surface or intracellular expression of MC80 protein. A representative plot of at least two independent replicates is shown. (C) HEK
293T and MEF-Ld cells expressing vector control or F-MC80S were immunoprecipitated with anti-FLAG antibody followed by
an EndoH-sensitivity assay. Blots are representative of at least two independent experiments each.

MC80 is well conserved among known MCV strains, sharing 24-36% amino acid identity to the
ectodomains of human classical and non-classical MHC-I (Figure 2-6,2-7). Interestingly, MC80
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shares more sequence similarity to the human nonclassical MHC-I molecules than to the human
classical MHC-I molecules and even less similarity to most poxviral MHC-I-like proteins. One
exception being the squirrelpox virus ORF64 (Figure 2-7).

MC80 has at least two potential start codons N-terminal to the MHC-I-like ⍺1 domain, termed
MC80L and MC80S, which both provide unusually long signal peptides (Figure 2-6A). While the
ectodomains of MC80 share moderate sequence-similarity with MHC-I, functionally distinct
regions exhibit varying levels of conservation (Figure 2-6A). Residues involved in peptide binding
and PLC interactions are not well conserved between MC80 and classical MHC-I (Figure 26A)(Fremont, Matsumura, Stura, Peterson, & Wilson, 1992; Jiang et al., 2017; Y. Y. L. Yu et al.,
1999). In contrast, residues known to be involved in β2m binding are well-conserved, consistent
with a previous study which found that MC80 associates with β2m (Tatiana

G

Senkevich

&

Moss, 1998; Tysoe-Calnon, Grundy, & Perkins, 1991). This same study found that MC80 did not
traffic to the cell surface, which we were able to recapitulate by flow cytometry and EndoH
sensitivity assays, indicating that MC80 is retained in the ER (Figure 2-6B, C).
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Figure 2-7: The MC80 ectodomain is sequence divergent from most other poxviral MHC-I-like proteins. The ectodomain of
MC80 type 1 and type 2 were aligned to human and viral MHC-I-like proteins using EXPRESSO structure-based protein alignment
(Armougom et al., 2006). Termini of the alignment were truncated to only include the residues which aligned to the ⍺1-⍺3 domains
of MC80_Type1 (H55-T323). The ectodomains were then phylogenetically assessed through 700,000 iterations of MrBayes using
a standard mixed amino acid model (prset aamodelpr=mixed)(Ronquist et al., 2012). The consensus tree was visualized using
FigTree (Hancock, Zvelebil, & Cummings, 2004). The referenced proteins include BAV214: YP_009329802.1, CD1d:
NP_001358691.1, COTV170: YP_005296358.1, DPX_MHC-I_like: AUI80712.1, EPTV178: YP_009408129.1, HCMV UL18:
YP_081477.1, MC80_Type1: NP_044031.1, MC80_Type2: AAC72821.1, MICA: AAO45822.1, MMPV037: YP_009408219.1,
MMPV038: YP_009408220.1, MMPV196: YP_009408378.1, MR1: NP_001522.1, NYPV033: YP_009408421.1, NYPV034:
YP_009408422.1, NYPV186: YP_009408574.1, SPV003/148: NP_570163.1, SQPV004: YP_008658429.1, SQPV027:
YP_008658452.1, SQPV064: YP_008658489.1, TPV 2L: AAO66454.1, YKPV MHCI: YP_004821526.1, and YMTV 2L:
NP_938264.1.

The cell surface half-life of MHC-I can be greater than 24 hours depending on the specific cell
line and peptide(s) displayed (Milner, Barnea, Beer, & Admon, 2006; Prevosto et al., 2016). We
investigated the kinetics of MHC-I surface downregulation using a transient transfection system,
finding that maximal expression of MC80 at 24 hours post transfection (hpt) did not coincide with
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maximal downregulation of MHC-I surface expression (Figure 2-5B). Instead, we found a
significantly lower level of surface MHC-I at 72hpt than 24hpt, even though there was less MC80
at the later time point. Additionally, our data demonstrated that continued expression of MC80
was necessary to maintain MHC-I downregulation (Figure 2-5B). As extended HLA class I halflives may have played a role in the apparent time-dependence of MC80-mediated MHC-I
downregulation (Figure 2-5B), we employed a stable retroviral transduction system to achieve a
steady state of MHC-I downregulation in further analyses. This time-dependence may also provide
insight into why the previous MC80 study reported no change in surface expression of HLA-A2
12 hours post-infection of an MC80-expressing vaccinia virus (Tatiana G Senkevich & Moss,
1998).
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2.3.2 MC80 specifically downregulates surface expression of peptide-binding
MHC-I

Figure 2-8: MC80 specifically downregulates peptide-binding MHC-I in human and murine cell lines. (A) The
downregulation of MHC-I and β2m (examined using either anti-HLA-ABC (W6/32) or anti-β2m) by F-MC80L and F-MC80S was
compared to respective untagged MC80 constructs in transiently transfected HEK 293T cells, two independent replicates each. (B)
Using C57BL/6-derived MEFs stably expressing Ld, the specific surface expression of Db, Kb, and Ld MHC-I alleles were
determined in the presence of F-MC80L or vector-control, two independent replicates each. (C) Using RMA cells, the surface
expression of Db, Kb, and Qa1 were determined in the presence of retrovirally transduced F-MC80S or vector-control, two
independent replicates each. (D) Using L cells stably expressing mouse CD1d, the surface expression of Kk and CD1d were
determined in the presence of retrovirally transduced F-MC80S/L, two independent replicates each. (E) Using murine Baf3 cells
stably expressing human MICA or murine Rae1⍺, the surface expression of Dk, hMICA, and mRae1⍺ were determined in the
presence of retrovirally transduced MC80L or vector-control. Error bars represent the standard deviation from two independent
replicates.

Since viral MHC-I evasion mechanisms can downregulate MHC-I with varying levels of
promiscuity (McCoy, Wang, Yokoyama, Hansen, & Fremont, 2012; Wagner, Gutermann,
Podlech, Reddehase, & Koszinowski, 2002), we next sought to determine the specificity of MC80mediated MHC-I downregulation. Flow cytometry analysis demonstrated that expression of MC80
markedly decreased the surface levels of classical MHC-I in multiple human cell lines, including
HEK 293T, Hela (human cervical cancer cell line), and HFF-1 (a human foreskin fibroblast cell
line) (Figure 2-8, Figure 2-9). A comparable effect was observed with untagged MC80 constructs
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with the canonical signal peptide, indicating that the Flag tag did not significantly affect MC80
function (Figure 2-8A). Interestingly, MC80 also downregulated all tested alleles of classical
MHC-I in murine cell lines (Figure 2-8B, C, D, E). Additionally, of the non-classical MHC-I
proteins examined, MC80 significantly decreased the surface expression of Qa-1 but did not
significantly affect surface expression of CD1d or the NKG2D ligands MICA and Rae1a (Figure
2-8C, D, E). Like classical MHC-I and Qa-1, CD1d requires β2m for stable expression, indicating
that MC80 is unlikely to function by competing for β2m. Instead, MC80 appears to be specifically
downregulating peptide-binding MHC-I through a cellular component/pathway that is conserved
between humans and mice.
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Figure 2-9: MC80 downregulates MHC-I surface expression in (A) Hela-A2 cells and (B) Human foreskin fibroblasts (HFF1). Cells were retrovirally transduced with the indicated MC80 constructs or vector control, followed by staining for HLA surface
expression by a pan-MHC-I (W6/32) or HLA-A2-specific (BB7.2) antibody. The mean fluorescence intensity (MFI) is indicated
for GFP+ and GFP- cells in each flow cytometry experiment. Plots are representative of (A) two independent experiments and (B)
one experiment run in duplicate.
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2.4 MC80 interacts with and leads to the degradation of PLC
components
2.4.1 MC80 impairs PLC-mediated peptide loading

Figure 2-10: MC80 prevents the maturation of MHC-I through dysregulation of peptide loading. (A) MEF-Ld cells
expressing vector control or F-MC80L were immunoprecipitated with anti-Ld followed by an EndoH-sensitivity assay, with
equivalent results demonstrated in two independent replicates. Ladder markers for western blots indicate the protein mass in
kilodaltons. (B) MEF cells stably expressing Cyt-SIINFEKL or ER-SIINFEKL were transduced with a vector control, MC80L, or
MC80S and stained for Db, or Kb-SIINFEKL. Error bars represent the standard deviation from two independent replicates. (C) Tpn/or TAP-/- MEFs expressing vector control, MC80L-F, MC80S-F, or CPXV203 were stained for Db and Ld. Quantification of Tpn/and TAP-/- MEF surface MHC-I is relative to the respective vector controls, which is considerably lower than MHC-I surface
expression on wild-type MEFs. All constructs were stably transduced using retroviral systems. Error bars represent the standard
deviation from two independent replicates.

As viruses are well known to have strategies to downregulate classical MHC-I by altering the
cellular trafficking of MHC-I (Hansen & Bouvier, 2009), we next examined the maturation state
of Ld by EndoH sensitivity in the presence or absence of MC80 (Figure 2-10A). We found that
MC80 did not appear to affect the steady state expression level of Ld. However, compared to the
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35% of EndoH-resistant Ld in the control, we found that Ld was completely EndoH-sensitive in
MC80-expressing cells (Fig 2-9A, Figure 2-11A). This indicates that MC80 interferes with MHCI trafficking to the Golgi, which consequently decreases the extent of surface MHC-I.

Figure 2-11: Quantified EndoH-sensitivity of Ld by MC80 and downregulation of MHC-I by CPXV012 and CPXV203 in
the presence of SIINFEKL. (A) Fraction of mature Ld (EndoH-resistant) in the presence or absence of MC80, as also depicted in
Figure 3A, is quantified. Error bars represent the standard deviation of two independent replicates. (B) SIINFEKL was expressed
in MEFs using a retroviral transduction system, as shown in Fig 3B. The relative MHC-I level of GFP+ / GFP- cells is indicated as
a percentage for each plot. CPXV012 inhibits TAP-mediated peptide transport, and therefore only downregulates MHC-I when
SIINFEKL is expressed in the cytosol. CPXV203 directly binds mature MHC-I, retaining it in the ER, and therefore downregulates
MHC-I independent upon the localization of SIINFEKL-expression. Representative plots of two independent experiments are
shown.

Virally-encoded MHC-I saboteurs are further dichotomized into PLC-dependent and PLCindependent mechanisms; as exemplified by the cowpox virus CPXV012 and CPXV203 proteins,
respectively(Alzhanova et al., 2009; Byun et al., 2009; Byun, Wang, Pak, Hansen, & Yokoyama,
2007; Luteijn et al., 2014). To determine which strategy is utilized by MC80, we next tested
whether MC80 downregulates MHC-I in murine embryonic fibroblasts (MEF) expressing
SIINFEKL, a Kb-specific peptide of egg ovalbumin, either in the cytosol or in the ER. Cytosolic
SIINFEKL requires TAP to be transported into the ER for MHC-I loading, whereas ER-SIINFEKL
is able to load onto MHC-I independent of TAP function. Because CPXV203 does not require the
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PLC in order to downregulate MHC-I surface expression, it dramatically affects Kb/SIINFEKL
expression in both cell lines (Figure 2-11B). However, CPXV012 only induces significant
downregulation of Kb/SIINFEKL in cells expressing cytosolic SIINFEKL, as its mechanism of
action is dependent on TAP (Luteijn et al., 2014). Similar to CPXV012, MC80-mediated
downregulation of Kb/SIINFEKL could be rescued by expression of SIINFEKL in the ER (Figure
2-10B, Figure 2-11B). SIINFEKL localization had only a marginal effect on the surface expression
of Db in the presence of MC80, indicating that this effect was specific to Kb/SIINFEKL (Figure 210B).

While TAP- and Tpn-deficient cells display low levels of MHC-I on the cell surface, these levels
can be further decreased by PLC-independent viral mechanisms, such as CPXV203. However, we
found that MC80 functionally relies on the presence of TAP and Tpn, as murine MHC-I alleles
were not further downregulated by MC80 in TAP- or Tpn-deficient cells, relative to vector control
(Figure 2-10C). Together, (1) the lack of MHC-I-maturation, (2) the specific rescue of MHC-I by
an ER targeted peptide, and (3) the TAP-/Tpn-dependence collectively suggest that MC80
sabotages the PLC-assisted peptide transport/loading of MHC-I in the ER.
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2.4.2 The luminal domain of MC80 is sufficient for PLC-association but not
MHC-I downregulation

Figure 2-12: MC80’s luminal domain associates with the PLC primarily through Tpn, but the transmembrane and/or tail
is necessary for MHC-I downregulation. (A) Schematic depiction of MC80 constructs fused with N-terminal or C-terminal Flagtags, truncating the extended signal peptide and/or the transmembrane and tail as described in the Materials and Methods. The
dashed box indicates mouse β2m signal peptide while dotted boxes indicate the location of the Flag peptide. (B) MEF-Ld
(untreated), Tpn-/- (+IFNɣ), and TAP-/- (+IFNɣ) cells retrovirally transduced with the indicated MC80 constructs or vector control
were lysed and immunoprecipitated with anti-Flag antibody. Flag-IP eluants were immunoblotted for Flag, CNX, CRT, TAP1, and
Tpn. Data are representative of two independent replicates. Ladder markers for western blots indicate the protein mass in
kilodaltons. (C) MEF-Ld cells expressing the indicated MC80 constructs or vector control were stained for Ld and Db, and quantified
relative to vector control by flow cytometry, representative of two independent replicates, with two technical replicates each.

Given the central role of Tpn in peptide loading and the partial conservation of Tpn-binding
residues within MC80 (Figure 2-6), we hypothesized that MC80 may subvert peptide loading by
competitively binding Tpn to block the interaction between MHC-I and the PLC. A Flag-IP of
MC80 followed by western blotting (WB) for PLC components supported this hypothesis;
demonstrating that Tpn, TAP, CRT and CNX co-immunoprecipitate (co-IP) with the full length
MC80 constructs (Figure 2-12B). While the N-terminal Flag-tag did not appear to impact MHC-I
downregulation in Fig 2-6A, we observed that an anti-Flag WB of F-MC80S (N-terminally Flagtagged MC80S) produced a laddering effect in non-reduced samples. Therefore, we used C-
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terminal Flag-tagged constructs, encoding the canonical signal peptide of MC80, for all further coIP experiments.

Figure 2-13: Immunoprecipitations of MC80 with MHCI-related proteins reveal that tapasin degradation by MC80 can
prevent identification of the association between MC80 and tapasin, depending on the cell line/treatment. (A) HEK-293T cells,
(B) untreated MEFs (Tpn -/- and TAP1 -/-), and (C) MEF-Ld cells were retrovirally transduced with MC80 constructs or vector
control. (A) HEK293T cell lysates were immunoprecipitated for FLAG. Elutants were blotted for FLAG, Tpn, TAP1, and lysate
was blotted for actin as a control. The soluble form of MC80 was found to associate with both Tpn and TAP1, while the association
with Tpn was not detectable in functional forms of MC80. HEK 293T FLAG-IPs and blots are representative of two independent
experiments, once with DSP-crosslinking and once without. Blots from the DSP-crosslinked experiment are shown. (B) FLAG-IPs
of untreated Tpn/TAP-deficient MEFs were blotted for FLAG, CNX, CRT, TAP, and Tpn. (C) MEF-Ld cell lysates were
immunoprecipitated for FLAG. Elutants were blotted for FLAG and β2m and lysates were blotted for actin as a loading control.
Representative blots of two independent experiments are shown. Ladder markers for western blots indicate the protein mass in
kilodaltons.

Notably, a truncated MC80S protein which lacks the putative TM and cytoplasmic tail (sol
MC80S-F) could also co-IP Tpn, CRT and CNX but only partially co-IP’d TAP1 in murine cells
(Figure 2-12B). This suggests that MC80 primarily associates with the PLC via the luminal domain
and that the interaction between MC80 and TAP1 may be further stabilized by the TM and
cytoplasmic tail. Using TAP1-deficient MEFs treated with interferon gamma (IFNɣ), we were able
to recapitulate the association of the MC80 luminal domain with Tpn, CRT and CNX. However,
in the absence of Tpn, we could not detectably co-IP TAP1 or CRT with MC80, even when the
Tpn-/- MEFs were treated with IFNɣ. These data suggest that MC80 interacts with CNX and Tpn
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via the luminal domain; and the latter association may bridge the interaction of MC80 with CRT
and TAP1, reminiscent of classical MHC-I assembly in the ER. A co-IP of PLC components with
MC80 in 293T cells demonstrated that soluble MC80S-F interacts with both Tpn and TAP1,
further suggesting that the TM and tail of MC80 may not be necessary for the association of MC80
and TAP (Figure 2-13A). Despite the observed PLC-associations, flow cytometry demonstrated
that soluble MC80 constructs do not markedly downregulate surface MHC-I in MEFs or HFF-1s
(Fig 2-12C, Figure 2-9B). As binding to the PLC appears to be insufficient for MC80 function,
Tpn-competition/blockade is unlikely to be the mechanism of MHC-I downregulation, as we had
hypothesized.
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2.4.3 The destabilization of Tpn and TAP requires the MC80 TM and
cytoplasmic tail

Figure 2-14: MC80 induces the degradation of Tpn independent of TAP, and induces the degradation of TAP in a Tpndependent manner. (A) MEFs were retrovirally transduced with the indicated MC80 constructs or vector-control were lysed and
the lysates were immunoblotted for Flag, CNX, CRT, TAP1, Tpn, ERp57, β2m and actin, representative of at least two replicates
each. (B) Tpn-/- and TAP1-/- MEFs were retrovirally transduced with the indicated MC80 constructs or vector-control, and either
incubated with or without mIFNɣ for 24hr. The Tpn/TAP1-deficient MEFs were then lysed, and lysates were immunoblotted for
CNX, CRT, TAP1, Tpn, and actin. Untreated Tpn/TAP1-deficient MEFs are representative of two independent replicates, and the
IFNɣ-treated Tpn/TAP1-deficient MEFs are representative of three independent replicates. (C) HEK 293T and (D) Hela-A2 cells
were retrovirally transduced with MC80 constructs or vector control. (C) Tpn and TAP1 were found to be downregulated by MC80
in HEK 293T cells. Additionally, soluble MC80 does not downregulate either Tpn or TAP1. Blots are representative of two
independent replicates. (D) Hela-A2 cells were treated with human 100U/mL hIFNɣ for 24-48hr followed by immunoblotting the
lysate for the indicated proteins. Tpn was undetectable in the presence of F-MC80L, while TAPBPR remained unchanged by FMC80L. Blots are representative of at least two independent experiments. Ladder markers for western blots indicate the protein
mass in kilodaltons.
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To determine the role of the transmembrane and tail in MC80-mediated MHC-I downregulation,
we assessed the steady state levels of PLC components in the presence of various MC80 constructs.
Remarkably, we found that MC80L and MC80S, but not soluble MC80S, dramatically reduced
the steady state levels of Tpn and TAP compared with vector control in MEFs and HEK 293Ts
(Fig 2-14A, C). However, CNX, CRT, and ERp57 were not downregulated by the expression of
MC80 in MEFs. While the soluble MC80S construct slightly increased β2m levels, they appeared
unchanged by active forms of MC80. These data suggest that MC80 selectively destabilizes Tpn
and TAP in a TM/tail-dependent manner. While full-length forms of MC80 downregulated Tpn,
the completion of tapasin degradation appears to be cell-line specific. For instance, the MEF-Ld
cells in Figure 2-12B (left panel) were not treated with drug or cytokine to rescue Tpn levels, yet
all MC80 constructs associated with Tpn. However, only soluble MC80S-F appeared to associate
with Tpn in untreated TAP-/- MEFs and 293T cells, presumably due to the degradation of Tpn by
the functional MC80 constructs (Figure 2-13). Therefore, to demonstrate the ability of functional
MC80 to associate with Tpn in the absence of TAP, we treated the Tpn-/- and TAP-/- MEFs with
mIFNɣ (Figure 2-12B; right panel). F-MC80L also downregulated Tpn in Hela cells in the
presence of IFNɣ, but did not markedly affect the steady-state levels of TAPBPR, a structural
relative of Tpn known to interact with classical MHC-I (Figure 2-14D)(Jiang et al., 2017).

Given the interdependence of Tpn and TAP, we next sought to determine whether MC80 primarily
targeted one component or both equivalently. Using TAP1-/- MEFs, we were able to recapitulate
the MC80 TM/tail-dependent degradation of Tpn observed in wildtype MEFs (Fig 2-14B).
However, the level of TAP in Tpn-/- cells expressing MC80 was comparable to the vector control.
This was more readily observable when the Tpn-/- cells were treated with IFNɣ for 24hr prior to
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harvesting, to upregulate TAP expression (Figure 2-14B, right panel). Thus, while the
destabilization of TAP by MC80 depends on the presence of tapasin, the MC80-mediated loss of
tapasin is independent of TAP, indicating that tapasin is the primary target of MC80 in murine
cells. TAP destabilization is potentially a consequence of the loss of Tpn, given that both this and
previous studies demonstrate that TAP is generally unstable in the absence of Tpn (Figure 2-14B,
left panel) (Garbi, Tiwari, Momburg, & Hämmerling, 2003; Lehner, Surman, & Cresswell, 1998).
We hypothesize that tapasin is also the primary target in human cells due to the homology of
murine and human PLC components. However, as previous studies suggest that murine TAP is
more Tpn-dependent than human TAP, our data does not rule out the possibility that MC80 directly
targets TAP for degradation in human cells.
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2.4.4 MC80-mediated degradation of Tpn requires β2m and N86-glycosylation
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Figure 2-15: β2m and Asn86 are required for the MC80-mediated degradation of Tpn. (A) MEF cells derived from Db/Kb/β2m
triple knock-out (3KO) mice were trans-complemented with β2m (3KO+β2m). Both the 3KO and 3KO+β2m cells were retrovirally
transduced with vector control, soluble MC80S-F, or MC80S-F. Lysates were either directly western blotted for Tpn, GFP, and
actin, or immunoprecipitated with anti-Flag or anti-β2m, followed by western blotting for the respective immunoprecipitant. Three
independent replicates were performed (2 FLAG-IP, 1 β2m-IP). Ladder markers for western blots indicate the protein mass in
kilodaltons. (B) Hela cells stably expressing HLA-A2 were retrovirally transduced with vector control, soluble MC80S-F, or
MC80S-F (with an N86Q mutation or WT sequence). Lysates were either directly western blotted for Tpn, and actin or
immunoprecipitated with anti-Flag followed by western blotting the respective immunoprecipitant. (C) Hela cells stably expressing
HLA-A2 and vector/MC80 constructs were stained for cell surface HLA-ABC or intracellular FLAG tag followed by flow
cytometry analysis.

While previous work demonstrated that MC80 associates with β2m, it was not clear whether this
association was functionally relevant. To determine whether β2m was necessary for MC80mediated downregulation of Tpn, we used a classical MHC-I (H2-Kb/H2-Db) and β2m triple
knock-out MEF cell line (3KO) with or without stably transduced β2m. As observed in wild-type
MEFs, the soluble form of MC80S-F did not cause Tpn degradation in either cell line. However,
β2m expression was necessary for MC80S-F to induce Tpn degradation (Figure 2-16). In addition,
the level of MC80 in 3KO cells without β2m is lower than that in 3KO cells with β2m
transcomplementation.

Along with β2m, the Asn86 glycan has long been known to be necessary for proper folding of
classical MHC-I, interaction with the PLC through association with calreticulin, and trafficking to
the cell surface (Ryan & Cobb, 2012). To assess the impact of the N-linked glycan on MC80
function, we compared WT and N86Q mutant MC80, where the glutamine mutation provides
similar biochemical properties to asparagine but prevents glycosylation at the position. Similar to
classical MHC-I, MC80 expression is dramatically diminished in the absence of the Asn86 glycan.
Both the functional MC80S-F and the soluble construct, which expresses at higher concentrations
in WT, were undetectable following immunoblotting of Flag-IP of the N86Q constructs or by flow
cytometry staining (Figure 2-15B,C). Compared to the WT MC80S-F construct, Tpn was not
observably degraded by the N86Q construct. The lack of Tpn degradation coincides with a rescue
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of classical MHC-I surface expression (Figure 2-15C). These findings indicate that, (1) β2m and
N86-glycosylation can stabilize MC80, (2) β2m and N86-glycosylation are required for MC80
function, and (3) MC80-mediated degradation of Tpn is classical MHC-I-independent.

2.4.5 MC80-mediated Tpn degradation is proteasome dependent

Figure 2-16: MC80 induces the degradation of Tpn through the ubiquitin-proteasomal pathway. (A) MEF-Ld cells stably
expressing vector control or MC80L-F were treated with mIFNɣ for 24hr and with MG132 or DMSO control for 9hr before being
subjected to WB for Tpn. Each Tpn band from MC80-expressing cells was quantified as a percentage of the respective vector
control Tpn band. Error bars represent the standard deviation from two independent replicates. (B) The lysates of MEF-Ld cells
expressing vector control or F-MC80L were treated with mIFNɣ and MG132 as in (A) and immunoprecipitated with anti-Tpn
antibody, followed by Tpn- and ubiquitin-WBs, representative of four independent replicates. Ladder markers for western blots
indicate the protein mass in kilodaltons. (C) Hela-A2 cells stably expressing vector control or MC80S-F were treated with hIFNɣ
for 40 hr followed by Epoxomicin or DMSO control for 9hr before being subjected to WB for Tpn. Each Tpn band from MC80expressing cells was quantified as a percentage of the respective vector control Tpn band. Error bars represent the standard deviation
from two independent replicates. (D) MEF-Ld cells stably expressing vector control or MC80S-F were treated with MG132 for 8
hours, followed by FLAG-IP. The elutants were immunoblotted for FLAG and Derlin1, while the lysates were immunoblotted for
Derlin1 and actin. Blots are representative of two replicates. (E) Proposed mechanism for MC80-mediated subversion of MHC-I
presentation. The cartoon depicts MC80 interacting with the PLC components Tpn and TAP in a manner similar to classical MHCI, but also recruiting host ERAD machinery to trigger the ubiquitination and subsequent degradation of tapasin.
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The majority of eukaryotic protein degradation is mediated through proteasomal and lysosomal
pathways (Balchin, Hayer-Hartl, & Hartl, 2016). Autophagy has also been implicated in trafficking
proteins from the ER to the lysosome/autophagosome for degradation (He & Klionsky, 2009). To
determine which host degradation pathway was being exploited by MC80, we assessed the effects
of two inhibitors of proteasomal degradation (MG132 and Epoxomicin) and one inhibitor of
lysosomal degradation (chloroquine). We also assessed an Atg5-/- murine microglial cell line,
which is deficient in classical autophagy. Due to the toxicity of the tested drugs and the slow
intrinsic turnover of Tpn, we treated the cells with IFNɣ prior to drug exposure to increase the
synthesis of Tpn. Following a nine hour incubation, MG132 treatment partially but significantly
rescued the expression of Tpn in the presence of MC80 in murine cells (Figure 2-16A, Figure 217A). The proteasome-dependence of MC80 was also demonstrated in hIFNɣ-stimulated Hela
(human) cells using the more specific inhibitor, Epoxomicin (Figure 2-16D, Figure 2-17C).
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Figure 2-17: MC80-mediated degradation of Tpn is specifically proteasome-dependent. (A) Representative data/blots from
the experiment depicted in Figure 2-16A. MEF-Ld cells retrovirally transduced with vector control of MC80L-F were treated with
mIFNɣ for 24 hours and with MG132, DMSO control, Chloroquine, or PBS control for 9 hours. Lysates were blotted for actin and
Tpn with either a high or low sample load onto the SDS-PAGE gel. Low sample loads were used for final quantification (Figure
2-17A right panel; Figure 2-16A). (B) Atg5 KO BV2 microglial cell lines, with and without Atg5 trans-complemented, were
retrovirally transduced with vector control of MC80L-F, followed by staining for Db or Kb and quantification by flow cytometry.
Error bars represent the standard deviation of two independent replicates. (C) Representative data/blots from the experiment in
Figure 2-16D are shown. Hela-A2 cells retrovirally transduced with vector control or MC80S-F were treated with hIFNɣ followed
by Epoxomicin or DMSO control for 9 hours. Lysates were blotted for actin and Tpn and respective Tpn levels were quantified
(Figure 2-17C right panel; Figure 2-16D). Error bars are representative of two independent experiments. Ladder markers for
western blots indicate the protein mass in kilodaltons.

In contrast to the proteasomal inhibitors, neither the Atg5-/- cell line nor chloroquine treatment had
a discernable effect on MC80 function (Figure 2-17A,B). Furthermore, upon treatment with IFNɣ
and MG132, anti-Tpn antibody co-immunoprecipitated ubiquitinated bands corresponding to the
size of multi/poly-ubiqutinated Tpn, specifically in the presence of MC80 (Figure 2-16B). This
suggests that the expression of MC80 leads to the ubiquitination of Tpn. Aside from ubiquitination,
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ER-associated degradation (ERAD) requires retrotranslocation of targeted proteins to the
cytoplasm for proteasomal degradation to occur. While multiple retrotranslocation complexes
exist in the ER, we have observed that MC80 associates with Derlin1 in the presence of MG132
(Figure 2-16C). Given that MC80 is retained in the ER, these data suggest that MC80 selectively
destabilizes Tpn by recruiting ER-associated degradation (ERAD) components for the
ubiquitination and retrotranslocation of Tpn (Figure 2-16E).
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Figure 2-18: Overview of MC80-mediated inhibition of MHC-I surface expression through degradation of PLC
components. In both uninfected and infected cells, the proteasome is degrading proteins into short peptides in the cytosol. This
canonically leads to the transport of peptides into the ER lumen, where they may be loaded onto classical MHC-I molecules. These
peptide:MHC-I complexes then traffic to the cell surface to present the peptide antigen to T cells (Left). However, during an MCV
infection, MC80 associates with Tpn and TAP, as well as an ERAD complex, directing the ubiquitination and degradation of Tpn
and TAP. Without TAP, the proteasomally-derived host and viral peptides cannot effectively traffic into the ER. Additionally,
peptides that an traffic into the ER in a TAP-independent manner will not load effectively onto classical MHC-I due to a lack of
Tpn. Without peptide, the unloaded MHC-I molecules remain in the ER instead of trafficking to the cell surface.

2.5 RNF145 and Pcyox1l are necessary for MC80-mediated
degradation of tapasin
2.5.1 A whole-genome CRISPR screen identifies host proteins which modulate
MHC-I surface expression in the presence of MC80

Figure 2-19: A CRISPR-Cas9 whole genome screen to identify host proteins involved in MC80-mediated MHC-I
downregulation. (A) A cartoon depiction of the whole genome CRISPR-Cas9 protocol. MEF cells stably expressing the Cas9
enzyme and a functional form of MC80 (along with GFP through an internal ribosomal entry site) were stably transduced with the
Zhang library of murine guide RNAs to knock out 1 host gene per cell. Following rapid selection, cells were stained to detect
surface MHC-I levels and sorted to acquire (1) a negative control of total live GFP+ cells, (2) live, GFP+, MHC-I high cells (which
indicate rescue of MHC-I in the presence of MC80, and (3) live, GFP+, MHC-I low cells (which indicate additive loss of MHC-I
surface expression above MC80 function alone. (B) Representative plots of the FSC-A vs SSC-A, FSC-A vs FSC-W, SSC-A vs
SSC-W, and GFP+ signals/gates for the CRISPR-Cas9 screen. (C) Representative plot of the GFP+ vs MHC-I (PE) gates used to
sort the MHC-I high (rescue) and MHC-I low (additive loss) populations for downstream analysis. Approximately 5E7 cells were
collected for the negative control bulk sort, and 2E7 cells were collected for the MHC-Ihigh and MHC-Ilow bulk sort populations.
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We next sought to determine which specific ERAD complex was recruited by MC80. However,
multiple ERAD complexes have been identified, each with a distinct E3 ubiquitin ligase which
directs the proteasomal degradation (Ruggiano, Foresti, & Carvalho, 2014). Due to this breadth of
human ERAD machinery, we chose to utilize an unbiased whole-genome CRISPR/Cas9 screening
approach to attempt to identify the E3 ubiquitin ligase (and other necessary proteins) employed by
MC80 to mediate tapasin degradation and subsequent MHC-I surface downregulation.

We first transduced mouse embryonic fibroblasts (MEFs) with lentiviruses that led to the stable
expression of the Cas9 enzyme as well as a function MC80 construct, along with an internal
ribosomal entry site to tandemly express GFP. These cells were then transduced with a lentiviral
library of guide RNAs at an MOI of ~0.1 (Sanjana, Shalem, & Zhang, 2014). Following selection
for cells harboring a guide RNA, cells were stained for surface MHC-I and flow sorted to acquire
bulk live/GFP+ control cells, MHC-I high/GFP+ cells, and MHC-I low/GFP+ cells (Figure 2-19).
These populations respectively represent the control unselected population, the host knockouts that
rescued MHC-I expression, and the host knockouts that further ablated MHC-I expression.

The guide RNAs from the bulk-sorted pools were then amplified by PCR and sequenced through
the Illumina platform. Following preprocessing read trimming, the guide RNA reads were counted
and statistically assessed through the MAGeCK program, comparing the MHC-Ihigh and MHCIlow populations to the unselected control guide RNA pool (W. Li et al., 2014; Martin, 2011).
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2.5.2 Loss of NFkB signalling or MHC-I/β2m leads to an additive loss of
surface MHC-I along with MC80

Figure 2-20: MC80 CRISPR-Cas9 whole genome screen identifies NFkB/MHC-I in additive MHC-I downregulation and
RNF145/Pcyox1L in rescue of MHC-I surface expression. (A) MAGeCK results of the CRISPR guide RNAs selected for after
sorting MC80+ (GFP+) cells that expressed low surface MHC-I relative to the MC80+ bulk population. (B) MAGeCK results of
the CRISPR guide RNAs which were selected respective to unselected GFP+ live cells, after sorting MC80+ (GFP+) cells that
expressed high surface MHC-I relative to the MC80+ bulk population. Results are derived from two independent experiments.

We first considered the MHC-Ilow population, which represents host protein KOs that additively
downregulate MHC-I surface expression in the presence of MC80. We found that β2m and MHCI have the highest fold change with the lowest p-value compared to all other genes relative to the
unselected guide RNA pool (Figure 2-20A). This was expected, as the loss of MHC-I or its obligate
heterodimerization partner, β2m, is known to lead to a loss of MHC-I surface expression (Y. Y. L.
L. Yu et al., 1999). Additionally, we found that the loss of any one of multiple components of the
NFκB signaling pathway lead to an additive loss of MHC-I surface expression compared to MC80.
This finding is supported by previous reports which indicate that NFκB signaling is implicated in
MHC-I expression levels (Lorenzi et al., 2012). This is particularly informative, given that the
MCV ORFs MC005, MC132, MC159, and MC160 have all been found to inhibit NFκB signaling
through distinct mechanisms (Biswas & Shisler, 2017; Brady et al., 2015, 2017; Nichols & Shisler,
2009).
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2.5.3 Loss of RNF145 or Pcyox1L rescues surface MHC-I expression in the
presence of MC80
Next we assessed which of the screened host proteins were essential for MC80-mediated
downregulation of MHC-I. RNF145 and Pcyox1l stood out as the most significantly and most
dramatically selected in the CRISPR screen (Figure 2-20B). Supporting our hypothesis that MC80
coopts a host E3 ligase, RNF145 is known to be an ER-localized membrane-bound E3 ubiquitin
ligase which is canonically associated with cholesterol biosynthesis (Cook et al., 2017; Menzies
et al., 2018; L. Zhang et al., 2017). However, there is currently a dearth of information regarding
the Pcyox1L gene, aside from its sequence which includes a signal peptide, no detectable
transmembrane domain, and a KTEL C-terminal motif (Krogh, Larsson, Von Heijne, &
Sonnhammer, 2001; Petersen, Brunak, Von Heijne, & Nielsen, 2011). Together, this implies that
the Pcyox1L protein is expressed in a soluble form and retained in the ER, and would therefore
colocalize with RNF145 and MC80 (Byun et al., 2007; Capitani & Sallese, 2009).
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2.5.4 Pcyox1L associates with and stabilizes RNF145

Figure 2-21: Pcyox1L binds to RNF145 leading to its transient stabilization. (A) MEF cells were stably transduced with Cas9
and a CRISPR guide RNA targeting either RNF145 (Rnf) or Pcyox1L (Pcy), followed by selection and clonal amplification. To
validate the initial CRISPR hits, clones were stably transduced with a functional MC80 construct, followed by
transcomplementation of the respective KO gene (rsc) or nonfunctional RING mutant (RM) into the clones. The surface MHC-I
expression levels for these cells was then determined by flow cytometry to determine whether MC80 was functional in each cell
clone. (B) MEF cells lacking canonical Pcyox1L were stably transduced with an RNF145 construct containing a V5 tag. These
cells were then either transduced with a Pcyox1L construct containing an HA tag or an empty vector control. Cell lysates were
immunoprecipitated for the V5 epitope followed by immunoblotting of lysates and/or IPs for respective antigens. (C) RNF145-KO
and Pcyox1L-KO clones were stably transduced with an RNF145 construct containing an HA tag. Following incubation of the cells
with cycloheximide for indicated amounts of time, cells were harvested and immunoprecipitated for HA. At the longest incubation
time, cells were additionally incubated with the proteasome inhibitor MG132. (Right panel) The loss of RNF145 signal throughout
the experiment time course is quantified comparing the RNF145-KO and Pcyox1L-KO.

To further decipher the functional roles of RNF145 and Pcyox1L, we generated MEF cell clones
which had either of these genes knocked out through CRISPR/Cas9. We then verified the
CRISPR/Cas9 results by demonstrating that transduction of either of these clones with MC80 did
not lead to MHC-I downregulation (Figure 2-21A). The rescue of MC80 downregulation of MHCI through respective transcomplementations demonstrated that the loss of function was specifically
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due to the lack of RNF145 or Pcyox1L. As the functional RING domain of E3 ubiquitin ligases
is well characterized, we were able to clone a mutant RNF145 which lacked a histidine necessary
for zinc chelation and proper folding/function. Transcomplementation of RNF145-KO cells with
this non-functional mutant RNF145 did not rescue MC80-mediated MHC-I downregulation
(Figure 2-21A). These results collectively indicate that RNF145 and Pcyox1L are both necessary
for MC80-mediated downregulation of MHC-I, but the extent of their functional interdependence
is not clear.

To determine whether RNF145 and Pcyox1L are functionally related, we first assessed whether
the two proteins associate with each other. To overcome the low expression levels of RNF145, we
transduced Pcyox1L-KO MEFs with an RNF145-V5 construct as well as a Pcyox1L-HA construct
or empty vector. Following immunoprecipitation of V5, we found that Pcyox1L-HA
coimmunoprecipitated with RNF145-V5 (Figure 2-21B). While the canonical function(s) of
Pcyox1L is not known, we wanted to assess whether Pcyox1L expression impacts RNF145
stability, and thus may impact RNF145-mediated ubiquitination. To accomplish this, we stably
transduced a tandem HA tagged RNF145 construct into either RNF145-KO or Pcyox1L-KO cells,
followed by an incubation time-course with cycloheximide +/- MG132. As cycloheximide (CHX)
inhibits protein translation, loss of RNF145 levels measured post CHX exposure would provide
an indication of its relative instability. In the presence of Pcyox1L (RNF145-KO), a two hour
incubation with CHX did not have a measurable effect on RNF145 expression levels (Figure 221C). However, in the absence of Pcyox1L, the immunoblotted levels of immunoprecipitated
RNF145 decreased over the two hour incubation. This decrease was partially rescuable by
cotreatment with MG132 to prevent proteasomal degradation (Figure 2-21C). Therefore, Pcyox1L
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appears to be necessary for stabilization of RNF145 to prevent the otherwise rapid proteasomal
degradation of RNF145. However, the structural basis for this stabilization is unclear, given that
Pcyox1L is a soluble protein localized to the ER lumen and the majority of the RNF145 protein is
intramembrane.

2.5.5 RNF145 associates with MC80 and is required for MC80-mediated Tpnubiquitination/degradation

Figure 2-22: RNF145 interacts with and is necessary for MC80 function. (A) MEF ΔRNF145 clone D9 was stably transduced
with MC80S-F as well as a vector control, RNF145-HA WT, or RNF145-HA RM (ring mutant, nonfunctional). Cell lysates were
harvested and either directly immunoblotted or FLAG-immunoprecipitated followed by immunoblotting for HA (RNF145),
Derlin1, FLAG (MC80), and actin. (B) WT and ΔRNF145 MEFs were stably transduced with MC80S-F. Respective cell lysates
were immunoprecipitated for tapasin followed by immunoblotting for ubiquitin (Ub) or tapasin (Tpn). (C) WT and ΔRNF145
MEFs which were stably transduced with MC80S-F were lysed and immunoblotted for Tpn and actin.

Given that the loss of Pcyox1L destabilizes RNF145, and loss of either results in loss of MC80
function, we reasoned that RNF145 is likely to be directly involved in MC80 function. Therefore,
we next sought to determine whether MC80 interacts with RNF145 through immunoprecipitation
experiments. Using ΔRNF145 MEF cells which were stably transduced with a FLAG-tagged
MC80 construct and either a vector control or RNF145-HA constructs, we found that RNF145
does co-IP with MC80 in both the wild-type form or in a ring-mutant (non-functional) form (Figure
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2-22A). However, it is not clear whether RNF145 directly interacts with MC80, or whether this
interaction is bridged by other ERAD components, as Derlin-1 co-IPs with MC80 even in the
absence of RNF145. Indeed, RNF145 appears not only to associate with MC80, but to be also
necessary for MC80 function. ΔRNF145 MEFs stably transduced with MC80 do not appear to lead
to the ubiquitination or degradation of Tpn (Figure 2-22B,C). This data supports our prior
hypothesis that RNF145 is the E3 ubiquitin ligase recruited by MC80 to degrade Tpn.
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2.5.6 Attempts to identify specific MC80 transmembrane/tail residues
involved in Tpn-degradation are so-far unsuccessful

Figure 2-23: The transmembrane and tail of MC80 are involved in MHC-I downregulation. (A) A schematic of MC80
chimeras with the HLA-A2 allele of human MHC-I. Light gray indicates MC80, dark gray indicates FLAG tag, and white indicates
HLA-A2 sequence. (B) MEFs were stably transduced with MC80 chimeras with C-terminal FLAG tags. Cells were then harvested
and lysed, followed by either IB or FLAG-IP and IB for respective antigens. (C) Coomassie blue stained gel of MEF lysates with
stably-transduced MC80 chimeras. (D) Surface expression of MHC-I alleles in MEF-Ld cells stably transduced with MC80
chimeras. (E) Western blots of lysates of MEFs stably transduced with MC80 chimeras which were incubated either with or without
MG132 proteasome inhibitor prior to harvesting. (F) MEF MHC-I surface levels of cells stably transduced with MC80 point
mutants, focused on residues in the transmembrane and tail of MC80. (G) Relative MFI of intracellular FLAG signal of cells
assessed in panel F, indicating expression-levels of each mutant.

As soluble MC80 constructs are nonfunctional and RNF145 is predominantly a transmembrane
protein, we hypothesized that the MC80 transmembrane domain is instrumental to function. To
demarcate the roles of the transmembrane and tail of MC80, we first constructed a set of
MC80/HLA-A2 chimeric proteins in which we swapped the transmembranes and/or tails (Figure
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2-23A). Remarkably, the stable-expression of the chimer with the MC80 ectodomain fused to the
HLA-A2 transmembrane and tail (MC80-HLA(Tm + Tail)) was dramatically overexpressed in
MEFs compared to wild-type MC80 (Figure 2-23B). While overexpression did not alter the
expression levels of Tpn or TAP1, this chimer did appear to associate with the PLC, leading to
extremely high levels of coimmunoprecipitation of Tpn and TAP1. Indeed, the PLC components
which co-IP’d with this chimer were readily visualizable by Coomassie staining (Figure 2-23C).
However, neither this construct nor the other chimers tested downregulated MHC-I similar to wildtype MC80 (Figure 2-23D).

In fact, neither the MC80 construct which only swapped the cytoplasmic tail or the HLA-A2
construct which contained the transmembrane and tail of MC80 were considerably stable.
Incubation of the MEFs with MG132 prior to harvesting lysates appeared to partially stabilize the
MC80 construct with the HLA-A2 tail (Figure 2-23E). This suggests that this MC80 construct is
directly being proteasomally degraded at a higher rate in the absence of its canonical tail. If
RNF145-mediated, this may suggest a role for the MC80 cytoplasmic tail in either focusing
RNF145-mediated ubiquitination or at least preventing the degradation or MC80. Indeed, the
canonical MC80 tail does not contain a lysine residue, the primary target of ubiquitination.
However, if the lack of a lysine residue was sufficient to prevent degradation, then the HLA-A2
chimer would also be readily expressed. However, even with MG132-mediated proteasome
inhibition, the HLA-A2 chimer with the MC80 transmembrane and tail was not observed by
immunoblotting of the FLAG-IP, indicating that additional elements may be involved in the
destabilization of this construct. It is unclear whether the transmembrane is sufficient for
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recruitment of RNF145. However, large scale perturbations of the transmembrane and/or tail of
MC80 clearly effect its stability and function.

The current model suggests that the MC80 transmembrane and tail are involved in two competing
functions, namely the recruitment of RNF145 to ubiquitinate Tpn and the prevention of selfubiquitination. However, the identification of specific residues involved in these processes has
proven difficult. In our initial testing, we were particularly interested in the two glutamate residues
that are located in the predicted transmembrane region of canonical MC80 (Figure 2-6A). As
negatively charged residues are exceedingly rare in the predominantly hydrophobic cell
membrane, we reasoned that their conservation must provide some functional advantage.
Confusingly, mutating these residues to their respective HLA-A2 equivalents has almost no effect
on the ability of MC80 to downregulate MHC-I (Figure 2-23F). Instead, these constructs appear
to be expressed at additively higher levels within MEFs compared to wild-type MC80 (Figure 223G). Therefore, the role of the transmembrane and tail in MC80-mediated recruitment of ERAD
components remains unclear.
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2.6 Attempts at recombinant protein purification
The primary step of most biochemical characterizations is to recombinantly purify the protein of
interest. Unfortunately, attempts using bacterial, insect, and mammalian expression systems have
not been particularly fruitful. Below we outline the major issues with production of recombinant
MC80 in each expression system.

2.6.1 Attempt to recombinantly purify MC80 - bacteria

Figure 2-24: Schematic of a bacterial expression strategy for the MC80 ectodomain. (A) To produce highly pure heterodimers
of MC80 ectodomain and human β2m, we first purified inclusion bodies of both proteins from E. coli. β2m was then refolded by
limiting dilution, concentrated, and purified by size exclusion chromatography. (B) MC80 inclusion was subsequently dissolved in
6M guanidinium hydrochloride and nickel purified. (C) Pure β2m was then added to fresh refolding buffer along with yeastolate
(for a heterogeneous source of short peptides) and the partially purified MC80 was then refolded by limiting dilution into this
modified refolding buffer. Following complete injection, the MC80 diluent was concentrated and filtered. (D) Filtered refold
concentrate was then aliquoted into four equal volumes and dialyzed two rounds against buffers with various similarities to the
initial refold buffer. The precipitate was then separated from the soluble fraction and assessed by SDS-PAGE/Coomassie blue
staining.

Bacterial expression is a favored method for the biochemical/structural study of many proteins,
due to the rapid experimental timeframe, high yields, inexpensive reagent costs, and homogenous
nature of proteins lacking many of the post-translational modifications found in other organisms.
Given the fact that MHC-I contains multiple disulfide bonds which appear conserved in the MC80
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ectodomain, we reasoned that refolding the protein from bacterial inclusion bodies would be the
preferred method of purification.

However, we found the MC80 did not stably refold in standard arginine refold buffer. Through
tandem cell culture experiments, we found that MC80 appeared interact with many host proteins
similar to MHC-I, including β2m (Figure 2-15A). So like the MHC-I ectodomain, we reasoned that
MC80 may be stabilized by β2m and potentially a short peptide. We therefore first would refold
and purify β2m to be added to the buffer used to refold MC80 (Figure 2-24A). Following
purification of MC80-6His inclusion bodies, an appropriate amount would be solubilized in 6M
GdnHCl and nickel purified under denatured conditions before refolding (Figure 2-24B). Since we
were unsure what peptide/small molecule might associate with the MC80 binding pocket, we
decided to use yeastolate (yeast extract) which contains a large assortment of short peptides and
biologically-relevant small molecules.

While SDS-PAGE of the refolded MC80 in refold buffer suggests this strategy is successful
(Figure 2-24C), we found that the refold buffer itself appears to be maintaining the solubility of
the refolded MC80. Removal of the refold buffer components (e.g. predominantly arginine and
glutathione), MC80 precipitates out of solution along with apparent associated β2m. Yeastolate
does not appear to have much of an effect on MC80 stability (Figure 2-24D). We were unable to
discern the component of the refold buffer responsible for this stability. As we reasoned the MC80instability may arise from additional stabilizing host proteins (e.g. chaperones or the PLC), we
migrated to other expression systems.
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2.6.2 Attempt to recombinantly purify MC80 – 293F (human) cells
While arguably the most appropriate system for expression of a protein from a human-infecting
virus, we have found that soluble MC80S is retained in the ER, associating with native calnexin,
calreticulin, tapasin, TAP, and other PLC components. Unfortunately, the heterogeneous copurification of MC80 complexed to various transmembrane proteins would not be a biochemically
viable reagent for either binding or structural studies8. Therefore, we opted to switch to insect cell
expression after validating that soluble MC80 ectodomain was not secreted from transiently
transfected 293F cells.

8

One exception to this would be cryo-EM, which would potentially be able to separately particle pick distinct MC80
complexes for class averaging.
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2.6.3 Attempt to recombinantly purify MC80 – insect cells

Figure 2-25: Insect cell expression of MC80 and related proteins. (A) Recombinant baculoviruses with one or two soluble
ectodomains of MC80-related genes were cotransduced into High Five insect cells in various combinations at an MOI of 2, and
incubated for 3 days. Supernatants were harvested and immunoblotted for 6His (Tpn, Pcyox1L), FLAG (CRT), or Streptactin
(MC80) tags. (B) Recombinant baculoviruses with one or two soluble ectodomains of MC80-related genes were cotransduced into
High Five insect cells in respective combinations at an MOI of 2. The cell pellet and supernatants were separated, cell pellets were
lysed, and both the lysates and supernatants were immunoblotted for 6His (Tpn, Pcyox1L), FLAG (CNX), or Streptactin (MC80).
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Insect cells can provide a means for the production of recombinant proteins in some instances
where both E. coli and mammalian cell expression systems may have failed. However, this system
is often not the first choice due to the relatively time-consuming expression process. Nevertheless,
we cloned constructs of the ectodomain of MC80 with a streptactin tag (with or without coexpressed β2m), along with FLAG-tagged soluble CRT and CNX, 6His-tagged ectodomain of
tapasin (with ERp57), and 6His-tagged Pcyox1L without the C-terminal KTEL motif.
Unfortunately, no matter the combination of baculoviruses tested, MC80 did not appear to secrete
out of cells into the supernatant nor was it expressed at high levels in the High Five cells (Figure
2-25).

2.6.4 Attempt to recombinantly purify Pcyox1L – insect and mammalian

Figure 2-26: Expression of Pcyox1L in insect and mammalian cell systems. (A) As demonstrated in Figure 2-25, Pcyox1L is
secreted from High Five insect cells if expressed without the KTEL C-terminal region. Following nickel purification, sizing, and
anion exchange chromatography, the yield of insect-cell purified Pcyox1L is detectable by western blotting for anti-6His tag, but
disappointingly low by Coomassie staining. (B) In the absence of the KTEL C-terminus, Pcyox1L is secreted from mammalian
(293F) cells. To cap apparently-free cysteines, we attempted adding either iodoacetamide or glutathione (reduced) to the
supernatant during concentration. Glutathione was maintained in the buffer system through nickel purification for the respective
purification. (C) Pcyox1L purified in the presence of glutathione was treated with EndoHf either under native or denaturing
conditions following manufacturer’s instructions. The size of Pcyox1L glycan species are shown after 0, 1, 4, or 24 hrs of treatment
with EndoHf.

Due to the lack of any identifiable research on the Pcyox1L gene in the literature, we aimed to
study the functional role of this protein. As indicated by the name, Pcyox1L is sequence-similar to
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the prenyl-cysteine oxidase 1 gene. Both Pcyox1 and Pcyox1L contain a C-terminal KTEL motif,
which is often involved in ER or lysosomal localization (Byun et al., 2007; Pagny, Lerouge, Faye,
& Gomord, 1999). In order to simplify purification, we cloned the Pcyox1L construct without this
KTEL motif, which we hypothesized would lead to secretion of Pcyox1L into the supernatant,
which could be separated from the cells prior to chromatographic purification. Indeed, our first
attempt at Pcyox1L expression was conducted through baculovirus co-infection studies (Figure 225). However, insect cell expression of Pcyox1L had unacceptably poor yields (Figure 2-26A), so
we migrated to a mammalian (293F) expression system.

Pcyox1 is a well-studied FAD-binding enzyme involved in the degradation of the posttranslational modification (prenylation) of cysteine residues (Tschantz, Zhang, & Casey, 1999).
We therefore thought the cysteine residues within in Pcyox1L may be of intrinsic importance to
the enzyme’s mechanism of action. Indeed, purification of secreted Pcyox1L formed non-specific
disulfide bonds, introducing unacceptable levels of heterogeneity. To overcome this, we
considered the effects of using either iodoacetamide treatment or glutathione (reduced) during the
concentration/purification of Pcyox1L. Because Pcyox1L is secreted over the course of 5 days
during 293F protein production, the protein would have ample time to nonspecifically disulfidebond with other secreted proteins in the oxidized media environment. Therefore, the addition of
iodoacetamide after protein production is not able to homogenize the purified Pcyox1L compared
to reduced glutathione (Figure 2-26B).

Glycosylation of a protein leads to increased size heterogeneity visualized by broadening of SDSPAGE bands. Remarkably, the secreted Pcyox1L appears to be a combination of two very specific
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species, distinguished by the addition of a single glycan. Remarkably, all 5/6 glycosylated species
of Pcyox1L are separable by SDS-PAGE over a time-course of EndoHf cleavage of the glycans.
Unfortunately, the crystallographic screening attempts with either glycosylated or deglycosylated
Pcyox1L were unsuccessful. Additionally, the enzymatic function of Pcyox1L is still uncertain,
limiting the biochemical assays to currently pursue toward understanding the role of Pcyox1L in
MC80 function and more generally in human biology.

2.7 Discussion of MC80 mechanism
Through this thesis, we demonstrate that (1) the MHC-I-like MCV protein, MC80, associates with
the PLC via its luminal domain; (2) MC80 remains localized to the ER, where it induces the
degradation of Tpn and TAP to impede peptide loading and consequent MHC-I surface expression;
(3) MC80 requires β2m and Asn86 glycosylation to sufficiently self-stabilize and degrade Tpn;
(4) MC80 primarily targets Tpn; (5) MC80 associates with the ERAD components Derlin and
RNF145; (6) MC80 function requires RNF145 and Pcyox1L to degrade Tpn; (7) MC80
recruitment and control of degradation machinery is tied to its transmembrane and cytoplasmic
tail. Taken together, these findings support a model wherein MC80 directly interacts with Tpn via
its luminal domain and Derlin/RNF145 via its transmembrane and/or tail to facilitate the
degradation of Tpn; which secondarily destabilizes TAP. The loss of Tpn/TAP in turn dramatically
affects the ability of nascent MHC-I to load high affinity peptides and subsequently traffic to the
cell surface. Our experiments indicate that MC80L and MC80S both downregulate classical MHCI, associate with Tpn, and degrade Tpn/TAP in human and mouse cells. Thus, the extended MC80
signal peptide does not appear necessary for MHC-I sabotage but may have an as-yet-unknown
independent function. To our knowledge, no other viral protein has been previous described that
primarily targets Tpn for degradation.
73

While no other identified viral mechanism directly targets Tpn for degradation, multiple virallyencoded proteins have been found to undermine Tpn function to evade CTL killing through distinct
methods. HCMV US3 directly competes for Tpn binding to prevent peptide loading, while
adenovirus E3-19K obstructs the TAP interface to prevent Tpn from bridging classical MHC-I to
the PLC (Bennett, Bennink, Yewdell, & Brodsky, 1999; Park et al., 2004). Unlike these
mechanisms, our data indicates that soluble MC80 can associate with the PLC, but does not prevent
MHC-I presentation. Therefore, at the expression levels tested in our retroviral system, MC80 does
not appear to be functioning as a competitive inhibitor of PLC-mediated peptide-loading. Instead,
we find that Tpn is degraded in the presence of MC80; but Tpn levels can be partially rescued in
MC80-expressing cells by inhibiting proteasomal degradation. We also found that Tpn was
multi/poly-ubiquitinated in the presence of MC80 in an RNF145-dependent fashion, suggesting
that MC80 induces the ER-associated degradation of Tpn through the RNF145 E3 ubiquitin ligase.
The fact that we can detect the association between functional MC80 and Tpn in our wild-type
MEFs and interferon-induced TAP-/- cells indicates that the downstream steps of ERAD
(ubiquitination, retrotranslocation, and/or degradation) may be rate-limiting.

However, this

hindrance may be cell-line/species specific, as the association between MC80 and tapasin is only
detectable for soluble (non-functional) MC80 in HEK 293T cells and untreated TAP-/- MEFs.

In comparison to other viral MHC-I-evasion mechanisms which utilize ERAD, HCMV US2/US11
are only known to target MHC while MHV68 mK3 primarily targets MHC-I with only a slight
effect on TAP levels (Rehm et al., 2002; Wang, Ye, Lencer, & Hansen, 2006). None of these
proteins have been shown to recruit RNF145. Recently, a virally encoded ER-resident ubiquitin
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E3 ligase, RHVP pK3, was found to degrade MHC-I, Tpn, and TAP (Herr et al., 2012). However,
the degradation of Tpn and TAP were found to be secondary effects of the pK3-mediated
degradation of MHC-I. Conversely, MC80 appears to degrade Tpn independent of TAP or MHCI. Thus, the MC80-mediated destabilization of Tpn is distinct from other known viral MHC-Ievasion mechanisms.

While US2 and US11 specifically target MHC instead of tapasin, their molecular mechanisms are
reminiscent of MC80. Indeed, while none of these viral proteins appear to encode an ubiquitin E3
ligase domain, all three appear to induce ubiquitination-mediated ERAD. Like MC80, the luminal
domains of US2 and US11 are able to associate with MHC-I. However, US2/US11 constructs
lacking the transmembrane or tail domains cannot induce MHC degradation (Chevalier, Daniels,
& Johnson, 2002; S. O. Lee et al., 2005). The disparate transmembrane and tail sequences of US2
and US11 are thought to be responsible for recruiting distinct ERAD pathways. Of note, Derlin1
associates with US11 and is essential for US11-mediated, but not US2-mediated, ER-associated
degradation of MHC-I (Lilley & Ploegh, 2004; Van Den Boomen et al., 2014; Ye, Shibata, Yun,
Ron, & Rapoport, 2004). MC80 also associates with Derlin1, which appears to be either a direct
contact or close within the ERAD complex, because Derlin1 still associates with MC80 in the
absence of RNF145.

MC80 likely mediates its interaction with Derlin1 through their transmembrane domains.
Intriguingly, MC80 contains two glutamic acid residues in its predicted TM domain. (Tsirigos,
Peters, Shu, Käll, & Elofsson, 2015), which are exceedingly rare in human type I TM
proteins(Landolt-Marticorena, Williams, Deber, & Reithmeier, 1993). However, neither the US2
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nor US11 TMs contain negatively-charged residues. We initially hypothesized that these
conserved nonstandard residues would need to be central to the function of MC80 to be
evolutionarily retained. Strangely, mutating the two glutamic acid residues in the MC80
transmembrane to valine or alanine does not appear to severely impact MC80 function, but does
increase the expression level of MC80 in stably-expressing cells. We were only able to abolish
MC80 function through swapping either the complete tail or transmembrane/tail of MC80 with
HLA-A2. It is possible that the role of the glutamates is to decrease the steady-state expression
level of MC80. This may then prevent excess MC80 from unintentionally trafficking out of the
ER to the cell surface and activating NK cells. However, this hypothesis is merely speculative
currently and further work may be warranted to discern the role of the MC80 transmembrane/tail
in recruitment of ERAD components.

The experiments we have conducted through this thesis work cannot rule out the possibility that
MC80 is able to actively degrade TAP through the proximal interaction with Tpn or direct
interaction with TAP. However, the loss of Tpn has been previously shown to destabilize TAP in
human and murine cells. Therefore, we speculate that the loss of TAP is secondary outcome to the
specific ubiquitination and degradation of Tpn (Garbi et al., 2003; Lehner et al., 1998).

Interestingly, MC80 is retained in the ER despite lacking a putative ER-retention motif (Pagny et
al., 1999); even when expressed as a truncated protein without a TM or tail. MC80's ability to
associate with β2m and members of the PLC suggest that it maintains an MHC-I-like fold, and
thus may exploit host machinery which canonically retains unloaded MHC-I in the ER. The
association of soluble MC80 with CNX and CRT supports this hypothesis, as both chaperones
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have been previously shown to bind and retain immature MHC-I in the ER.(Blum, Wearsch, &
Cresswell, 2013; Nößner & Parham, 1995; Wearsch et al., 2004). Indeed, while the wild-type
soluble MC80 construct is overexpressed, the soluble MC80 variant lacking an N86 glycan is not
detectably expressed, likely due to its inability to associate with the necessary ER chaperones.

Furthermore, four of the eight residues critical to sequence-independent association of MHC-I with
peptides are not conserved in MC80, suggesting that MC80 may not bind peptides in an analogous
manner. Potentially, the divergence of MC80 from MHC-I functions to mimic the peptidereceptive conformation of MHC-I to continually associate with CNX/PLC. Unfortunately, this
theory is likely oversimplistic, as co-expression of soluble variants of many of the known PLC
components and MC80 in insect cells does not result in secretion of MC80-bound PLC. MC80
may be associating with insect cell ER proteins, addition human proteins/peptides may be required
for complete stability, or another ER-intrinsic factor may be central to MC80 stability.

Recent studies have made significant progress toward a structural understanding of MHC-I peptide
loading by employing a protein with sequence similarity to Tpn, TAPBPR (Jiang et al., 2017;
Thomas & Tampé, 2017). Like Tpn, TAPBPR is capable of peptide editing through association
with MHC-I; however, its functional role in antigen presentation has not yet been fully resolved.
It is interesting to note that, while expression of MC80 in Hela cells (even treated with IFNɣ)
dramatically decreased Tpn levels, TAPBPR levels remained unchanged compared to vector
control. We hypothesize that this specificity is a result of the fact that E3 ligases usually conjugate
ubiquitin with lysine residues (Berndsen & Wolberger, 2014); whereas the cytoplasmic tail of Tpn
has four lysines, the cytoplasmic tail of TAPBPR does not have any. However, it is possible that

77

MC80 preferentially interacts with Tpn over TAPBPR; or that TAPBPR may be present in other
cellular compartments where MC80 is absent. Regardless, MC80 expression appears to cause the
specific degradation of Tpn and not TAPBPR.

While the role of RNF145 in MC80 function appears straightforward, the molecular mechanism
underpinning the dependence of RNF145 on Pcyox1L remains unclear. Pcyox1L appears to play
a role in preventing proteasomal degradation of RNF145. Given that Pcyox1L is natively soluble
and localized to the ER, it is unlikely to be mediating this stabilization through association with
the RNF145 ring-finger domain to directly prevent self-ubiquitination. The human homolog
Pcyox1 is characterized as an oxidoreductase of cysteine prenylation modifications. As prenyl
groups are hydrophobic and RNF145 is a multipass transmembrane protein, Pcyox1L may instead
modify the hydrophobicity of RNF145, and the subsequent conformational changes may in-turn
stabilize RNF145. Further biochemical studies are warranted to determine the general functional
role of Pcyox1L in human cells.

While MC80 was originally predicted to be involved in NK-subversion, the mechanism described
herein suggests that MC80 is involved in subverting CTL responses by downregulating MHC-I,
which may in turn increase NK killing (Lanier, 2005). However, our data does not preclude MCV
from encoding additional ORFs which subvert NK and CTL responses through distinct
mechanisms. In fact, multiple of the immune modulators described in Section 1.7 could impact T
and NK killing, including MC148, the inhibitor of CCR8 chemotaxis, and MC54, the IL-18
antagonist (Damon et al., 1998; Y. Xiang & Moss, 2001). MC80 likely works in concert with
MC148 to prevent the activation of surveilling T cells, specifically those which have been able to
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localize to the MCV lesion. Comparatively, cowpox virus encodes at least seven distinct proteins
suspected of antagonizing host chemokines (Nelson, Epperson, Singh, Elliott, & Fremont, 2015),
while also downregulating MHC-I expression by two independent mechanisms (McCoy IV et al.,
2013), and encoding at least one separate protein to directly prevent NK activation (Campbell et
al., 2007). We therefore believe it unlikely that the functions listed in Section 1.7 make up the
complete repertoire of immune evasion proteins that allow for apparent MCV subversion of both
T and NK cell surveillance.
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Chapter 3: MCV genomic recombination
3.1 Introduction to poxviral recombination
The genomes of DNA viruses are often considered to be stable compared to RNA viruses, with
estimated mutation rates of 1-6 x 10-6 substitutions/site/year, which would equate to less than 1
substitution/year for the MCV 190kbp genome (I. V. Babkin & Shchelkunov, 2006; Igor V. Babkin
& Babkina, 2011; Hughes, Irausquin, & Friedman, 2010). This genomic stability presents a unique
problem for poxviruses seeking to overcome host immune responses. As one potential immuneevasive strategy, poxviruses have long been known to recombine with foreign DNA in host cells
(Johnston & McFadden, 2003). Due to the co-evolution of virus and host, an initial question
regarding recombination is whether the host or the virus was the initial source of a given genetic
material. However, phylogenetically-related poxviruses often lack copies of these host orthologs,
and host-related organisms often encode these orthologs, suggesting that the host is frequently the
source of genetic material (Shackelton & Holmes, 2004). This recombination may result in uptake
of a selectively advantageous ORF, leading the virus to retain and potentially adapt the ORF to
further suit its purpose.

Host-orthologous ORFs are commonplace in published poxvirus genomes. Sometimes referred to
as “host range factors,” these viral ORFs generally expand host tropism through inhibition of
immune responses (Johnston & McFadden, 2003). This can be exemplified by viral cytokines such
as vIL-10 (Fleming, McCaughan, Andrews, Nash, & Mercer, 1997; H. J. Lee, Essani, & Smith,
2001; Tulman et al., 2001), vEGF, and MC148 (Joachim J. Bugert, Lohmüller, Damon, Moss, &
Darai, 1998); cytokine antagonists such as IL-18 binding proteins (Yan Xiang & Moss, 1999),
multi-chemokine antagonists, complement-binding protein, IL-1β receptors (Spriggs et al., 1992),
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IFN receptors (G. L. Smith, Symons, & Alcamí, 1998), and TNF receptors (Cunnion, 1999);
antigen presentation inhibitors such as M153 (Aguilar et al., 2019), and MC80 (See Chapter 2);
and signal transduction inhibitors such as vFLIPs (Biswas & Shisler, 2017; Nichols & Shisler,
2009).
Aside from host-virus fusions, tandem poxvirus infections are also known to result in
recombination in culture, generating hybrid viruses (Bedson & Dumbell, 1964b, 1964a; Qin &
Evans, 2014; Strayer et al., 1983; Woodroofe & Fenner, 1960). Variola minor, a smallpox variant
known for an unusually-low case fatality rate, has also been suggested to be a result of in vivo
recombination between two more pathogenic smallpox variants (Esposito et al., 2006).
Additionally, a specialized form a recombination termed “accordion expansion” has been observed
in cell culture to result in the rapid localized copying of viral ORFs (Elde et al., 2012).

Unfortunately, the process underlying poxviral recombination remains difficult to transiently
observe and therefore mechanistically unclear. The two predominant hypotheses on the subject
diverge on whether recombination follows reverse transcription of host mRNA or is a result of
direct recombination with host genomic DNA. Both the cytoplasmic localization of poxviral
replication and the lack of introns in poxviral genomes argue that host mRNA are the template of
recombination. However, sequenced poxviral genomes likely have undergone multiple selection
events in vivo post-recombination so as to eliminate unnecessary intron regions; and
retrotranscription machinery is not encoded by wild-type poxviruses.

Regardless of the basis of recombination, the event has the potential to either lead to a loss or gain
of function. Under steady-state infections, insertion of random genetic material into the viral
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genome would likely prove deleterious but may be more justified when presented with an
evolutionary pressure which requires rapid adaptation. However, it is unclear whether poxviruses
are able to modulate the rate of recombination due to extrinsic factors. For example, in the case of
MCV infections, the inflammatory and adaptive responses are two disparate yet equally
challenging evolutionary pressures which may drive recombination.

Through this chapter, we assess the phylogenetic divergence of MCV variants with particular
emphasis on recombination. We find that three genomic regions known to encode proteins
involved in immune-evasion appear to be undergoing horizontal gene transfer between MCV
variants. All three of these regions (i.e. cassettes) have locally high NGS short read coverages and
two of these regions each contain three sequence-similar ORFs, indicative of accordion expansion.
However, instead of the expected localized duplication events, we observe more generalized
inverted duplication events throughout the MCV genomes. While the functional relevance of the
inverted duplications is unknown, the recombination of cassette #3 leads to swapping of a highly
antigenic protein between MCV variants. We hypothesize that this swapping is a means to
diversify the antigenic repertoire, alleviating the selective pressure of the host humoral response
which would otherwise inhibit re-infection.
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3.2 MCV genomes recombine and accordion expand in vivo
3.2.1 Three cassettes in the MCV genome are highly polymorphic

Figure 3-1: Three major genomic cassettes account for the majority of polymorphisms distinguishing MCV variants. (A)
Whole core (no ITR) MCV genome phylogenetic analysis of all 33 assembled genomes plus the 16 previously published genomes.
MAFFT-aligned genomes were phylogenetically analyzed using the MrBayes General Time Reversible (GTR) substitution
evolutionary model with gamma-distributed rate variation across sites and a proportion of invariable sites. Markov chain monte
carlo simulations were run until the split differences of the standard deviations were < 0.01. (B) The local polymorphisms between
variant groups were calculated over the multiple sequence alignment for each window of 200bp, incrementing 100bp. Maximum
y-axis value is 200. (C) Genome diagram of MCV-1p (NC_001731.1) coloring each ORF by the number of orthologs found in
other chordopoxviruses including variola virus, camelpox virus, cowpox virus, vaccinia virus, taterapox virus, ectromelia virus,
raccoonpox virus, monkeypox virus, squirrelpox virus, canarypox virus, yokapox virus, turkeypox virus, Orf virus, pseudocowpox
virus, parapoxvirus red deer, pidgeonpox virus, penguinpox virus, fowlpox virus, goatpox virus, sheeppox virus, lumpy skin disease
virus, swinepox, deerpox, myxoma virus, rabbit fibroma virus, yaba-like disease virus, tanapox virus, bovine popular stomatitis
virus, and nile crocodilopox virus. Locations of the three major polymorphic cassettes are shown in green.
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105 formalin-fixed paraffin embedded (FFPE) tissue sections diagnosed as MCV+ from the St
Louis area and 31 from South Korea were screened by short length PCR-Sanger sequencing to
identify potentially novel MCV variants. 33 of these FFPE samples were subsequently Illumina
sequenced and assembled into whole genomes. Following truncation of the inverted terminal
repeats, a whole genome phylogenetic analysis demonstrated considerable divergence between
MCV genotypes, roughly clustering into three clades (Figure 3-1A). The BamHI sites of the
assembled genomes (and publicly available MCV genomes) proved useful in assigning most
genome isolates to previously designated MCV variants (Nakamura et al., 1995). This provided
sufficient information to definitively label the MCV-1p, MCV-1va, MCV-1vb2, MCV-1vc, MCV3, and MCV-4 clusters (Figure 3-2A) of the phylogenetic tree.

However, two type 1 and three type 2 clusters were found which contain either novel BamHI
restriction maps or encode sequence divergence not distinguishable through BamHI restriction
fragment analysis (Figure 3-1A, Figure 3-2A). In keeping with the nomenclature, these novel
clusters were termed MCV-1vd, MCV-1ve, MCV-2va, MCV-2vb, and MCV-2vc.

To determine the dispersal of nucleotide divergence, we next quantified local polymorphisms
distinguishing MCV variant clusters. Remarkably, we found that the intra-clade sequence
divergence was dominated by three cassettes (Figure 3-1B). In the case of MCV-1ve, all three
cassettes were distinct in MCV-1vb2, while only two of the cassettes appeared to diverge in MCV1vc and MCV-1vd. Similar patterns of sequence-dissimilarity within the cassettes were observed
between most intra-clade variant pairs (Figure 3-2B). Aside from these three cassettes, the majority
of the intrastrain genomes were highly sequence similar.
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Figure 3-2: Phylogenetic analysis of MCV variants demonstrates high levels of localized polymorphism between intra-clade
strains and general background polymorphism rates between inter-clades strains. (A) BamHI restriction maps of all MCV genome
isolates (orange). HindIII restriction maps were also included for MCV-1vb2 to demonstrate differentiation from MCV-1vb1
(green). (B) Paired variant local polymorphisms for all phylogenetic subtypes following established equations (Esposito et al.,
2006). (C) Each annotated ORF from the known/assembled MCV isolates were aligned using ClustalO (Sievers & Higgins, 2014)
and PAL2NAL (Suyama, Torrents, & Bork, 2006). Resulting nucleotide sequence alignments were phylogenetically assessed using
the MrBayes codon nucleotide model to determine the omega value (dN/dS) for each ORF. Locations of the three major
polymorphic cassettes are shown in blue.

Interestingly, these regions each encode at least one protein involved in the immune response. The
vaccinia ortholog of MC035R, B22R, is hypothesized to inhibit T cell activation. Relatively unique
to MCV, MC054L antagonizes IL-18 (Figure 3-1C). And MC133 is both one of the most antigenic
proteins encoded by MCV along with MC084L (Sherwani et al., 2014; Watanabe et al., 1998,
2000). While the antibody response is often viewed as a strong evolutionary pressure, neither of
these highly antigenic MCV proteins appear to be undergoing positive selection (Figure 3-2C).
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3.2.2 Cassettes 1 and 3 are recombining between MCV variants

Figure 3-3: Cassette #1 and #3 appear to be undergoing inter-clade recombination. (A) Phylogenetic analyses of the aligned
nucleotide sequences of each cassette using MrBayes and FigTree (Hancock et al., 2004; Ronquist et al., 2012). Local
polymorphism plots (as described earlier) demonstrate that phylogenetically distant MCV variants share near-identical copies of
cassette #1 and #3. (B)

Instead, cassette #1 and #3 appear to be under negative selective pressure compared to the more
neutral cassette #2. To determine the extent of each cassette’s variance between MCV clusters, a
phylogenetic analysis was conducted for each cassette. Remarkably, cassette #1 and #3 each
appear to form three highly conserved subclusters with considerable dissimilarity from the whole
genome phylogenetic analysis (Figure 3-3A, Figure 3-1A). MCV-1vc and MCV-2va are
evolutionarily distant clusters, yet share almost identical cassette #1 sequences. MCV-1vd and
MCV-3 similarly share near-identical cassette #3 nucleotide sequences (Figure 3-3A).
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Given the apparent swapping of highly conserved sequences between phylogenetically distinct
MCV strains observed in our work and previous studies (López-Bueno, Parras-Moltó, LópezBarrantes, Belda, & Alejo, 2017; Zorec et al., 2018), we hypothesized that co-infecting MCV
strains may be recombining cassette #1 and #3 regions in vivo. To determine whether individual
patient isolates contain tandem MCV infections, we wrote a sensitive NGS abundance estimator
to distinguish between highly-similar subvariants using strain-unique kmers (SPeQ: See Appendix
1.4.1, 1.4.2). This is primarily due to the fact that large regions of MCV subvariants share (near)
identical sequences, which would be indistinguishable as short reads and difficult to classify9.
Intriguingly, we found that multiple sample isolates appear to contain significant percentages of a
similar MCV variant (Figure 3-3B). We additionally sought to determine whether there was any
evidence of recombination between the tandem-infecting MCV variants by determining whether
any short reads contained a kmer unique to each of the variants. In line with the recombination
hypothesis, we detected low levels of these fused reads in tandem-infected isolates (Figure 3-3C).

3.2.3 MCV recombines with self and human genomic DNA
We next sought to assess whether in vivo MCV recombination was inter-strain limited or whether
it could also occur within one MCV strain or between MCV and human DNA. To accomplish
this, we conducted Pacific Biosciences long read sequencing of total DNA isolated from inflamed
and noninflamed MCV skin lesion biopsies. Given the considerable accordion expansion within
the vaccinia genome upon exposure to a selective pressure, we had initially hypothesized that we
may observe increased duplication events in inflamed MCV lesions (Elde et al., 2012; Sasani,
Cone, Quinlan, & Elde, 2018). Indeed, high Illumina read coverage of the three cassettes provided

9

Kmers were chosen instead of whole reads for estimating abundance as to account for the majority of information
from reads that are a result of recombination.
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initial support that accordion expansion may be occurring in vivo during an MCV infection (Figure
3-4).

Figure 3-4: Illumina read coverage of MCV isolates. Illumina short reads of each isolate were mapped to the respective
consensus genome using bowtie2 with option -a (Langmead & Salzberg, 2013). Base coverages of the resulting sam files were
determined using bedtools2 (Quinlan & Hall, 2010) and plotted against the multiple sequence alignment of assembled genomes,
masking the inverted terminal repeats. Gray indicates a gap in the alignment, while the colored region is a normalized logarithmic
read coverage for comparison between isolates with varying coverage. The left-most column represents the median coverage of the
core MCV genome. The top panel is the MCV-1ve vs MCV-1vb2 local polymorphism analysis for reference.

However, the structural variant analysis of PacBio CCS reads indicated almost no direct
duplication events and instead that 1-3% contained inverted duplications of the consensus MCV
genome (Figure 3-5A). Unlike accordion expansion, these inverted duplications were found to be
distributed across the genome with no clear region of focus. A preliminary junction analysis
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additionally suggests that this structural rearrangement may be a result of moderate sequence
similarity between the two fused regions (Figure 3-5B). However, a more quantitative assessment
of the inverted duplication junctions is warranted to potentially provide insight into the
mechanism/motifs involved in strand displacement.

Figure 3-5: MCV forms inverted duplications with itself and recombines with human genomic DNA. (A) MCV selfrecombination structural variant analysis using NGMLR-Sniffles demonstrates that inverted duplications predominate compared
to other common structural variants. Samples are labelled by patient ID as well as whether the MCV lesion was inflamed or not at
the time of biopsy. (B) Cartoon diagram of three example CCS reads containing inverted duplications identified in the Patient #001N sample. The first set of MCV ORFs are labeled in blue, while the inverted set of ORFs are labeled green. The joining region of
the third example was aligned to the respective regions of the KY040277 reference genome, demonstrating moderate sequence
similarity between the two regions. (C) The fraction of MCV reads containing kmers unique to at least two distinct MCV variants
were determined using SPeQ, separated by whether lesions were inflamed or noninflamed. (D) Fraction of MCV reads which also
contain human sequence were determined using NGMLR-Sniffles, separated by whether lesions were inflamed or noninflamed.
(E) A cartoon diagram of three example CCS reads depicting human:MCV recombination. Where appropriate, the first set of MCV
ORFs are labeled blue, the second MCV ORF set are labeled green, and human genes are labeled in orange. Introns are represented
by thin lines.
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As observed through the Illumina short read analysis, disparate MCV strains appear to be
recombining equivalently (~3% of MCV reads) in inflamed and noninflamed lesions (Figure 35C). The fraction of inter-strain recombination events observed in Illumina reads is likely lower
due to differences in read length. Remarkably, we were also able to observe low levels (0.1% of
MCV reads) of recombination between MCV and human genomic DNA using the high quality
CCS PacBio reads, as identified by the presence of introns (Figure 3-5 D,E). Similarly to the intrastrain inverted duplications, these human:MCV recombinations are distributed throughout the
genome. While some of these human:MCV reads contain only one junction, some reads contain
two junctions (Figure 3-5E). In the example shown, this tandem junction results in an insertion of
human DNA along with a direct duplication of a region of the MCV genome.

This tandem-junction structural variation is reminiscent of accordion expansion, with the
exception of a non-self DNA insertion. Cassettes #2 and #3 each contain three sequence-similar
ORFs (MC51, MC53, and MC54; MC130, MC131, MC133) with one additional ORF inserted
(Figure 3-1C). We reasoned that the observed tandem-junction recombination may provide a
rationale for these non-self ORF insertions at sites of gene amplification.

3.2.4 Cassette #2 sequence diversity does not impact MC54:IL18 association
Gene amplification/accordion expansion may also provide an explanation for the increased relative
phylogenetic diversity of cassette #2 compared to cassettes #1 and #3 (Figure 3-3A) and greater
dN/dS than surrounding genomic regions (Figure 3-2C). Therefore, we sought to determine if
sequence variance led to functional divergence between cassette #2 ORFs. The sole cassette #2
ORF with a known role, MC54, is known to antagonize IL-18 (Y. Xiang & Moss, 2001).
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Figure 3-6: MC54 sequence variance does not impact IL-18 binding or antigenicity. (A) MrBayes phylogenetic analysis of
MC54 using the codon nucleotide model and a general time reversal model. (B) Top panel: Sequence alignment of MC54-3a and
MC54-3b proteins encoded by the sole MCV-3 isolate. Bottom panel: Visualization of the MCV-3 assembly graph depicting the
MC54-3b appendage that projects off the consensus genome. (C) ELISA-like binding assay, coating MC54 variants and hIL-18bp
onto Maxisorp plates and using hIL-18-avitag (biotin) as the primary followed by streptavidin-HRP for detection. IC50 values from
8 data-points is reported. (D) ELISA of MC54, hIL-18bp, and MC84 to assess the seroresponse of patients with dermatologistconfirmed MCV infections. MC54-1vb1 refers to MCV-1ve, which were mistaken as MCV-1vb1 early in the sequence analysis.

MC54 variants share similar levels of sequence diversity as the overall cassette #2 (Figure 3-6A).
Through visualization of the assembly graph (Wick, Schultz, Zobel, & Holt, 2015), a second
MCV-3 MC54 sequence was found to project from the MCV-3 consensus genome (Figure 3-6B).
A sampling of the phylogenetic diversity of MC54 was then recombinantly purified and assessed
for binding to IL-18 and antigenicity. However, the sequence divergence of MC54 variants did not
appear to impact IL-18 binding (Figure 3-6C) nor was MC54 found to be particularly
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immunogenic to an MCV+ patient (Figure 3-6D). Therefore, the evolutionary pressures leading
to cassette #2 divergence remain unclear.

3.2.5 Cassette #3 sequence diversity may impact MC133 antigenicity

Figure 3-7: Comparison of all strain ORFs to the MCV-1p reference. The open reading frames of all genomes were subject to
BLAST against the prototype MCV-1p reference ORFs. Each hit was pairwise aligned to the respective reference to determine the
percent identity and compare sizes of the ORF to the reference. Where only one ORF was identified by BLAST for a genome, the
ORF is colored with respect to the percent identity and size compared to MCV-1p (NC_001731.1). If more than one ORF is
identified by BLAST as a hit to a given MCV-1p reference protein, and the multiple ORFs align to distinct regions of the reference
protein, the ORF is considered fragmented, and it is colored pink. If no ORF equivalent was identified for any given genome, the
ORF is considered undetected, and colored red.
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Figure 3-8: MC133L variants are considerably more sequence-divergent than MC084L variants. (A) A phylogenetic analysis
of MC84 variants using the MrBayes codon nucleotide model with generalized time reversal. (B) A phylogenetic analysis of
MC133 sequences using the same MrBayes model in 3-8A. (C) A multiple sequence alignment generated with clustal omega of
the MC84 variants. N-linked glycan positions are colored blue, while all other sequences are colored by similarity. (D) A Clustal
Omega MSA of MC133 variants, coloring N-linked glycans in blue and all other positions by sequence similarity.
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Aside from cassette #2, cassette #3 sequences group into three highly conserved clusters (Figure
3-3A), but the encoded proteins demonstrate remarkable sequence-dissimilarity between clusters
compared to other MCV ORFs (Figure 3-7). MC133 is a known sero-dominant antigen encoded
in cassette #3. MC133 clusters are considerably more evolutionarily distant than the clusters
formed by the other immunodominant antigen, MC84 (Figure 3-8A,B). This divergence is also
reflected by considerable shifts in the N-glycan profile of MC133 variants, which could potentially
impact physiological antigenicity (Figure 3-8C,D). Additionally, host antibodies generated against
the vaccinia ortholog of MC133 are known to neutralize virus and limit infections (Fogg et al.,
2008). Therefore, additional serology studies are warranted to determine whether cassette #3
recombination provides a means for MC133 to overcome host sero-responses.
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3.2.6 Seroconversion does not coincide with MCV lesion clearance

Figure 3-9: Protocol for flow sorting cells isolated from MC lesions. (A) An example of non-inflamed and inflamed lesions to
be biopsied, tissued digested, stained and subjected to flow sorting under BSL2+ conditions. (B) Live cell gating from skin biopsies,
including FSC-A:SSC-A, FSC-A:FSC-W, SSC-A:SSC-W, and FSC-A:7AAD. (C) FMO vs whole cocktail staining of cells with a
two FITC-conjugated anti-desmosome (keratinocyte-specific) antibodies.

Antibodies are clearly seminal to immune protection against other poxviruses. In the case of MCV,
selection for cassette #3 recombination may be driven by the host seroresponse’s antagonism of
viral entry. However, given the length of MCV infections, it is unclear how MCV+ cells undermine
the second arm of the sero-response, antibody-dependent cellular cytotoxicity. It is possible that
MCV localizes to the epidermal layer to physically avoid sero-responses or effectively overcomes
ADCC through its immune-evasion repertoire. Therefore, we sought to determine whether the
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MCV-infected cells in patient lesions are decorated by IgG. As MCV is thought to replicate solely
in keratinocytes, we focused on the live, desmosome-positive population (Figure 3-9).

Figure 3-10: MCV-infected cells are decorated with host IgG. (A) Flow cytometry of patient noninflamed and inflamed MCV
lesions as well as patient-matched negative control skin. Results are plotted of the anti-hIgG vs anti-MHC-I signals. Cells were
pre-gated on live desmosome+ cells. (B) qRT-PCR analysis of b-actin, MC80, and MC84 using ~30 sorted cells-equivalents for
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each curve, separated by bulk sorted IgG+/- populations from 3-10A. (C) RNA-seq of bulk-sorted populations was performed for
two sets of patient samples. Human and MCV read counts per million were quantified, MCV-coding reads shown in red for each
population. (D) Transcript analysis and clustering of four cell populations from two MCV lesions (noninflamed and inflamed) from
a single patient bulk sorted by MHC-IhighIgGlow and MHC-IlowIgGhigh.

Given our recent work on MC80, we reasoned that low MHC-I levels would be a potential marker
for MCV-infected cells (Harvey et al., 2019). Remarkably, we found that keratinocytes in MCV
lesions predominantly split into two populations: MHC-IhighIgGlow and MHC-IlowIgGhigh (Figure
3-10A). As the patient-matched negative control demonstrates only the former population, we
reasoned that the latter represents the MCV-infected cell population. Similar populations were
found in a second patient, but not in a patient who had undergone imiquimod treatment prior to
biopsy.

To confirm that the MHC-IlowIgGhigh population represented the MCV-infected population, we
conducted preliminary qRT-PCR analysis on the IgG- and IgG+ sorted populations. The MC80
and MC84 transcripts were much more prevalent in the IgG+ population (Figure 3-10B). To follow
up on this, we performed bulk RNA-seq analysis on two sets of MCV-infected patient samples.
The patient #2 pilot samples had only been sorted as desmosome+, not on MHC-I and IgG, but
still revealed considerable levels of MCV-coding mRNA compared to the negative control skin.
Follow-up patient #4 samples were subsorted on MHC-I and IgG levels, further demonstrated that
the MCV mRNA is specifically localized to the MHC-IlowIgGhigh population (Figure 3-10C). As
expected, MCV infection drives pathway activation and considerably different transcriptional
expression patterns compared to non-infected keratinocytes (Figure 3-10D). In all, these
experiments suggest that MCV-infected cells are decorated by host IgG in vivo, but are
counterintuitively not being cleared due to inflammatory infiltrate.
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3.3 Discussion of MCV recombination
Through this study, we successfully assemble 33 MCV genomes, including the first reported whole
genome sequences of MCV-3 and MCV-4. The genomes form three major clades, with the caveat
that three genomic cassettes appear to be accounting for a large amount of the sequence divergence.
Cassette #2 may be diversifying through accordion expansion, while cassettes #1 and #3 appear to
be undergoing homologous recombination between MCV variants. In support of inter-strain
recombination, approximately half of MC lesions contain multiple MCV variants. The data
presented here suggest that recombination is a persistent semi-random phenomenon occurring
throughout the MCV infection.

Poxviruses have long been known to sequester genetic material from their hosts to overcome
selective pressures. However, it is currently unclear whether poxviruses acquire this information
through reverse transcription of mRNA or directly through recombination with host DNA. The
dogma that poxviruses replicate in the cytosol and lack of introns in poxviral genomes make
mRNA reverse transcription the primary hypothesis. However, we report consistent, albeit low
rates of recombination between MCV DNA and intron-laden human DNA through PacBio
sequence analysis. We do not observe recombination of MCV DNA with spliced human cDNA.
Similar to intra-strain structural variation, this process appears semi-random, as human:MCV
junctions were found to occur irrespective of chromosome/genomic location. Interestingly, some
of these human:MCV fusions contain two junctions, resulting in tandem duplication of a region of
the MCV genome. This process resembles vaccinia accordion expansion, and may indicate why
MC52 and MC132 are inserted between sequence-similar ORFs in MCV.
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As accordion expansion is described as a means of functional diversification, we focused on the
two ORFs with known functions within the seemingly expanding cassette #2 and cassette #3
regions, MC54 and MC133. As, all tested MC54 variants associated similarly with IL-18, we
thought that sequence divergence may play a role in overcoming the antibody response. However,
we did not find MC54 to be particularly antigenic.

Unlike MC54, the cassette #3 MC133 is one of the most serodominant antigens in MCV, along
with MC84. The considerable sequence and glycan diversity of MC133 variants suggests that this
protein may be more likely to be attempting to subvert seroconversion through diversification.
Given the fact that the MC133 ortholog in vaccinia is considered a target for antibody-mediated
neutralization, we hypothesize that MCV is diversifying MC133 to allow for reinfection of
individuals who have been infected with distinct strains. Further work is presently ongoing to
determine if there are strain-specific seroresponses to MC133 variants.

It is unclear whether the selective pressure driving MC133 divergence is solely the antibodymediated prevention of reinfection or whether seroconversion of ongoing infections plays a role.
Seroconversion canonically leads to IgG decoration of infected cells and subsequent ADCC 10. We
therefore set out to determine whether inflamed MCV lesions contained fewer infected cells than
noninflamed lesions. While MCV+ patients appear to decorate infected keratinocytes with IgG,
we do not observe a remarkable difference between MCV+:MCV- keratinocytes in lesions, given
the imprecise nature of biopsy. This is particularly remarkable given the fact that MCV+ cells also
lack MHC-I and should therefore be prime targets of both ADCC and missing-self NK activation.

10

Additionally, any extracellular viruses would be associated and likely cleared through immune complexes.
However, this is not viably observable without a contrived model system, which is not currently possible with MCV.
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Appendix 1: Dry Lab Methods
Bioinformatic methodologies are central to many aspects of a biologist’s work. Below I outline
some of the methods used and data/figures generated to answer specific questions that arose
through my thesis work.

1.1 NAMCS analysis
The NAMCS dataset provided by the CDC is an instrumental statistical approximation of
diagnosed diseases that occur in the U.S per year. Briefly, this dataset is generated by randomly
sampling of diagnosed clinical cases of disease from various emergency/outpatient departments
throughout the country. These selected cases document patient age, sex, and other nonidentifiable
variables for each given diagnosis. From this sampling, overall estimates of disease burden are
estimated for each given year. However, given the limited sampling that occurs on any given year,
demographic-based observations require averaging of multiple years-worth of data.

1.1.1 Parsing NAMCS datasets
The use of NAMCS datasets is considerably obfuscated by the fact that these dataset files are
compressed to a level that is not human readable and requires a year-specific set of formatting
files in order to parse the data in each file. These supplemental files are further split between an
input statement file, value label file, and variable label file. To organize this data, I chose to use
object-oriented programming to load each year’s NAMCS records (NAMCS/NCHS.py). First I
constructed a dictionary of dictionaries to relate the value codes to the full value names for each
variable in any given year. For each record within a dataset file, I then set a new attribute to the
Record object with the given value as defined by the dictionary. To determine the estimates for
each diagnosis, I then wrote a simple program to output the visit month, visit year, patient age,
[1]

patient sex, diagnosis 1, diagnosis 2, diagnosis 3, and patient weight (NAMCS/pullPerDIAG.py)
to distinct files for each diagnosis.

1.1.2 Comparison of age distributions of MC and other diagnoses
Age Distributions of NAMCS Diseases Similar to MC
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Figure S2-1: Age distributions of NAMCS-registered diagnoses that correlate highest to the MC age distribution.

Identifying other diseases which have similar age distributions to MC may be able to inform this
understudied disease. This is particularly informative as the adolescent human immune response
is severely understudied. By running the correlation function in R on the age-binned NAMCS
diagnoses, I found that other bacterial and fungal infectious diseases provide the strongest
correlations to the MC age distribution (Figure S1-1). Remarkably, two of the top four diagnoses
with similar age distributions to MC were specifically skin infections (impetigo and

[2]

dermatophytosis). Considering the intrinsic/extrinsic factors that may lead to pathogenic
infections, this may indicate that adolescent human skin is more amenable to infection.

The python code base written to parse the NAMCS databases for this analysis is hosted at
https://github.com/ibharvey/NAMCSpy.

1.2 MCV DNA – NGS Genome Assembly
The current methodology in de novo genome assembly is to utilize iterative deBruijn graph
assemblers. The power in this methodology is that they can use a large amount of information from
each given read, while efficiently overcoming errors in sequencing. As genomes assembled using
these methods are often on the order of gigabases in size, all of these algorithms could handle the
paltry 180,000bp MCV genome.

1.2.1 Choosing and modifying Unicycler
The majority of the samples used in this study were derived from FFPE tissue sections. Multiple
iterative deBruijn graph assemblers are capable of assembling MCV DNA derived from FFPE
tissue sections into near-complete genomes (Bankevich et al., 2012; Peng, Leung, Yiu, & Chin,
2012). After assessing a few options, I chose to utilize SPAdes through a modified version of the
program Unicycler (Wick, Judd, Gorrie, & Holt, 2017). Unicycler has the added benefit of
automatically determining optimal parameters for SPAdes options and cleans up the output
SPAdes assembly graphs for downstream processing.

However, given that formalin-fixation damages DNA, we did not have accompanying long-read
sequencing data for any of our FFPE-derived MCV samples. To aid in scaffolding the assemblies
without overbiasing the genome, I chose to add access to the underlying SPAdes “--untrusted[3]

contigs” option from within Unicycler and input known MCV genome references into this option.
I justified this addition by the fact that all MCV strains/variants were previously found to be
colinear by Southern blot analysis (Nakamura et al., 1995).

As I attempted multiple methods of assembling the genomes at this point, I found that initially
producing a temporary assembly with 10% of the reads and inputting these scaffolds as trustedcontigs when reassembling with 100% of the reads dramatically aided in genome assembly. I also
added the SPAdes “--careful” option, which extended the time to completion of each genome, but
I found produced more complete genomic assemblies.

1.2.2 Post-Unicycler processing and refinement
Following SPAdes assembly, I found that the post-processing steps after Unicycler applies bridges
(generating 003_bridges_applied.gfa) made incorrect assumptions about the linearity of the MCV
assembly graph. This is primarily due to the inverted terminal repeats (ITR) encoded in all poxvirus
genomes. As these two termini are sequence-similar, assemblers such as SPAdes cannot
distinguish the two, and instead produce assembly graphs where both termini of the MCV genome
are conjugated to a single ITR sequence. In Unicycler’s assumptions of nucleotide linearity, it
often breaks the ITR link to one of the genomic termini, losing viable information.

[4]

Figure S1-2: Bandage representation of MCV genome assembly graph of 2017-CTCAATG following Unicycler assembly.
Nucleotide sequences are represented as colored lines (green: core MCV genome, yellow: ITR, gray: reverse complement). Blue
arrows indicate regions of the graph assembly which were unambiguously connected by Unicycler. Red arrows indicate regions of
the graph assembly which were ambiguous following SPAdes/Unicycler assembly.

Therefore, to produce full scaffolds of MCV genomes, I traced a connection from one strand of
the resolvable ITR to the other strand of the resolvable ITR, traversing the core genome (Figure
S1-2). Given the repetitiveness of the ITR and our limit to short read data for these FFPE samples,
a considerable portion of the ITR remained unresolvable, and was discarded from further analyses.

In some cases, SPAdes output assembly graphs without connecting all viable scaffolds that it had
identified evidence for during the run. Unicycler identifies these discrepancies and connects them
through a short red-colored linker, which separated the two scaffolds in the original SPAdes output
(Figure S1-2E). However, given the lack of longer scaffolding information over these FFPE
genomes, occasional breaks in the assembly do occur. As previous studies have highlighted that

[5]

all known MCV variants are colinear, we fuse these breaks in the assembly with a short N-gap,
informed by the general MCV genome structure (Yamashita et al., 1996).

Using the Abyss-sealer program, we were successfully able to close many of the gaps which
remained in the assemblies (Paulino et al., 2015). The majority of remaining gaps consisted of
repetitive regions longer than the Illumina read length. Assembled MCV genomes were then
polished using the iterative Bowtie2-Pilon technique until Pilon documented no new changes
(Langmead & Salzberg, 2013; Walker et al., 2014). This bowtie2-pilon method is documented in
a python script adapted from Unicycler (Wick et al., 2017), which is available at
https://github.com/ibharvey/Unissembler

1.2.3 PacBio: CCS – Miniasm – Racon Workflow
All MCV DNA used for long-read sequencing was purified through phenol chloroform extraction
and shipped to Genewiz on dry ice for library preparation and sequencing. Long-read sequencing
through PacBio technology provides an unbiased means to determine whether accordion expansion
was occurring in MCV genomes. Thankfully, multiple research groups have developed programs
which can be used to assess structural variations within PacBio genomic datasets.
For the construction of a consensus genome from PacBio reads, utilization of CCS is useful as a
means to produce extremely accurate DNA consensus reads that average all SMRTbell subreads
for a single piece of DNA. Therefore, when a highly processive DNA polymerase is used to
perform the PacBio sequencing, the polymerase can repeatedly sequences the same DNA, reading
out the complementary and reverse-complementary orientation (Rhoads & Au, 2015). However,
given the heterogeneity of sample library prep and limited processivity of DNA polymerases, the
[6]

use of CCS often leads to exclusion of many reads that do not pass through the terminally ligated
barcode. These extremely long reads can hold valuable information regarding large structural
variants, but are not necessary to observe small structural variants or to generate a consensus
genome.

Therefore, I used the CCS program provided by PacBio to determine the consensus sequences of
each single molecule template DNA in the run. This was done with the shell script:

for x in demultiplexed/*.subreads.bam; do
ccs -j 16 $x CCS/${x:14:8}.ccs.bam;
samtools bam2fq CCS/${x:14:8}.ccs.bam > CCS/${x:14:8}.fastq;
done

The consensus bam files were then de novo assembled using the minimap2/miniasm pipeline as
demonstrated below.

for x in CCS/*.fastq; do
minimap2 -x ava-pb -t32 $x $x | gzip -1 > CCS/miniasm/${x:4:8}.paf.gz;
miniasm -f $x ${x:4:8}.paf.gz > CCS/miniasm/${x:4:8}.gfa;
done

This generates surprisingly complete MCV genomes, even when a single PacBio Sequel lane is
split between 6 samples. In the first set of MCV samples, only one did not produce an MCV
genome. This sample was isolated from an inflamed MCV lesion and there was minimal MCV
DNA in the sample overall. The second set of samples were less successful, but included more
inflamed lesions than the first set.
[7]

To further increase the accuracy of the whole genomes produced using only PacBio data, the
program racon was employed (basic script outline below) iteratively 10 times to produce a
consensus whole genome sequence:

for x in CCS/miniasm/*.gfa; do
awk ‘/^S/{print “>”$2”\n”$3}’ $x | fold > CCS/miniasm/${x:12:8}.fa;
blasr demultiplexed/${x:12:8}*.subreads.bam CCS/miniasm/${x:12:8}.fa –bam –
out CCS/miniasm/${x:12:8}.blasr.bam –nproc 32;
samtools view -@ 32 -h CCS/miniasm/${x:12:8}.blasr.bam >
CCS/miniasm/${x:12:8}.blasr.sam;
racon -t 32 demultiplexed/${x:12:8}*.subreads.fastq.gz
CCS/miniasm/${x:12:8}.blasr.sam CCS/miniasm/${x:12:8}.fa >
CCS/miniasm/${x:12:8}_racon_1.fa
rm CCS/miniasm/${x:12:8}.blasr.bam;
rm CCS/miniasm/${x:12:8}.blasr.bam;
done

This would produce whole MCV genomes with moderately high accuracy to known MCV
genomes (~96-99% similar). While these whole genomes are useful to scaffold high complexity
regions of the MCV genome, the comparatively lower cost and higher coverage/accuracy of
Illumina NGS data mandates that final genomes be assembled and/or polished with Illumina short
reads included.

1.3 Phylogenetic analyses
1.3.1 Coding HOPA: Homogenize Orientation through Pairwise Alignments
Solving 40+ genomes simultaneously introduces unique hindrances to phylogenetic analysis. One
issue is that de novo deBruijn graph assemblers do not have a preconceived orientation for the
[8]

genomes. Manually orienting all genomes against the reference MCV 1996 genome (T G
Senkevich et al., 1996) would have taken an unreasonable amount of time, especially considering
how many trial runs were involved in finding the optimal graph assembly method for the genomes.
Additionally, I could not identify a program which would provide a straight-forward means of
orienting nucleotide sequences against a reference.

Therefore, I wrote a short program which I acronymed HOPA (Homogenize Orientation through
Pairwise Alignments) to orient all nucleotide sequences in a file. As the name suggests, it takes a
file of sequences (FASTA, FASTQ, etc) and will perform a pairwise alignment of each sequence
(both forward and reverse complement) in the sequence file against the first sequence in the file.
As dynamic programming of long sequences can be computationally expensive, this step of the
program is multithreaded. Whichever orientation produces a higher pairwise alignment score is
defined to be the “correct” orientation and an output file is generated with all of these oriented
files, in the same order as the input file.

This program was written in C++ with considerable support through the seqan3 library (Rahn et
al., 2018). The build system was implemented through the cmake/make axis. However, due to
current limits in cross-compilation11, I also implemented a Dockerfile so the program can be run
on any Linux/Mac operating system. Additionally, the source code for hopa is hosted at
https://github.com/ibharvey/hopa.

11

The limit in this code’s portability stems from the seqan3 package’s reliance on C++ concepts and other
C++17/C++20 principles which are still only partially supported by major compilers.

[9]

1.3.2 Estimation of Global Phylogenetic Relationships using MrBayes
Following HOPA alignment of assembled genomes, all known MCV genomes in the NCBI
database were concatenated into the FASTA file. The concatenated file was then aligned using the
default options of the MAFFT program (Katoh & Toh, 2008). The inverted terminal repeats of the
genomes were trimmed so that only the core MCV genome was considered for phylogenetic
analysis. MrBayes has subsequently run on the cores of aligned MCV genomes, using a General
Time Reversible (GTR) substitution evolutionary model with gamma-distributed rate variation
across sites and a proportion of invariable sites (Ronquist et al., 2012). A Markov chain monte
carlo simulation was then run for 650,000 generations to achieve a standard deviation of split
frequencies below 0.01 for the MCV whole genomes.

1.3.3 Estimating the nonsynonymous/synonymous of ORFs using MrBayes
For each of the 163 annotated MCV ORFs, the largest respective ORF per assembled genome with
the highest sequence similarity to each ORF NC_001731.1 was combined into a FASTA file and
aligned using clustal omega (Sievers & Higgins, 2014). These alignments were then reverse
transcribed to the respective DNA sequence using PAL2NAL and converted to the NEXUS format
using Biopython (Cock et al., 2009; Suyama et al., 2006). These alignments were then subjected
to phylogenetic analysis using the MrBayes codon nucleotide model using GTR until convergence
of the split standard deviations (in most cases < 0.01), which outputs an estimate of the omega
value (dN/dS).

1.3.4 Visualizing local inter-strain polymorphisms
Global phylogenetic relationships do not inform on the heterogeneity of divergence between
genomic regions. Therefore, we sought to visualize the local polymorphisms that distinguish MCV
strains using previously developed methods (Esposito et al., 2006). The premise of this method is
[10]

to normalize the number of polymorphisms within a specified window when considering all
isolates of two distinct variants, and then iterate that window across the multiple sequence
alignment. This was practically accomplished by plotting the output of the python code outlined
below, comparing MCV variant clusters identified through initial whole-genome phylogenetic
analysis and comparison of restriction maps to known MCV variants .
snps = lambda x,y: sum(x[i]!=y[i] for i in range(len(x)) if x[i]!='-'!=y[i])
def gaps(x,y):
count = 0
for i in range(len(x)):
if x[i]=='-' and y[i]!='-':
# if its the first nucleotide, it is a new gap
# elif this is not an extension of another gap
# elif the previous line was both gap, now only one gap
if i==0 or x[i-1]!='-' or y[i-1]=='-':
count += 1
elif y[i]=='-' and x[i]!='-':
if i==0 or y[i-1]!='-' or x[i-1]=='-':
count += 1
return count
dij = lambda x,y: snps(x,y) + gaps(x,y)
# Generate the Pi values for an alignment of one strain
def genSame(s,window=200,step=100):
allPI = [0 for i in range(int(window/2),len(s[0]),int(window/2))]
for i in range(len(s)-1):
for j in range(i+1,len(s)):
counter = 0
gapc = 0
snpc = 0
for x in range(int(window/2),len(s[0]),step):
first = s[i][x-int(window/2):x+int(window/2)]
second = s[j][x-int(window/2):x+int(window/2)]
snpc += snps(first,second)
gapc += gaps(first,second)
allPI[counter] += dij(first,second)
counter += 1
print(i,j,snpc,gapc)
return [2.0 * float(x)/(len(s)*(len(s)-1)) for x in allPI]
# Generate the pi values for an alignment between two strains
def genDiff(l1,l2,window=200,step=100):
allPI = [0 for i in range(int(window/2),len(l1[0]),int(window/2))]
for i in range(len(l1)):
for j in range(len(l2)):
counter = 0
gapc = 0
snpc = 0
for x in range(int(window/2),len(l1[0]),step):
first = l1[i][x-int(window/2):x+int(window/2)]
second = l2[j][x-int(window/2):x+int(window/2)]
snpc += snps(first,second)
gapc += gaps(first,second)
allPI[counter] += dij(first,second)
counter += 1
print(i,j,snpc,gapc)
return [2.0 * float(x)/(len(l1)*len(l2)) for x in allPI]

[11]

1.4 Abundance estimation
1.4.1 Coding SPeQ: Strain PErcentage Quantification

Figure S1-3: A Bandage representation of a genome assembly graph output from SPAdes. Two distinct core sequences were
distinguishable by the assembler, which correlate to a tandem infection of two MCV variants. This graph was generated with the '-careful' option of SPAdes.

A previous report suggested that some patients who present with an MCV infection are coinfected
with two strains in individual lesions (Thompson et al., 1990). Additionally, one of my preliminary
SPAdes/Unicycler assembly graphs reinforced the possibility that some of the lesions may
constitute coinfections (Figure S1-3).

[12]

In designing a more quantitative means of deriving the percentages of different variants of MCV
in individual samples, the first obvious choice was to use a read/reference aligner and variant
caller. While many variant callers exist, these can only identify variants which were correctly
aligned against the reference genome. Additionally, determining the percentage of reads that are a
specific defined genotype/strain (not just a single point mutation) is nontrivial when starting with
a VCF file. Comparatively, the mathematical basis for determining the percentage of a given
genotype/strain within a sample of reads/kmers is fairly straightforward (Equations S1-S3).

𝑇𝑜𝑡𝑎𝑙𝑁𝑢𝑚𝑏𝑒𝑟𝑂𝑓𝐾𝑚𝑒𝑟𝑠 ∗ 𝑃𝑟𝑜𝑏(𝑁𝑜𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑖𝑛𝑔𝐸𝑟𝑟𝑜𝑟𝑠) = 𝑁𝑢𝑚𝑏𝑒𝑟𝑂𝑓𝑃𝑒𝑟𝑓𝑒𝑐𝑡𝐾𝑚𝑒𝑟𝑠

(S1)

𝑁𝑢𝑚𝑏𝑒𝑟𝑂𝑓𝑃𝑒𝑟𝑓𝑒𝑐𝑡𝐾𝑚𝑒𝑟𝑠 ∗ 𝑷𝒆𝒓𝒄𝒆𝒏𝒕𝑽𝒂𝒓𝒊𝒂𝒏𝒕 ≈ 𝑁𝑢𝑚𝑏𝑒𝑟𝑂𝑓𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝐾𝑚𝑒𝑟𝑠

(S2)

𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝐾𝑚𝑒𝑟𝑠 ∗ 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠 = 𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠

(S3)

𝑷𝒆𝒓𝒄𝒆𝒏𝒕𝑽𝒂𝒓𝒊𝒂𝒏𝒕 =

𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠 ∗ 𝑇𝑜𝑡𝑎𝑙𝑁𝑢𝑚𝑏𝑒𝑟𝑂𝑓𝐾𝑚𝑒𝑟𝑠 ∗ 𝑃𝑟𝑜𝑏(𝑁𝑜𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑖𝑛𝑔𝐸𝑟𝑟𝑜𝑟𝑠)

(S4)

In the above equations, the blue variable is a known value for any given sequencing technology,
black variables can be calculated algebraically using the other equations, and green variables
would need to be determined. I chose to represent the data as kmers instead of full reads, so that a
sequencing error would not void the rest of the data in that read from analysis. To reiterate, this
includes (1) the total number of kmers, (2) the percentage of variant-specific kmers that are unique
to that variant, and (3) the number of variant-specific unique kmers that are actually identified in
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an NGS dataset. One caveat of this approach is that Equation S2 does not account for “unique”
kmers that are actually sequencing errors of similar, but not group-unique sequences.
KMER HASHING ALGORITHM
To this end, I devised an algorithm in which I would first consider every kmer in a set of reference
genomes to identify kmers that were only found in one strain/variant (as specified by the user).
This was initially done by first finding the union of all scaffolds within a group and then
incrementally setting each kmer hash table to the difference between itself and every other group’s
kmer hash table. This produced kmer hash tables for each group that only included kmers unique
to that group. By maintaining variables for all kmers considered and all kmers which were found
to be unique to each strain/variant, I would have derived solutions for both the first and second
variables, as specified above. I referred to this process as indexing, as it is performed using
reference sequences independent of any NGS data.

I then wrote a scanning algorithm to find the intersection between each group’s unique kmer hashes
and each read’s kmer hashes to count the number of unique kmers of each type in the NGS data.
While the Seqan3 kmer hashing function guarantees no collisions between distinct kmers, it does
so by using large amounts of memory for storing kmer hashes, especially when considering full
genomes. I did not realize the extent of the memory issue until after completing the indexer and
scanner, and finding that the program could not index the human genome with 100gb of RAM12.

KMER FM-INDEXING ALGORITHM

12

An effort was made to implement serialization of the hash_table to offload the large datasets from memory when
unnecessary. However, this was abandoned for the FM-indexer, which seemed like a more viable alternative.
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To decrease the memory usage, I decided to switch to an FM-indexing approach to search for
unique kmers (Ferragina & Manzini, 2000). A side benefit of this technique is that FM-indexing
does not have the same size limitations as kmer hashing. This is because the Seqan3 kmer hash
produces a unique hash for each unique kmer, implicitly preventing collisions but also yielding
large integers. Due to these mathematical limits, a 64bit computer can only hash kmers up to 32
nucleotides long.

However, FM-indexing is essentially a compressed data structure designed for efficient string
searches, regardless of kmer size. This significantly decreases the overhead involved in generating
genomic indices, and allows for much longer kmers to be used in the program.

Writing the SPeQ indexer using the FM-index search algorithm in Seqan3 was split into two
functions. The first method generates the FM-index file used for searching by iterating over all
reference sequences in both the forward and reverse complement orientation. This is currently by
far the most memory intensive segment of the entire program, using nearly 85GB of RAM to index
the complete human (GRCh38.p13) reference genome and ~45 additional viral genomes. Next, the
program re-iterates over the reference sequences to determine, for a specified kmer, (1) how many
total kmers are in each group, and (2) how many unique kmers are in each group13. I have
implemented this asynchronously through Seqan3 so that a distinct thread is spawned to handle IO
and pre-fetch a small set of sequences from file into memory to maximize concurrency without
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One caveat of this approach is that if a group includes multiple full genomes that are not identical, this could lead
to incorrect weighting on unique kmers. For instance, if 1 out of 5 genomes in a group has a specific unique kmer,
then the total kmers would be 5xgenome size but that specific kmer would only be accounted for once. If a sample
has that unique kmer (it is that specific genomic substrain), then that kmer will be counted many more times than it
would be weighted against by indexing. This may skew the result, depending on how often this phenomena occurs
for any given group of genomes.

[15]

much memory overhead. After counting the total and unique kmers per reference group, the SPeQ
program outputs a small kmer-specific “.dat” file to store the information necessary for the next
algorithm, scan, to compute the percentages of each strain in a sample. This “.dat” file includes
the kmer integer value, an ordered vector of the names of the groups, an ordered vector relating
the group names to the actual reference sequences, a vector of the unique kmers per group, and a
vector of the total kmers per group. The groupings information is necessary for keeping track of
whether a kmer in an NGS read is unique to a group. Additionally, the unique counts per group
divided by total kmers per group defines the PercentVariantUniqueKmers variable in Equation S3,
and is therefore instrumental in deriving the percent of each genome in an NGS sample.

The SPeQ scanner performs a similar task as the indexer, conducting a search of each kmer in each
read against the FM-index to determine whether any given kmer is unique to one of the defined
groups. I implemented two distinct methods for defining “Prob(NoSequencingErrors)” in Equation
S1: the first being kmer-specific probabilities defined by Phred scores and the second being an
overall error-rate applied to all kmers equally. These implementations would be equivalent if the
probabilities (Di) remained constant (Equation S5).

𝑃=

∑"!#$ 1/𝐷!
𝐴
=
𝐵∗𝐶∗𝐷
𝐵∗𝐶

Where 𝐷 = 𝐷! for 0 ≤ 𝑖 < 𝐴

(S5)

Where A is the number of perfectly sequenced variant-unique kmers, B is the percent of variantunique kmers, C is the total number of kmers, D is the probability of a kmer not having any errors,
and P is the percentage of a specific variant. The value derived from 𝐴/𝐷 or ∑"!#$ 1/𝐷! is an
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approximation of the expected number of unique kmers in a dataset after error correction. Dividing
this term by B and C, provides the estimated percentage of a specific variant in an NGS dataset14.

The prior of the percent of variant-unique kmers in a group of reference sequences is calculated
by the first step of speq-scan. However, this calculation assumes that kmer coverage is equivalent
over the entire genome. If this assumption does not hold, then the estimated percentage of each
variant will be incorrect. From my previous MCV analyses, it was clear that coverage varied
considerably over these genomes. To overcome this, we next iteratively calculate the experimental
PercentVariantUniqueKmers variable using the current PercentVariant estimate.

𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠 =

𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑈𝑛𝑖𝑞𝑢𝑒𝐾𝑚𝑒𝑟𝑠
𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑇𝑜𝑡𝑎𝑙𝐾𝑚𝑒𝑟𝑠

(S6)

As Equation S4 relied on deriving the number of variant-unique kmers, the numerator of Equation
S6 remains constant through this stage of the program, leaving only the denominator for
estimation. As an estimate of the percentage of each variant is now known, we will now reiterate
over the dataset and for each kmer, regardless of uniqueness, we will apply Equation S7.
&

ℎ! ∗ 𝑝! /𝑛!
𝑁𝑢𝑚𝑉𝑎𝑟𝑖𝑎𝑛𝑡𝑇𝑜𝑡𝑎𝑙𝐾𝑚𝑒𝑟𝑠 = ~ &
∑%#$ ℎ% ∗ 𝑝% /𝑛!

(S7)

!#$
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By identifying variant-unique kmers within reads, we can determine whether a given read contains two kmers that
are unique to different genotypes/strains. We mark these reads as potentially derived from recombination events in
the output, counting the number of reads associated with each variant set fusion. However, it is possible that these
ambiguities are the result of sequencing errors, non-consensus polymorphisms that appear unique to one variant, or a
read derived from an unincluded organism.
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Where G is the total number of variant groups being analyzed, h is the number of kmer hits for a
given variant group in the reads, p is the current estimate of the percentage of that variant in the
data, and n is the number of individual genomes in a variant group. The new estimate of the number
of total kmers for a given variant is then applied to Equation S6 to re-estimate the percentage of
each variant, and the process is iterated until the maximum difference between iterations is less
than a user-specified value.

1.4.2 Running SPeQ on MCV FFPE Illumina datasets
Unfortunately, due to time constraints, an exhaustive analysis of the MCV genomes was not
feasible within this thesis. SPeQ would ideally be run on an FM-indexed file containing all
genomes expected to be present in a metagenomic sample, but we ran the indexer on a file which
only contained the current assemblies/public MCV genomes. The problem with this approach is
that the assumptions and iterative nature of equation S7 are flawed in the absence of all highabundance expected organisms (e.g. human, phiX174). To overcome this issue, we used the SPeQ
output for the first iteration of equation S7 to prevent a skewed fit to the data. Additionally, we
subsampled 1% of the reads in the full datasets (H. Li, 2015). A preliminary comparison to
Bowtie2 demonstrated that this SPeQ method produces similar percentage abundance as the
fraction of reads mapped to each cassette #2 variant. The output of this SPeQ analysis is depicted
in Figure 3-3B,C.

1.4.3 Running SPeQ on MCV PacBio CCS datasets
The simple abstraction of the Seqan3 library and design of the SPeQ algorithm allows for the
analysis of both short and long-read sequencing runs. Given the intrinsically low accuracy of longread sequencing, CCS data is preferred for SPeQ for direct FM-index searching against consensus
genomes. Following CCS processing, the same FM-index as described in Appendix 1.4.2 was used
[18]

to estimate the abundances of different strains in the samples, as well as counting ambiguous reads
(i.e. fusion reads between two distinct MCV variants). To determine the percent of MCV reads
that were fusions, the total MCV-aligning reads was determined by using NGMLR (Sedlazeck et
al., 2018).

1.5 Structural variant detection in PacBio reads
1.5.1 De novo assembly of consensus MCV genomes
For maximal sensitivity in down-stream SV processing, we sought to assemble the whole genome
of each sample. Prior to publication, the complete genomes of these samples will be assembled
using both PacBio and Illumina reads. However, due to time constraints, we generated quick
assemblies using CCS PacBio reads with a default minimap2-miniasm pipeline followed by
iterative racon polishing. This produced genomes with 96-99% sequence similarity to published
MCV genomes.

1.5.2 NGMLR - Sniffles
Samples that produced complete MCV genomic assemblies were then each concatenated with the
GRCh38.p13 human reference genome and used to map all respective CCS reads using NGMLR
(Sedlazeck et al., 2018). Samtools was used to convert the NGMLR sam files to sorted bam files
(H. Li et al., 2009). Resulting bam files were then passed to Sniffles to produce a vcf file using
options (-s 1 -d 100 -n -1 -t 32) to report each structural variant at least 100bp apart which were
identified using the high quality CCS reads. This file contains both the intra-strain structural
variants and MCV:human recombination events.

[19]

Appendix 2: Wet-lab Methods
2.1 DNA protocols
2.1.1 Phenol chloroform extraction
From a 4mm punch/shave MCV lesion biopsy, I can recover approximately 20-40 µg of DNA by
this method.

Day 0:
Standard sample would be in 1mL of buffered saline (usually 10mM Tris pH 8.0, 150mM NaCl).
Samples can be incubated on ice for a couple hours prior to starting the overnight digestion, but
longer pre-incubations should be avoided to maintain DNA integrity.
1. Add 2µL of 0.5M EDTA
2. Add 50µL of 20% SDS
3. Add 5.4µL of 18mg/mL proteinase K
4. Incubate overnight at 37°C
5. Either proceed with the Day 1 protocol or freeze the digested sample at -80°C until able
to process
Day 1:
1. Thaw sample if frozen
2. Add 1 volume of saturated phenol
3. Vortex for 30 seconds to 1 minute
4. Centrifuge at 1000g for 10 minutes
5. Transfer aqueous fraction to a new tube
[20]

6. Repeat #1 - #5
7. Add 1 volume of 25:24:1 phenol:chloroform:isoamylalcohol
a. You can buy this premade
8. Vortex for 30 seconds to 1 minute
9. Centrifuge at 1000g for 20 minutes
10. Transfer aqueous layer to new tube
11. Add 1 volume of TE to phenol:chloroform:isoamyl layer and repeat #8-#10
12. Add 1 current TE volume of 24:1 chloroform:isoamylalcohol
13. Vortex 30 seconds to 1 minute
14. Centrifuge at 1000g for 10 minutes
15. Transfer aqueous layer carefully to new tube
16. Add 1:10 of TE volume of sodium acetate 3M pH 5.2 (mix by inversion)
17. Add 2.5 volumes 100% ethanol (mix by inversion)
18. Incubate overnight at -20°C
Day 2:
1. Centrifuge at 8000g for 30 minutes
2. Carefully decant liquid
3. Add 1 volume of 100% ethanol
4. Vortex to mix briefly
5. Centrifuge for 15 minutes at 8000g
6. Carefully decant liquid
7. Dry tube until no liquid is visible
8. Add TE to tube to reconstitute DNA
[21]

2.1.2 Southern blotting for detection of MCV structural variations
Traditional southern blotting techniques utilize radioactive probes for detection of specific
nucleotide sequences. However, we chose to utilize a biotin-streptavidin method instead.

Day 0: Restriction digestions
1) Digest ~50ug+ of DNA in appropriate restriction enzyme overnight at 37°C.
* All enzymes were high fidelity versions, purchased through NEB
Day 1: Running agarose gel
1) Set up a standard size agarose gel with TAE
2) Add an appropriate marker and the digested DNA to sample wells
3) Run the agarose gel at a very low voltage (~10V) overnight to achieve maximum
resolution
Day 2: Capillary transfer
1) Depurination: Cover the agarose gel with depurination solution and incubate with
shaking for 10 minutes at room temperature **exactly**
a. Depurination solution: 0.2M HCl (Add 16.4 of HCl stock to 1L ddH2O)
2) Denaturation: Rinse the gel in ddH2O three times with gentle shaking. Then add the
denaturation solution and incubate with shaking at room temperature for 15 minutes.
Replace with fresh denaturation solution and incubate again for 15 minutes.
a. Denaturation solution: 0.5M NaOH, 1.5M NaCl (20g NaOH pellets, 87.6g NaCl
in 1L of ddH2O)
3) Neutralization: Rinse the gel in ddH2O three times with gentle shaking. Then add the
neutralization solution and incubate with shaking at room temperature for 20 minutes.
[22]

a. Neutralization solution: 0.5M Tris pH 7.0, 1.5M NaCl (60.6g Tris base, 87.6g
NaCl, ~40mL HCl (pH 7.0 +/- 0.3), up to 1L of ddH2O)
Assemble transfer apparatus
20X SSC: 88.2g sodium citrate, 175.3g NaCl, 30µL HCl, pH 7.0-7.4, 1L ddH2O
1) For each membrane, cut 3 pieces of 3M filter paper and 1 positively charged nylon
membrane.
2) Hydrate each filter paper and membrane.
3) Add 20X SSC to Pyrex dish with empty pipette tip box on top
4) Place filter paper on pipette tip box, with edges in SSC
5) Use a 10mL pipette to roll out bubbles between filter paper layers
6) Flip the agarose gel so that the wells are facing down and put on the filter paper bridge
7) Seal edges of the gel/filter paper with plastic wrap
a. Make sure none of the lower filter paper is not covered by plastic wrap/gel or else
the buffer current may be short-circuited
8) Use a 10mL pipette to roll out bubbles between gel and filter paper layers
9) Put the pre-wet positively-charged nylon membrane on the gel
10) Use a 10mL pipette to roll out bubbles between membrane and gel
11) Put 3 layers of pre-wet 3M Whatman filter paper
12) Use a 10mL pipette to roll out bubbles between filter paper and membrane
13) Seal edges of filter paper with plastic wrap.
14) Use plastic wrap to seal the Pyrex container to prevent SSC evaporation
15) Put a stack of paper towels on the 3M filter paper (10cm+)
16) Place a weight on top of paper towels (stabilize the paper towel stack)
[23]

17) Incubate at room temperature overnight
Hybridization
1) Disassemble the transfer apparatus and keep the membrane wet
2) UV crosslink the DNA to the positively charged membrane (Stratalinker)
3) Set the hybridization rotating oven temperature to 42°C
4) Prewarm Ultrahyb buffer at 68°C
5) Put the membrane in a small hybridization tube. Add 5-10mL of Ultrahyb buffer, rotate
for 1 hour
6) Boil the probe for 5 minutes, quickly transfer to ice to maintain single-stranded probe
a. Probe is pregenerated using Biotin Decalabel DNA labeling kit
7) Add denatured probe to Ultrahyb solution (2-4µL / 5mL) rotating at 42°C overnight.
Washing
1) Wash the membrane twice with a 2x SSC, 0.1% SDS solution at room temperature for 10
minutes
2) Wash blots twice in a 0.5X-1X SSC, 0.1% SDS solution at 42°C for about 20 minutes per
wash
3) Use the Biotin Chromogenic detection kit according to the manufacturer’s instructions
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2.1.3 DNA extraction from FFPE samples
Two types of Qiagen kits were successfully used for DNA extraction from MCV tissue samples
for this study. The first being the “QIAamp DNA FFPE Tissue Kit” (Cat No./ID: 56404) and the
second being the “GeneRead DNA FFPE Kit” (Cat No./ID: 180134). From 6 tissue sections, I
would consistently acquire between 40ng and 800ng of DNA (as determined by Qubit), finding
this yield to be sufficient for Illumina sequencing.

2.2 Protein expression
The three major recombinant protein expression platforms used in the Fremont lab are (in order of
time commitment/difficulty) bacterial cell-based, mammalian cell-based, and insect cell-based.
Bacterial is often preferred for biochemical/structural studies not only due to the lower cost, but
also because of the often higher yield and limited heterogeneity, due to a lack of glycans or other
post-translational modifications (PTMs). However, in cases where bacterial expression systems do
not produce high yields of protein or where PTMs are functionally necessary, mammalian and
insect cell expression systems can often be rapidly deployed to produce sufficient protein. This
section is meant as a guideline for protocol development, as distinct recombinant proteins (or even
constructs of the same protein) require slightly different conditions for optimal growth/stability.

2.2.1 Bacterial soluble induction
Often, the simplest method of protein purification, this is a basic protocol for the expression and
purification of natively folded proteins from a BL21(DE3) E. coli. Recombinant expression of
proteins natively expressed in mammalian cells (human or virus) can often result in low yields.
This may be a result of a missing co-factor, post-translational modification, or other component.
Solubility tags such as small-ubiquitin modifier (SUMO) can aid in the stabilization of the
recombinant protein/domain, resulting in high expression yields. SUMO has the added benefit of
[25]

being efficiently cleavable by the protease Ulp-1, resulting in a “scarless” recombinant protein
following purification. Therefore, the His-SUMO tag was used extensively through this thesis
work to successfully purify full-length wild-type IL-1 family human cytokines and variants of a
domain of molluscum contagiosum virus MC133.
Transformation (heat shock)
1) Maintain 4°C: Add ~1ng15 of plasmid DNA (usually with a T7 promoter under the lac
operon) to a tube of 50-100µL of transformation-competent BL21 (DE3) E. coli.
2) Maintain 4°C: Quickly flick tube to homogenize the added DNA in the tube.
3) Incubate the tube on ice for 30 minutes
4) Incubate the tube in a 42°C water bath for 45 seconds
5) Incubate the tube on ice for 2 minutes
6) Sterile technique under flame: Add >9X volumes of SOC media
7) Sterile technique under flame: Transfer SOC/bacteria to falcon tube
8) Incubate with shaking at 37°C for 1 hour
a. Note: If the selection antibiotic is ampicillin/carbenicillin, the 1 hour incubation
step is unnecessary.
9) Sterile technique under flame: Add 5-50µL of SOC/bacteria to room-temperature agar
plate with appropriate selection antibiotic. Spread out equally on plate.
10) Incubate the plate at 37°C for 12-18 hours.
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The amount of DNA required for heat-shock transformation can be orders of magnitude lower depending on the
transformation efficiency of the competent cells.
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Pre-inoculation culture
1) Pick one colony from the selection plate of BL21 (DE3) cells and add to 25-50mL of LB
+ 1X selection antibiotic
2) Incubate with shaking at 37°C overnight (16-24 hours).
Protein Expression
1) Add 5mL of pre-inoculum after overnight incubation to 1L of sterile bacteria broth (e.g.
Luria Broth, Terrific Broth, etc) with respective antibiotic selection.
2) Incubate with shaking at 160-200rpm at 37°C until the OD600 reaches 0.5-0.7 (0.6
optimal)
3) Add 100µM final concentration of IPTG
4) Incubate for 4 hours at 37°C with shaking.
a. Note: Lowering the temperature post-induction to 16-18°C and incubating
overnight often increases yield of natively folded proteins. However, the flasks
should be removed from the shaker until the shaker has completely dropped to the
intended temperature.
5) Centrifuge bacteria at 4000g for 20 minutes at 4°C
6) Decant the supernatant
7) Resuspend cell pellet in a buffer such as: 20mM Tris pH 8.0, 300mM NaCl, 10mM βME,
10mM Imidazole, Protease Inhibitors.
8) Freeze at -80C or start purification protocol.
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2.2.2 Bacterial inclusion induction
Autoinduction solution (AIS): 2% glucose, 8% lactose, 24% glycerol
To simplify protein induction when the construct does not remain soluble within the bacteria
cultures (i.e. forms an inclusion body upon induction), we use a rapid yet simple platform to induce
protein expression with almost no user intervention, using a modified version of an established
autoinduction protocol (Studier, 2014). Following the Section 2.2.1 heat shock of BL21(DE3) E.
coli cells and overnight growth on antibiotic-selective plates, we simply add 1X antibiotic solution,
25mL of AIS, and one picked BL21(DE3) colony to 1L of sterile LB broth. This solution is then
incubated at 37°C for ~24 hours with shaking. After 24 hours, the cells are harvested by
centrifugation at 4000g and the pellet is stored at either -20°C or -80°C until future purification.
This method has worked to produce inclusion bodies for many constructs, and has yet to fail where
IPTG is known to successfully generate inclusion bodies.

2.2.3 Mammalian secreted transfection
Before starting this transfection protocol, grow 200mL of 293F cells to 1E6/mL through incubation
in a shaker at 37°C with 5-8% CO2. Maintain/grow cells as instructed by the manufacturer. We
primarily utilize a CMV promoter with a Kozak sequence upstream of the recombinant gene of
interest. Following verification of the construct sequence, it may also be necessary to first perform
a maxiprep of the plasmid prior to starting the transfection protocol. All manipulations of 293F
cells prior to harvest must be done under aseptic technique (See Appendix 2.5.1) with
Penicillin/Streptomycin +/- an antimycotic. Finally, make the Hyclone boost media prior to Day 2
of the protocol by adding 2% Hyclone boost to ExpiMedia and filter sterilize.
Day 0:
1) Add 250µg of plasmid DNA to 5mL of Opti-MEM, mix by inversion
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2) Add 375µL of Hype5 reagent to 5mL of Opti-MEM, mix by inversion
3) Incubate both solutions separately for 5 minutes
4) Add DNA solution to Hype5 solution, mix by inversion
5) Incubate for 15 minutes
6) Slowly add the DNA/Hype5 solution to 200mL of ExpiMedia 293F cells
7) Incubate with shaking overnight at 37°C
Day 1: Add 50mL of ExpiMedia
Day 2: Add 50mL of ExpiMedia + 10mL 2% Hyclone boost media
Day 3: Add 50mL of ExpiMedia + 20mL 2% Hyclone boost media

Day 3: Add 30mL of 2% Hyclone boost media
Day 4:
1) Harvest cells by centrifugation at 1000rpm for 10 minutes
2) Filter supernatant to remove excess cells/debris

2.2.4 Baculovirus secreted transduction
Attempts to solubly express MC80 with or without PLC components were unsuccessful in insect
cells. However, this does not detract from the potential power underlying this expression system.
Indeed, most of the human PLC components were found to be secreted using this system (See
Figure 2.6.3). Baculovirus systems are generally useful in the biochemical expression of proteins
that would could not otherwise be stably expressed in a physiologically relevant manner. However,
advances in baculovirus expression have recently seen the rise of faster and simpler protocols that
take shrink the expression timeline from months to weeks.
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This is due to (1) the use of the Oxford Expression Technologies flashBAC system for rapid
baculovirus recombination, (2) the use of an IRES-GFP on the vector to be recombined with the
gene of interest. The flashBAC system produces recombinant baculovirus directly within Sf9 cells,
to avoid bacterial bacmid cloning altogether. Since the vector contains a baculovirus ORF
necessary for replication, only the recombinant virus can expand. Additionally, the IRES-GFP
provides an extremely fast and simple readout of infected cells. We have found this feature useful
to verify/troubleshoot P0 recombination/expansion, to determine viral titers without plaque assays,
and to temporally assess cell infection percentages during protein expression.
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Vectors for flashBAC cloning

Figure S2-1: Modified pOET1 vectors for use with the flashBAC system to drive single or tandem expression of recombinant
proteins along with a GFP reporter.

The constructs that we use with the flashBAC system are derived from the pOET1 vector supplied
by Oxford Expression Technologies. However, we have heavily modified the region between the
two AcMNPV homologous recombination sequences to either express one or two gene(s) of
interest (pOET1.1 and pOET1.2, respectively). Like the standard pOET1 vector, pOET1.1 is
driven by the polyhedron promoter. However, 3’ of the polyhedron multiple cloning site and 5’ of
the SV40 polyA sequence, both pOET1.1 and pOET1.2 encode an EGFP sequence driven by the
RhPV IRES sequence (Wu, Wu, Chen, Chen, & Wang, 2007). The pOET1.2 vector additionally
contains a p10 promoter reverse complement to the polyhedron promoter, which is complemented
by a HSV tk polyA sequence.

Recombination of baculovirus using flashBAC
1) Grow Sf9 cells as per manufacturer’s instructions
2) Seed 12 well plate with 30% density Sf9 cells in 1 mL of Sf900 III
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3) Incubate for at least 1 hour to allow cells to attach and recover from manipulation.
4) Add 0.1µg of a flashBAC bacmid16 and 0.5µg of respective vector to FuGene 6/Sf900 III
media, mix by flicking.
5) Add 6µL of FuGene 6 to 100µL of Sf900 III media, mix by flicking.
6) Incubate for 15 minutes
7) Add Sf900 III/FuGene 6/DNA mixture to respective Sf9 12-well
8) Incubate overnight
9) Add 1 mL of fresh Sf900 III
10) Incubate for 4 additional days
a. Note 1: If an IRES-GFP construct is used, the propagation of the recombined
baculovirus through the Sf9 cells will be visible.
b. Note 2: If cells become confluent, we have continually observed a loss in the
baculovirus’s ability to spread between cells, dramatically limiting the P0 titer.
11) Harvest the supernatant and 0.45µm filter
12) Store baculovirus P0 stocks at 4°C in the dark and/or at -80°C
High-titer baculovirus stocks production and protein expression
We have had success with two distinct methods for generating sufficient baculovirus for protein
expression. The first is the standard manufacturer recommended protocol, involving the
amplification of the P0 stock using Sf9 cells, harvesting the supernatant, and checking the titer.
Standard passaging of the baculovirus stock is preferable to produce stocks to be stored and used
later. However, one caveat is we do not obtain consistently high titer baculovirus from this method.
The second is a simpler method involves titerless infected-cell preservation and scale-up to
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We mainly used the flashBAC GOLD system for our secreted protein work.
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generate baculovirus-infected insect cells (BIICs) (Wasilko et al., 2009). We have found this
method to often be preferable, as it is slightly faster than the standard baculovirus stock passaging,
and can be rapidly scaled up with little concern of whether titers will be sufficiently high, as the
previously infected cells will continue to secrete virus to infect the protein-expression cells. We
followed most aspects of these established protocols which are detailed elsewhere, except where
the IRES-GFP could be exploited as a control or to simplify the process.

For example, instead of conducting baculovirus plaque assays to determine viral titer, we simply
at serially-diluted baculovirus stocks to Sf9 or High Five cells plated at ~50% in appropriate media.
Following a 24 hour incubation, the primarily-infected cells will be in the late stages of the
baculovirus life-cycle, and would therefore be the only cells expressing GFP. Therefore, we can
derive the titer of each baculovirus stock within 1 day by counting GFP+ cells after the 24 hour
incubation. This method not only simplifies titer quantification, but allows for the user to assess
the effect of almost any change in the media or cell line on the titer/ability of the baculovirus to
infect cells.

2.3 Protein purification
Most modern methods of protein purification are based on chromatographic methods. While batch
chromatography is a popular means of rapidly producing multiple moderately pure recombinant
proteins, fast protein liquid chromatography systems such as the GE Healthcare AKTA system are
central to the consistent production of highly pure proteins suitable for biochemical/structural
studies. A general guideline in protein production is that three distinct purification methods should
be sufficient for producing highly pure proteins. This section will outline the most common
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chromatographic options used in academic labs. However, many protein-intrinsic factors must be
taken into account in protocol design, so the chosen purification methods may require varying
levels of optimization for some proteins-of-interest.

2.3.1 Affinity chromatography
Nickel chromatography is an extraordinary versatile, yet simple and inexpensive purification
method. However glutathione s-transferase and maltose binding proteins are other common
recombinant tags that are commonly used for affinity purification. However, nickel
chromatography is often the first step in a multicolumn protein purification strategy.
1) If recombinant protein is to be extracted from whole cells, first lyse the cells with protease
inhibitors and centrifuge/filter the lysate to clear cell debris
2) If recombinant protein is secreted from cells, concentrate and buffer exchange the
supernatant to remove excess media components which may impact affinity binding
3) Running in batch, add 3-5mL of nickel resin bed to a gravity column
4) Wash the column with 5-10 column volumes (CV) of wash buffer
a. Standard Ni wash buffer: 20mM Tris pH 8.0, 300mM NaCl, 10mM Imidazole
5) Load cleared lysate onto column
6) Wash the column with 10 CV of wash buffer
7) Elute with 2-3 column volumes of nickel elution buffer
a. Standard Ni elution buffer: 20mM Tris pH 8.0, 300mM NaCl, 300mM Imidazole
b. Note: Do not leave protein in high concentration imidazole buffers for extended
periods of time.
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2.3.2 Ion exchange chromatography
Ion exchange chromatography can be subdivided into cation (S) exchange and anion (Q) exchange
chromatography. As the names suggest, S columns bind to positively-charged molecules and viceversa. In order to determine which is more appropriate for any given protein, one should first
determine the estimated isoelectric point of the protein. As an example, a high isoelectric point
(e.g. 10) would suggest that the protein is more likely to be positively charged under physiologic
conditions (e.g. pH 7.4). Therefore, a high isoelectric point suggests that the protein would bind to
S columns. To further drive a positive charge, the pH of the buffers used for cation exchange
chromatography are often lower than physiologic (pH 6). The opposite reasoning applied to anion
exchange chromatography. However, cation exchange chromatography is often a preferable
method if possible, especially for the purification of recombinant proteins expressed in bacteria.
Bacteria do not contain a nuclear membrane and therefore encode very few net-positively charged
proteins, so as not to non-specifically bind negatively-charged DNA. This generally results in
higher purity of bacterially-expressed recombinant proteins purified on S columns relative to Q
columns.

Unlike affinity columns, ion exchange columns are not recommended to be run in batch, as the
standard protocol involves a continuous gradient between two buffers, slowly increasing the salt
concentration. The salt acts as a charged competitor for the resin, which dissociates bound proteins
once a certain threshold is met. Therefore, it is recommended to load an ion exchange column with
as little salt in the buffer as possible (0-10mM). Regardless of type of ion exchange and protein
assessed, most proteins elute at a NaCl concentration less than 500mM. However, this elution is
rarely 100% efficient, and some protein remains on the column post-elution.
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If the same column is to be used for the purification of different proteins, regular cleaning is
recommended. Sodium hydroxide is often recommended by GE to clean columns as it does not
react with the resin but leads to the autocleavage of peptide bonds, degrading the protein(s) stuck
on the column. Another highly effective cleaning method involves injecting 6M guanidinium
hydrochloride with 10mM beta-mercaptoethanol onto the ion exchange column. This denatures
the contaminating proteins, elutes them as guanidinium has a high ionic strength, and reduces any
disulfide bonds. The reduction of disulfide bonds is often key, as dense intermolecular disulfide
networks can create a protein matrix in the resin that is physically stuck.

2.3.3 Size exclusion chromatography
Often the final polishing step of a purification, size exclusion chromatography is particularly
advantageous as being both a purification method and efficient buffer exchange method. While
many resin sizes exist, the two predominant size exclusion chromatography column types are S75
and S200, referring to the theoretical maximum molecular weight (kDa) that can be separated by
the column. Unlike affinity and ion exchange methods, there is no distinct elution buffer. Instead,
macromolecules are separated by whether they are able to interact with the porous resin. Smaller
proteins will fit in the resin pores, which increase the migration-time through the column. Large
proteins do not fit in the resin, migrate faster through a size exclusion column and are thus collected
in earlier fractions by the system. Given this, the input volume of sample must be limited for proper
separation of macromolecules by this method (consult manufacturer recommendations for
individual columns).
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2.4 Protein interaction assays
There are many biochemical assays which have been developed to assess protein interactions. In
the interest of space, this section is limited to the practical protocols used during this thesis work
studying MCV17.

2.4.1 Co-IP WB
Co-immunoprecipitation (adherent cells)
TBS/PBS-IAA:
20mM iodoacetamide
…in 1X either Tris or phosphate buffered saline
Lysing buffer18:
20mM iodoacetamide
100mM PMSF or cOmplete protease inhibitor
1% digitonin (for co-IP) or 1% NP-40 (for IP)19
…in 1X either Tris or phosphate buffered saline
Washing buffer20:
20mM iodoacetamide
1% digitonin (for co-IP) or 1% NP-40 (for IP)
…in 1X either Tris or phosphate buffered saline
1) Decant media into separate 50mL conicals.
a. Note: This will be used to stop the trypsin digestions
2) Add 0.05% trypsin-EDTA (T25: 2mL; T75: 4mL)
3) Suspend the cells by incubation for ~10 minutes
4) Homogenize cells fully prior to stopping

17

Isothermal calorimetry (ITC) was a major component of my early graduate studies (Leung et al., 2015), but this
assay was not been included in Appendix 2.4 due to the fact that ITC was not directly used to assess the major MCV
questions of this thesis. Additionally, crystallography was heavily employed through this work, but has not been
included as the crystallographic studies have not yet produced structural insight into protein-protein interactions
relevant to this thesis work.
18
To save time: use the TBS/PBS-IAA buffer as the base for making lysing/washing buffers.
19
Add iodoacetamide to buffered saline first, after IAA dissolves add the digitonin to hasten homogenization.
20
To save time, washing buffer can simply be a 1:10 dilution of the lysis buffer in TBS/PBS-IAA.
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a. Increases lysis efficiency
5) Transfer trypsin-EDTA cell suspension to respective 50mL conicals
**Cells should be placed on ice (4°C) for all further steps
6) Centrifuge 50mL conicals at 1500rpm for 3 minutes
7) Aspirate supernatant with sterile tip (vacuum or pipette)
8) Wash cells with 4-5mL of PBS
9) Centrifuge at 1500rpm for 4 minutes
10) Decant PBS
11) Wash cells with 4-5mL of PBS + IAA
12) Centrifuge at 1500rpm for 4 minutes
13) Decant PBS + IAA
a. Note: Cell pellets can be frozen at -80°C after this step for storage
14) Add 1.2mL of lysis buffer and transfer cells to 1.5mL Eppendorf
a. This is often performed in two steps (900µL transfer and 300µL to pick up
remaining material in the tube)
15) Incubate on ice for 1 hour
a. Vortex every 10 minutes to homogenize
16) Wash ProteinA resin 3x with PBS (~15µL of resin bed volume/Co-IP)
17) Resuspend ProteinA resin in lysis buffer
18) Add ~15µL of resin bed volume (highly homogenized) to a fresh Eppendorf tube for each
sample.
a. Verify equal bed volume across all co-IP tubes
19) Add 1-4µL of co-IP antibody to each tube
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a. Note: If using pre-conjugated resin instead of ProteinA, skip this step.
20) Centrifuge lysate for 5 minutes at 14000rpm, 4°C.
21) Perform a BCA analysis on cleared lysates
a. No standard is necessary
22) Add equivalent amounts of each cleared lysate sample to the respective resin:Ab.
23) Tumble on rocker for 1 hour at 4°C.
24) Centrifuge for 1 minute at 14000rpm, 4°C.
25) Aspirate supernatant
26) Wash with 1mL of wash buffer
27) Repeat steps 24-26 x4 times
28) Elute with either 1X LDS or respective competitive peptide (e.g. 300µM FLAG peptide)
29) Use immediately or store frozen at -20°C
Western blot
Transfer buffer: 50mL 20X Transfer Buffer, 100mL Methanol, 850mL ddH2O
1) Remove bubbles from 6 pads soaked in 1X transfer buffer by scraping submerged pads
2) Rehydrate PVDF membrane in 100% methanol, replace methanol with transfer buffer
3) Add 1 filter paper slightly larger than membrane on top of membrane in transfer buffer
4) Place 3 soaked pads on bottom of WB apparatus
5) Lift polyacrylamide gel out of cartridge with soaked filter paper
6) Place gel-side up on top of 3 soaked pads
7) Place rehydrated PVDF membrane on top of gel
8) Soak another filter paper in transfer buffer
9) Remove bubbles between membrane and gel delicately with a roller
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10) Place second filter paper on top of PVDF membrane
11) Remove bubbles between filter paper and membrane delicately with a roller
12) Place 3 soaked pads on top of second filter paper
13) Add top component of WB apparatus
14) After squeezing apparatus shut, do not release until securely fastened in gel box
15) Add transfer buffer to central WB apparatus to maintain wetness of gel and membrane
a. If leaking, you can replace buffer other time during the run
16) Transfer proteins to membrane for 65 minutes at 30V
17) Carefully transfer membrane from apparatus to blocking buffer (e.g. 10% milk in PBST)
18) Block with gentle shaking for 1 hour
19) Replace blocking buffer with diluted primary antibody (often diluted into blocking
buffer)
20) Cover and block the membrane overnight
21) Wash the membrane three times with distilled water
22) Wash the membrane three times with PBST
23) Add diluted secondary antibody (often in PBST)
24) Incubate for 30 minutes to 1 hour
25) Wash the membrane three times with distilled water
26) Wash the membrane three times with PBST
27) Add desired substrate (e.g. ECL) and incubate/expose as directed by manufacturer

2.4.2 Enzyme-linked immunosorbent assay (ELISA)
Coating
1) Dilution protein(s) of interest to ~1-2ug/mL in 50mM Na2CO3.
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2) Aliquot 70µL-100µL of diluents into each well of 96-well Maxisorp clear plates
3) Incubate overnight at 4°C
Blocking
1) Aspirate the spent coating buffer from each well of the 96 well plates
2) Add 200µL of coating buffer to each well
a. Note: Coating buffer may change depending on protein non-specific binding, but
one example would be PBS + 0.05% Tween2021 + 1% BSA + 4% milk + 0.02%
sodium azide.
3) Incubate overnight at 4°C
a. Note: Incubation of blocking buffer for 1 hour at 37°C is a viable alternative to
achieve near-complete blocking of nonspecific regions of the plate.
Core assay
1) Perform the necessary serial dilution of primary antibody / serum in a 96 well
polypropylene plate. Make sure to have extra sample per well for transfer to ELISA plate.
2) Aspirate the blocking buffer from the wells of the ELISA plate.
3) Aliquot serial-diluted samples (from low concentration to high concentration) from
polypropylene plate to coated Maxisorp plate.
a. Add less sample than the level blocked to prevent high background signals.
4) Incubate at room temperature for 1 hour
a. Longer incubations do not usually impact signal
5) Wash plates three times with PBST
21

Once Tween20 is added to [EF]LISA plates, the plates should be used within a week to avoid de-adsorption of the
coated proteins, which would decrease the signal generated by the ELISA. If longer-term storage is required, consider
preblocking in a nonperishable buffer without detergent (e.g. PBS + 1% BSA + 0.02% azide). Block in complete
blocking buffer overnight at 4°C or for 1 hour at 37°C before use.
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6) Add secondary antibody diluted in PBST to all wells
7) Incubate for 30 minutes to 1 hour
8) Wash plates three times with PBST
9) Add 50-100µL of room temperature TMB substrate
10) Incubate for 15 minutes
11) Add an equal volume of 2M H2SO4 and immediately read absorbance 450nm signal

2.4.3 Fluorescence-linked immunosorbent assay (FLISA)
1) Coat black opaque Maxisorp plates with neutravidin (2ug/mL in 50mM NaCO3 pH 9.6)22.
2) Incubate plates overnight at 4°C.
3) Aspirate coating solution from wells and replace with blocking buffer.
a. 1X PBST + 1% BSA + 0.02% NaN3 is often sufficient for assessing purified
proteins
4) Incubate plates overnight at 4°C.
5) Aspirate blocking buffer.
6) Add biotinylated analyte and fluorescent ligand at appropriate concentrations depending
on expected interaction Kd.
a. See Appendix 4 for information (e.g. 2nM analyte and serial dilution ligand)
b. Using detergent can reduce background signal at this point (PBST+BSA)
7) Incubate for 1-4 hours at room temperature
8) Wash 3X with PBS, no detergent23. Last wash leave PBS in wells.

22

ELISAs generally produce high signals following simple direct coating of plates with antigens. However, this same
process produces unacceptably low fluorescent signals in a FLISA. Therefore, neutravidin coating is preferable. This
additionally provides a means of potentially quantifying the binding constants of the interactions being assessed (See
Appendix 4).
23
Detergent will obscure the fluorescent signal detected by the reader
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9) Read fluorescence signal(s) using appropriate plate reader 24.

2.4.4 Biolayer interferometry
Running buffer: 10mM HEPES pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% v/v Surfactant P20,
1% BSA
1) Streptavidin-coated Octet tips are preferable for simple, consistent quantification.
2) Pre-biotinylate analyte protein either non-specifically (NHS-chemistry) or specifically
(BirA ligase). Remove excess biotin (e.g. Zeba column) prior to starting BLI assay.
3) Column 1, 3, and 5 are often reserved for running buffer
4) Add ~20ug/mL biotinylated analyte to column 2 in running buffer
a. Note: Large buffer mismatches will result in baseline shifts during the assay, so
try to start with a high concentration of analyte so as to not severely dilute
running buffer to produce the 20ug/mL solution.
5) Add serially diluted concentrations of ligand which span the estimated Kd to be measured.
a. Note: Same as step 4, try not to alter running buffer too much.
6) Preincubate the streptavidin tips in running buffer for 10 minutes prior to start of assay.
7) Conduct the BLI experiment on the Octet instrument with appropriate association and
dissociation times for the system, iterating down the columns of the plate with at least 30
seconds per running buffer baseline.
a. Optimal association times are determined by the curves collectively reaching
steady-state (level) response units.
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This method provides a potential means of obtaining multiple signals from a single well if multiple ligands (or
secondary antibodies) conjugated to different fluorophores are added to a given well and fluorescence signals are
cross-compensated.
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b. Optimal dissociation times are determined by the loss of more than half of the
response unit signal gained during association.
c. Total assay time is limited to ~ 1 hour due to expected evaporation during the
experiment which would effect [ligand] and therefore shift the kinetic curves off
the expected steady-state.

2.5 Cell culture protocols
2.5.1 General aseptic technique
All manipulation of live cells should be conducted under a biosafety cabinet (BSC) which has been
running for at least 10 minutes prior to starting work. Many aspects of aseptic technique stem from
basic hygiene, along with liberal usage of 70% ethanol on all objects entering the BSC.

However, maintaining cell cultures without contamination largely stems from the premise of
laminar flow. BSC’s maintain sterility through a persistent flow of air downward which has just
been HEPA-filtered. But this air only remains sterile so long as it does not come in contact with
anything unsterile (such as your arm). Therefore one should never pass their hands, arms, or
anything else that would not be completely sterile over something else that is sterile under the
hood.

2.5.2 Stable recombinant protein expression in murine cells
The Platinum-E (plat-E) cell line has been designed to be an highly efficient means of producing
safe, recombinant retroviruses that specifically infect murine cells (Morita, Kojima, & Kitamura,
2000). Methodologically, production of lentiviruses in this system simply involves the transient
transfection of a single appropriate plasmid (e.g. pMXs) containing the gene of interest with the
option of an IRES to also express a selection marker (e.g. GFP) flanked by two long terminal
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repeat retrotransposons (LTR). Packaging of replication-deficient retroviruses occurs entirely
within the plat-E cells, which are co-expressing the Env and Gag ORFs not encoded by the pMXs
(or related) plasmid.
1) Plat-E cells are cultured in RPMI-1640 supplemented with 10% FBS and 1X
Penicillin/Streptomycin (R10).
2) Plat-E cells to be used are plated into a 24-well plate at a density between 50% and 70%
and incubated in 500µL-1mL of R10 for at least 1 hour at 37°C with 5% CO2 to allow for
cells to attach to plate.
3) Using aseptic technique: 3µL of FuGene 6 is added to 50uL of room temperature OptiMEM
mixed by flicking, and incubated for 5 minutes
4) 1µg of respective plasmid encoding the gene of interest is added to the FuGene
6/OptiMEM, mixed by flicking, and incubated for 15 minutes (no more than 45 minutes).
5) The FuGene 6/OptiMEM/plasmid mixture is added drop-wise to a 24-well with plat-E
cells.
6) Cells are incubated in transfection reagent overnight at 37°C, 5% CO2
7) The media of each 12 well is replaced with fresh R10 and cells are incubated for an
additional 1-3 days. If a plasmid with an IRES-GFP is used, transfection efficiencies can
be assessed by expression of GFP.
8) Supernatant virus stocks are harvested and 0.45µm filtered under sterile technique.
a. Excess virus stock can be frozen at -80°C for future use.
9) Viral supernatants are then added to subconfluent murine cells and incubated for 1-2
days25.
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Polybrene can be used to enhance transduction efficiencies of packaged retroviruses, but is not always necessary
to achieve moderate transduction efficiencies up to 30%.
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10) Murine cells are subsequently subcultured for 2+ days to allow for stable GFP expression.
11) The GFP+ murine cells are bulk-sorted to obtain a 100% GFP+ (and gene-of-interest+)
cells.
12) An aliquot of each sorted cell line should be frozen to maintain a low-passage stock.

2.5.3 Stable recombinant protein expression in human cells
This protocol is highly similar to Appendix 2.5.2, aside from the listed differences:
Table S2-1: Differences between the production of stable murine and human cell lines expressing recombinant proteins.

Packaging cell line
Plasmid(s) transfected
Virus generated
Cells infectable

2.5.2
Plat-E
pMXs
Retrovirus
Murine

2.5.3
293T
Gag, Env, pMXs (2:1:3)
Lentivirus
Human+

2.5.4 Flow cytometry/sorting
PBS+ buffer: 1X PBS, 1% BSA, 0.1% NaN3
1) Resuspend cells in PBS+ at about 2.5E6 cells/mL
2) Add 200µL/well (about 5E5 cells) in a 96-well plate
3) Spin at 200g, 4°C for 2 minutes to pellet the cells
4) Aspirate the supernatant in each well with a sterile tip under vacuum
5) Add appropriate concentration of primary antibody to saturate binding (25-50µL of
volume / well)
a. If using multiple primary antibodies with distinct fluors, remember to include
appropriate compensation controls: (e.g. negative, single color, FMO).
6) Mix well by vortexing
7) Incubate on ice for 30 minutes in dark
a. Mix intermittently during incubation to homogenize antibody binding
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8) Wash 2X with 200µL PBS+ (200g, 4°C for 2 minutes)
9) Aspirate supernatant in each well
10) Add 25µL of diluted secondary antibody (e.g. 1:100 PE-Goat anti-Mouse IgG) to each
well
a. If using direct-fluor conjugates, this step is unnecessary
11) Vortex to mix
12) Incubate on ice for 30 minutes in dark
13) Wash 2 times with 200µL PBS+ (200g, 4°C for 2 minutes)
14) Resuspend cell pellet in 200µL PBS+, transfer to appropriate tube for flow
cytometry/sorting
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Appendix 3: COVID-19 antibody response
3.1 Significance
The speed of the COVID-19 pandemic mandated a rapid and robust scientific response to devise
a viable health strategy. While therapeutic drugs (small molecules and monoclonal antibodies) and
an effective vaccine would each take considerable time and money to complete, convalescent
serum transfer provides a quick and relatively inexpensive method to temporarily pass
immunologic memory from a surviving patient to others. Given the breadth of the pandemic, this
seemed like a favorable option to deploy to hospitals nationwide. In addition to convalescent serum
therapy, knowing the serological state of individuals would provide a means of determining their
risk (e.g. amount of PPE for individual health care workers, or whether someone who was infected
and has recovered could be permitted to go back to work). However, this would require a reliable
serological test to determine which convalescent patients would be good candidates for plasma
donation and subsequent transfusion into the necessary patients.

Given the understanding of the coronavirus seroresponse prior to the pandemic, this need lead to
the rapid development of a monoantigenic ELISA which could quantify the serum titer against the
SARS-CoV-2 spike protein (Amanat et al., 2020). This test became widely and quickly adopted
by the health care field to provide a preliminary assessment of anti-COVID-19 serum titers.
However, concerns began to mount that the test was not completely reliable. Indeed, in our hands,
using the mammalian-expressed receptor binding domain (RBD) of the COVID-19 spike protein
produced moderate background signals against some otherwise negative serum controls. We
sought to develop a set of distinct COVID-19 recombinant proteins that each produced a
seroresponse, so that the collective ELISA results would provide a more definitive determination
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of seroconversion and breadth of anti-SARS-CoV-2 responses. This test would be of particular
use, as it was not clear what antigenic responses correlated with physiological protection from
disease, which would be the pivotal aim for determining if an individual has developed a protective
memory response for themselves as well as for convalescent serum transfer.

3.2 ELISA protocol development
3.2.2 Initial antigen panel selection
The Fremont lab is particularly adept at rapidly cloning and recombinantly purifying proteins of
interest. Indeed, as I conducted these ELISA experiments, multiple lab members were
simultaneously purifying a variety of relevant coronavirus antigens for the follow-up assays.
Additionally, the structural biology community shipped multiple COVID-19 proteins to our lab
for our initial screening. It was clear from the beginning that our unique contribution to the
diagnostic community would be through development of a second-generation serological test to
assess multiple viral antigens, which may provide important correlations with disease progression
and/or protection.

Most nonstructural COVID-19 proteins that we were able to test yielded little to no signal by
ELISA, even at high serum concentrations. We instead found that COVID-19-patient IgG can react
strongly with recombinant SARS2 spike protein, nucleoprotein, and ORF8 (Table S3-1, Table S32).
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Table S3-1: Patient seroresponses to viral antigens (panel #1). An ELISA serial dilution of patient serum against 12 viral
antigens. DHF5 and DHF7 were independent negative controls for the assay, assessing the variability in background. Background
signals are likely a result of infection/vaccination history. DHF8 was the first RT-PCR-confirmed COVID-19+ serum sample
assessed in this study. Three influenza hemagglutinin positive controls were assessed for relative reactivity to patient sera. BSA
and Chk P62E1 were assessed as negative controls.
WU
Spike

mRBD

bRBD

NPRNA

InBios
Spike

BSA

ORF7a
S1

ORF7a
S2

HA Col

HA
Phu

HA Mic

Chk
P62E1

1

2

3

4

5

6

7

8

9

10

11

12

A

0.183

1.37

0.634

0.636

0.375

0.112

0.652

0.831

2.951

2.644

2.7

0.339

1:80

B

0.137

0.934

0.494

0.402

0.204

0.081

0.438

0.442

2.585

2.871

2.631

0.193

1:160

C

0.102

0.646

0.353

0.23

0.124

0.067

0.284

0.323

2.512

2.304

2.384

0.156

1:320

D

0.077

0.338

0.262

0.161

0.091

0.059

0.165

0.195

1.877

1.837

2.353

0.097

1:640

E

0.071

0.208

0.185

0.109

0.073

0.052

0.113

0.135

2.003

2.011

2.058

0.085

1:1280

F

0.058

0.117

0.135

0.081

0.061

0.048

0.081

0.092

1.484

1.481

1.934

0.068

1:2560

G

0.055

0.083

0.093

0.074

0.06

0.049

0.066

0.074

1.025

1.056

1.514

0.062

1:5120

H

0.055

0.071

0.078

0.076

0.065

0.052

0.065

0.062

0.68

0.614

1.323

0.057

1:10240

1

2

3

4

5

6

7

8

9

10

11

12

A

0.226

0.228

0.789

0.512

0.44

0.155

1.77

1.994

2.61

2.449

2.413

1.937

1:80

B

0.168

0.157

0.522

0.315

0.274

0.109

1.309

1.519

2.045

2.505

2.476

1.504

1:160

C

0.115

0.112

0.375

0.2

0.175

0.083

0.977

1.253

2.596

2.65

2.62

1.141

1:320

D

0.087

0.086

0.262

0.136

0.11

0.067

0.558

0.759

1.808

2.11

1.998

0.683

1:640

E

0.073

0.071

0.179

0.095

0.082

0.058

0.332

0.42

1.723

1.79

1.697

0.464

1:1280

F

0.063

0.061

0.126

0.077

0.065

0.051

0.211

0.274

1.267

1.547

1.491

0.255

1:2560

G

0.058

0.057

0.091

0.067

0.06

0.05

0.133

0.18

1.016

1.042

1.031

0.172

1:5120

H

0.057

0.056

0.073

0.07

0.057

0.051

0.091

0.116

0.537

0.549

0.687

0.108

1:10240

1

2

3

4

5

6

7

8

9

10

11

12

A

2.401

2.073

1.987

2.231

2.218

0.163

1.306

1.515

1.912

2.149

2.243

0.899

1:80

B

2.308

1.994

2.007

2.188

2.112

0.111

1.085

1.217

1.868

1.982

1.854

0.487

1:160

C

2.31

2.027

2.109

2.101

2.22

0.082

0.639

0.751

1.739

1.886

1.608

0.279

1:320

D

2.043

1.893

1.702

2.006

2.129

0.067

0.374

0.438

1.468

1.783

1.423

0.175

1:640

E

2.019

1.623

1.639

1.757

2.12

0.057

0.233

0.268

1.02

1.685

1.034

0.125

1:1280

F

1.965

1.388

1.445

1.491

2.026

0.052

0.132

0.144

0.626

1.576

0.728

0.089

1:2560

G

1.692

0.883

0.884

1.217

1.767

0.051

0.091

0.107

0.384

1.136

0.458

0.07

1:5120

H

1.483

0.603

0.774

1.136

1.94

0.053

0.083

0.086

0.261

0.821

0.291

0.062

1:10240

DHF5

DHF7

DHF8
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Table S3-2: Patient seroresponses to viral antigens (panel #2). An ELISA serial dilution panel run with 12 antigens against a
signal serum sample per plate. DHF5 is a representative negative control serum sample. DHF11 and DHF12 were serum samples
derived from COVID-19-infected individuals. Serum samples were run as a serial dilution from 1:80 to 1:10240 at 1:1 dilutions
down the plate. Influenza hemagglutinin (HA Colorado) response was used as a positive control and BSA/Chk P62E1 were used
as tandem negative controls.
NSP1

NSP8

NSP9

NSP15

ADRP

PLP

RBD

NSP7+8

HA Col

DHF5

1

2

3

4

5

6

7

8

9

10

11

12

A

0.168

0.174

0.137

0.132

0.225

0.177

0.079

0.28

3.139

0.159

0.712

0.439

1:80

B

0.147

0.169

0.115

0.152

0.155

0.152

0.061

0.318

2.92

0.155

0.822

0.445

1:160

C

0.087

0.121

0.093

0.112

0.136

0.121

0.053

0.345

3.017

0.152

0.801

0.283

1:320

D

0.071

0.092

0.071

0.084

0.1

0.088

0.05

0.258

2.603

0.111

0.562

0.171

1:640

E

0.068

0.07

0.063

0.066

0.072

0.066

0.046

0.175

2.929

0.082

0.35

0.109

1:1280

F

0.065

0.06

0.056

0.056

0.058

0.054

0.047

0.112

2.482

0.063

0.228

0.079

1:2560

G

0.053

0.055

0.05

0.054

0.056

0.058

0.048

0.079

2.193

0.055

0.144

0.064

1:5120

H

0.073

0.054

0.058

0.075

0.078

0.104

0.084

0.105

1.652

0.071

0.104

0.066

1:10240

DHF11

1

2

3

4

5

6

7

8

9

10

11

12

A

0.174

0.174

0.11

0.164

0.135

0.27

0.078

0.164

2.723

0.124

2.262

2.07

1:80

B

0.117

0.125

0.099

0.11

0.098

0.208

0.066

0.11

2.552

0.094

1.894

1.436

1:160

C

0.088

0.096

0.081

0.082

0.077

0.131

0.052

0.091

2.802

0.075

1.341

0.93

1:320

D

0.065

0.072

0.065

0.064

0.063

0.087

0.049

0.069

2.446

0.062

0.786

0.583

1:640

E

0.058

0.059

0.054

0.055

0.054

0.069

0.047

0.058

2.263

0.052

0.473

0.358

1:1280

F

0.052

0.052

0.056

0.05

0.051

0.058

0.125

0.059

1.779

0.05

0.279

0.217

1:2560

G

0.05

0.051

0.048

0.05

0.05

0.054

0.048

0.052

1.51

0.049

0.174

0.135

1:5120

H

0.049

0.051

0.054

0.063

0.056

0.06

0.056

0.055

1.168

0.055

0.12

0.101

1:10240

DHF12

1

2

3

4

5

6

7

8

9

10

11

12

A

0.574

0.541

0.223

0.295

0.275

0.644

0.087

0.545

2.852

2.582

2.943

2.921

1:80

B

0.401

0.469

0.244

0.312

0.272

0.585

0.069

0.569

2.649

2.488

2.735

2.438

1:160

C

0.266

0.336

0.192

0.255

0.237

0.486

0.06

0.481

2.714

2.572

2.578

2.322

1:320

D

0.161

0.201

0.128

0.17

0.17

0.256

0.055

0.304

2.499

2.593

2.429

2.236

1:640

E

0.108

0.129

0.088

0.109

0.116

0.176

0.052

0.191

2.155

2.159

2.586

1.842

1:1280

F

0.09

0.094

0.071

0.081

0.084

0.112

0.052

0.125

1.787

1.758

1.831

1.262

1:2560

G

0.078

0.078

0.059

0.067

0.068

0.083

0.052

0.087

1.556

1.089

1.547

0.943

1:5120

H

0.079

0.074

0.06

0.07

0.07

0.077

0.059

0.076

1.24

0.839

1.176

0.593

1:10240
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S2 bRBD S1 bRBD

M bRBD

3.2.3 Optimized blocking
Our initial ELISA experiments yielded promising data regarding our ability to capture the breadth
of the seroresponse. However, it was not clear whether the interspersed reactivity of negative
controls to COVID-19 antigens was a result of cross-reactivity from previous similar infections or
general non-specific interactions. Therefore, we next compared the background signals generated
by various blocking reagents, maintaining patient serum concentrations at 1:80 (Table S3-3). A
1% BSA + 5% milk solution was selected as the optimal reagent from the panel due to the low
BSA/p62E1 (negative) signal and high HA (positive) signal.

Table S3-3: Screen of ELISA blocking reagent identifies 1% BSA + 5% milk as optimal. A panel of COVID-19 antigens and
control antigens were coated on Maxisorp plates and stored in PBS + 1% BSA + 0.02% azide prior to use. Plates were then blocked
in respective blocking buffers for 1hr+ and previously characterized patient serum was added to the plate in respective blocking
buffer at 1:80 dilution. DHF5 and DHF7 are unconfirmed negative patient samples.
HZ trimer

HZ mam
RBD

SARS2
Ecoli
RBD

NW-NP

InBios
Trimer

BSA

SARS2
ORF7a

SARS1
ORF7a

HA
colorado

HA
phuket

HA michi

Chk
p62E1

1

2

3

4

5

6

7

8

9

10

11

12

A

0.425

2.441

1.463

1.743

0.797

0.16

1.517

1.798

3.051

3.053

2.867

0.921

B

0.277

2.025

0.608

1.034

0.46

0.133

0.726

1.291

2.985

2.775

2.965

0.295

DHF5

1% BSA
5% milk
1% BSA + 5%
milk
1% BSA + 1%
PEG3350

C

0.178

2.438

0.501

0.957

0.387

0.07

0.683

0.714

2.915

2.779

3.186

0.26

D

0.513

2.491

1.599

1.446

0.975

0.238

1.658

1.832

2.865

2.873

2.981

1.23

E

0.416

0.762

1.189

1.248

0.686

0.648

1.44

1.349

2.692

2.57

2.741

0.771

LICOR
LICOR + 0.05%
Tween20

F

0.572

0.964

1.26

1.289

0.96

0.542

1.059

1.027

2.698

2.765

2.677

0.728

G

0.337

1.669

1.147

1.283

0.503

0.169

1.335

1.557

2.693

2.739

2.489

0.908

10% FBS
10% FBS + 5%
milk

H

0.328

2.116

0.44

1.067

0.496

0.127

0.937

1.226

3.109

3.253

3.08

0.411

1

2

3

4

5

6

7

8

9

10

11

12

A

0.551

0.448

1.406

1.093

0.998

0.298

2.204

2.513

2.836

2.628

2.549

2.508

B

0.333

0.147

0.436

0.68

0.585

0.233

2.438

2.408

2.578

2.522

2.783

0.953

DHF7

1% BSA
5% milk
1% BSA + 5%
milk
1% BSA + 1%
PEG3350

C

0.18

0.116

0.287

0.404

0.187

0.125

1.946

2.131

2.594

2.638

2.609

1.068

D

1.59

2.147

2.378

2.368

2.245

1.977

2.499

2.354

2.295

2.502

2.371

2.695

E

1.232

1.738

1.896

1.704

1.614

1.857

2.013

1.784

2.435

2.931

2.405

2.485

LICOR
LICOR + 0.05%
Tween20

F

1.339

1.44

1.759

1.55

1.657

1.75

1.86

1.802

2.695

2.611

2.549

2.44

G

0.394

1.615

1.278

1.042

1.09

0.352

2.083

2.292

2.693

2.668

2.673

2.697

10% FBS

1.4

10% FBS + 5%
milk

H

0.22

0.149

0.455

0.386

0.56

0.18

2.121
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1.682

2.529

2.51

2.918

3.3 Correlation between FRNT EC50s and ELISA assays
From our preliminary experiments with available antigens, we selected the 12 proteins: Chk
P62E1, BSA, HA Colorado, MERS RBD refolded from a bacterial expression (bRBD), SARS1
bRBD, SARS2 bRBD, SARS2 RBD expressed in mammalian cells (mRBD), SARS2 trimeric
spike, SARS2 ORF8, SARS2 nucleoprotein RNA-binding domain (NP-RNA), SARS2
nucleoprotein full-length protein (NP-FL), and SARS2 ORF7a. Similarly to the preliminary
studies, we heat inactivated all serum samples at 56°C for 1 hour prior to the ELISA assays. Given
the high titers of anti-COVID-19 responses in the preliminary patient serum, and our interest in
accurately estimating EC50 values for relevant antigens, we decided to modify our the protocol to
include 1:1 dilutions ranging from 1:320 to 1:40960. Additionally, we reasoned that the TMB
signal loss from concurrently processing 20+ plates at once would be significant if too much time
elapsed between H2SO4 addition and plate reading. Therefore, after the first set of plates that we
ran, we chose to stagger the final processing step in this analysis to maintain consistent signal
readouts. The absorbance values from this initial set of plates was normalized to account for the
loss in signal prior to downstream analysis.

3.3.1 COVID-19 antigens exhibit varying reactivity to patient sera
As expected for ongoing infections, the SARS2 antigen responses varied considerably between
samples compared to the HA responses (Figure S3-1). ORF7a demonstrated minimal IgG
reactivity above the negative controls (BSA and Chk P62E1). While bacterial expression is often
desirable due to increased yield at low cost, the maximum absorbance signals of bacterially
expressed receptor binding domains (RBD) appeared disappointingly low compared to other
antigens in the panel.
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Figure S3-1: COVID-19 Spike, Nucleoprotein, and ORF8 antigens react with patient sera by ELISA. (A) The Mayo Clinic
cohort of 42 COVID-19 patient sera were run in 8-point ELISA serial dilutions against 12 distinct antigens. BSA and ChkP62E1
were used as negative controls while influenza HA (Colorado strain) was used as a positive control. 4-parameter sigmoidal curves
were fit to independent duplicates of each serial dilution. (B) Heat map of the ELISA EC50s sorted by correlation to other patient
sera and antigens. (C) Inter-antigen Pearson correlations based on the ELISA EC50 values.
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One of the first reagents widely adopted to assess seroconvergence, the mammalian-expressed
SARS2 RBD antigen is FDA-approved for diagnostic ELISA applications. We employ this antigen
in our ELISA, with the only major differences between our assay and the mRBD ELISA previously
reported being that we coat Maxisorp plates with pH 9.6 NaCO3, block in 1% BSA + 4% milk
PBST, and are comparing EC50s instead of single point absorbance values. Indeed, we observe
considerable signal using mRBD, and find that the EC50 response progressively increases
throughout the course of infection (Figure S3-1 B). The SARS2 mRBD EC50 values are also
highly correlated with SARS2 bRBD EC50 values (Figure S3-1 C).

Along with mRBD, the spike trimer (mammalian-expressed), nucleoprotein (NP) RNA-binding
domain (bacteria-expressed), and full length NP (bacteria-expressed) proteins from SARS2 are all
generally reactive with COVID-19+ patient sera. The EC50s of the two NP constructs are highly
correlated, as are the responses of the spike trimer and mRBD. However, the SARS2 intraprotein
correlations are demonstrably higher than the SARS2 interprotein correlations (Figure S3-1 C).

Intriguingly, the SARS2 ORF8 (bacteria-expressed) protein appears to be highly reactive with only
a subset of the COVID-19+ sera, in a patient-specific manner (Figure S3-1 B). This is particularly
remarkable for Patient 8, 14, and 17 who each have a high EC50 to the spike trimer and/or NP
constructs, but lack any reactivity to SARS2 ORF8. As coronaviruses have been reported to nonsynonymously mutate ORF8 in the past, it is likely that these patients were infected with a variant
that lacked an expressible copy of ORF8 (Muth et al., 2018; Oostra, de Haan, & Rottier, 2007).
ORF8 is known to inhibit IRF3-mediated IFN signaling, so this observed loss of ORF8-specific
IgG may serve as a useful tool to correlate with disease severity (Wong et al., 2018).
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Figure S3-2: SARS2 Spike and NP seroresponses correlate with FRNT values. (A) Three patient seroresponse time-series from
the Mayo Clinic dataset of the FRNT EC50, as well as ELISA EC50s against multiple viral antigens. (B) Correlations of the ELISA
EC50s of individual antigens to the matched FRNT EC50s.

[56]

3.3.2 COVID-19 Spike and NP responses correlate with FRNT EC50s
While the timing of seroconversion can vary following symptom onset (Figure S3-2A), the
progression of an IgG response is generally considered a key determinant driving protection
through adaptive immunity, including through direct virus neutralization. Individual patient timecourses suggest that the spike trimer and NP antigens appear to correlate most consistently with
FRNT titers. However, a global analysis of patient-matched Mayo Clinic samples demonstrates
that spike trimer, NP constructs, and SARS2 RBD appears to each linearly correlate with FRNT
titers to the same degree with Pearson correlation coefficients between 0.59 and 0.65 (Figure S32B).

Clearly the speed afforded by ELISA-based assays would be ideal in large-scale screening
approaches toward determining protective seroconvergence. Indeed, a PCA analysis of the EC50s
of the six identified FRNT-correlative antigens [p-value < 0.05] (Figure S3-2B) can distinguish
most high-neutralizing titer sera from low-neutralizing titer sera. However, it is not clear that 8
datapoint serial dilutions of six antigens is necessary to accurately predict FRNT values.

To determine the minimal dataset necessary for distinguishing FRNT titers while maintaining or
increasing the predictive quality of COVID-19-antigen ELISAs, we conducted k-means clustering
on all combinations of the six predictive antigens, considering each dilution-point of the ELISA
curve individually. We then calculated the absolute difference of the mean reciprocal FRNT value
per cluster, looking for absolute differences greater than that of the six-antigen EC50 clusters
[ΔFRNT = 774.25]. This allowed us to quantify the predictive capacity of each antigen-set without
setting an arbitrary threshold-definition for a positive FRNT sample to assess precision/accuracy.
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Figure S3-3: Combinations of RBD ELISA responses predict FRNT titers. (A) The six antigens which significantly correlate
with FRNT titers were combinatorially (6 choose n) grouped by k-means clustering with two clusters to determine which antigen
set and dilution best separates high- and low-neutralizing responses. The absolute difference of the mean FRNT value of the two
clusters is plotted, with a threshold set at the respective Δ mean FRNT value for all six antigen EC50s. (B) A list of the
dilution:antigen sets that outperformed the six-antigen EC50 benchmark in distinguishing samples by FRNT values. (C) Principal
component analysis of the six antigen EC50s, colored by sample-matched FRNT values, along with sero-trajectories for three
patients. (D) Principal component analysis of one of the highest scoring dilution:antigen sets, along with equivalent sero-trajectories
to C. Sixteen pre-COVID-19 common coronavirus patients’ sera were additionally assessed at this condition (red).

The antigen sets that out-performed the six antigen panel consisted exclusively of 1:320 and 1:640
dilutions and mainly comprised multiple receptor-binding domain (RBD) constructs (Figure S33A,B). Despite only marginal independent correlation with FRNT values (Figure S3-2B), SARS1
bRBD responses in concert with SARS2 RBD responses appear particularly useful in
distinguishing high and low FRNT values. However, MERS bRBD did not appear to exhibit a
similar predictive potential. As SARS1 mRBD was not assessed in this study, it is not clear whether
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mammalian-expression of this construct would further enhance the predictive potential of this
assay.

We next performed a comparative PCA analysis of the six antigen EC50 panel and SARS1
bRBD/SAR2 mRBD 1:320 responses (Figure S3-3C,D). In both instances, the clusters of low and
high FRNT sera titers were clearly distinguished. Of note, these PCA graphs can provide a visual
aid to track individual patient sero-trajectories over the course of COVID19 infections, and may
prove useful in demarcating multi-dimensional thresholds for distinguishing sera by
neutralization-potential.

To assess the accuracy of the two antigen, one dilution assay we next screened sixteen serum
samples from patients infected with a common coronavirus prior to the COVID-19 outbreak
(Figure S3-3D). Given the genomic similarity between common coronaviruses and SARS-CoV-2,
we were concerned that this may represent a patient population prone to false-positive predictions.
However, all sixteen of these samples clustered in close proximity to the low-FRNT titer cohort
(Figure S3-3D).
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Appendix 4: A basis for quantitative FLISA
4.1 The problem with slow, sigmoidal kinetic binding curves
During my work in attempting to quantify the affinity of MC54 variants for IL18, I came upon an
issue where the biolayer interferometry (BLI) binding curves had remarkably slow on and off rates.
If this were the only issue, kinetic traces could still be readily obtainable by simply running
extended association and dissociation steps. Unfortunately, the resulting binding curves were also
dramatically sigmoidal and the response units consistently decreased late in the association phase,
and thus could not be reliably fit to standard kinetic models. Given that BLI is measuring the
thickness of material attached to the pin, this sequential decrease-increase-decrease in signal could
be thought of as either binding-induced changes in the oligomeric state or binding-induced
conformational changes. However, neither of these were easy to model/fit to the data.

Figure S4-1: Complex biolayer interferometry kinetic traces of various MC54 variants and human IL-18 binding protein
vs. hIL-18 ligand concentrations. hIL18bp (top left), MC54-1p (bottom left), MC54-3b (top right), and MC54-4 (bottom right)
each contains a specific biotinylation at the C-terminus of the protein, which is used to load the protein to the streptavidin pin. The
pin is then transferred to buffered saline containing BSA and detergent followed by incubation in various IL18 concentrations
(indicated above) for the association stages and subsequently incubated in buffer for the dissociation stages. For each graph, the yaxis is the change in response units compared to the negative control and the x-axis is time in seconds. Each trace represents the
association of a specific concentration (M) of recombinant human IL18 to the respective hIL18bp/MC54 variant.

Standard kinetic mathematical models often make assumptions, one of which is the use of an Rmax
value to represent the maximum response possible in a given kinetic trace. Using this Rmax value,
kinetic models are able to derive a “fraction bound” percentage at any given point in the kinetic
[60]

trace in order to produce a viable fit. Given this mathematical assumption, neither a drop in
response units late in the association phase nor a sigmoidal curve would be modellable.

Next, I set out to determine whether a mathematical model could be devised to fit this BLI data.
Using SAGE, scipy, numpy, and matplotlib I devised kinetic models which replaced the Rmax
variable and fraction-bound concept with a set of species-specific R weights (Hunter, 2007;
Oliphant & Millma, 2006; Stein & Joyner, 2005; Virtanen et al., 2020). The basic premise of this
method being that:
∆𝑅𝑈(𝑋) = ∆[𝑋] ∗ 𝑅(𝑋)

(S8)

Where ΔRU(X) is the change in response units due to species X, Δ[X] is the change in the
concentration of X, and R(X) is the R weight for species X.

Using this premise, I constructed a model in which a protein V changes to VV, either through
oligomeric alteration or a detectable conformational rearrangement. The V and VV species each
bind to ligand C equally well, but association changes the propensity of V to become VV.
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While I was working on the mathematical models to explain the data, I was also attempting to
determine whether the observation was instead an artifact. To that end, we conducted extensive
troubleshooting, including flipping the system so IL-18 was on the pin, prewashing the MC54bound pins in pH 1.5 glycine to remove contaminants, utilizing non-specific biotinylation instead
of specific biotinylation in the assay, and decreasing the amount of protein loaded on the pin.
However, none of these methods provided satisfactory data for quantification by Rmax-based
models. While the residuals of the fits to these experiments were often large and contained a
nonrandom trend, the most glaring issue was the immeasurable off-rate (Figure S4-2).

𝑉
+
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Figure S4-2: BLI kinetic traces of a low loaded tip to assess MC54:IL18 association. (Top left) 1 to 1 binding fit of the BLI
kinetic traces with residuals. (Top right) Scatchard plot of the 1 to 1 binding equilibrium either including all traces or ignoring the
top two concentrations (as these may deviate from a model resembling 1 to 1 binding). (Bottom) Heterogeneous ligand binding fit
of the BLI kinetic traces and residuals for the same dataset.

We additionally attempted surface plasmon resonance (SPR) instead of biolayer interferometry to
prevent evaporation during the experiment in an attempt to capture a reliable fit for the off-rate.
Unfortunately, dissociation was still an insurmountable obstacle to obtaining accurate kinetic fits,
with 10 hour dissociations resulting in only marginally decreases in response units. Additionally,
these traces do not appear to be well represented by 1 to 1 binding models or other tested models.
Without additional information regarding the hIL18bp/MC54 system, it is difficult to discern what
model would be most appropriate to estimate binding affinity. Even still, we attempted competition
SPR experiments to quantify MC54 affinities. This was achieved by preincubating IL18 with
varying concentrations of MC54 and then flowing these equilibrium solutions over an hIL18bp
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CM5-coupled chip. While this method was somewhat successful, the slow on rate mandated
considerable time per association to achieve a reasonable steady-state. Given the number of MC54
variants to be tested, and limited time available on the shared SPR instrument, I decided to explore
alternative biochemical assays to quantify the relative affinities.

Many standard biochemical techniques were not viable, primarily due to the high affinity nature
of the interactions. As scalability was a concern for this assay, we chose to focus on assays that
could be completed in a 96-well plate. Additionally, the slow association and dissociation rates of
this system motivated us to chose a system which could be sealed during long incubations to
achieve equilibrium. This led us to consider fluorescence polarization and ELISA. Unfortunately,
both hIL18 and hIL18bp are macromolecules, and thus the change in each spin upon binding would
be insufficient for fluorescence polarization readout. Therefore, we focused our efforts on the
mathematical underpinnings of an ELISA experiment and whether one could discern a Kd from
some form of this assay.

[64]

Figure S4-3: Surface plasmon resonance to resolve the affinity of IL18 to hIL18bp/MC54. (A) SPR kinetic traces of hIL18bp
association with hIL18, with 1 hour associations and 10 hour dissociations. (B) Competition SPR steady-state response units with
varying concentrations of MC54 preequilibrated with hIL18. All steady-state association RU were determined following a 1 hour
association. (C) Kd estimates for MC54 variants from the competition experiment with hIL18bp assuming 1 to 1 binding.

4.2 Theoretical and practical considerations of a qFLISA
4.2.1 Issues preventing Kd quantification from a standard ELISA
There are five problems of a standard ELISA protocol that each obfuscate the underlying Kd of
the interaction being observed.
1) Adsorption coating leads to an unknown concentration of viable protein in the well before
addition of the ligand.
[65]

2) Multiple wash steps and incubations after association, prior to detection can result in nontrivial dissociation which would decrease the amount of ligand bound.
3) An enzymatic output signal is nonlinear with respect to ligand concentration.
4) It is unclear whether the fact that the coated analyte in not in solution would impact/disrupt
the equilibrium in the well.

4.2.2 Neutravidin-coating allows for defined analyte concentrations
Adsorption of analyte directly onto ELISA plates results in random orientation and unknown
amount of protein coated. To overcome both of these issues, we instead coat neutravidin on the
plate and add the specifically-biotinylated analyte to wells in tandem with the fluorescent-ligand.
Specific-biotinylation allows for identical orientation of all plate-bound analyte, so that all analyte
remains viable for ligand association.

4.2.3 Fluorescence readout overcomes issues with multiple wash steps and the
non-linearity of enzyme detection
By directly conjugating a fluorescent tag to the ligand, we overcome the need for
addition/incubation of a secondary antibody, which would alter the steady-state association of
analyte:ligand. While a final wash step would be required to remove excess ligand from the plate
prior to signal readout, the loss in fluorescence signal would be negligible save for analyte:ligand
interactions with fast off-rates. Therefore, this assay would not be recommended for determining
the binding constants of interactions with fast off-rates. Such interactions would likely be more
amenable to well-established biochemical assays such as BLI/SPR, ITC, or FP.

Replacing the standard ELISA HRP-TMB system with a fluorescently-tagged ligand also allowed
for a linear readout of the ligand in a given well. A linear readout of bound-ligand is central to
non-linear least squares fitting to obtain reliable equilibrium constants for the system.
[66]

4.2.4 Non-homogenous analyte concentrations do not alter equilibrium
To determine whether the designed qFLISA experiment reports on the equilibrium Kd26 of the
protein interaction, we first define equilibrium as:
𝐾' =
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Where Kd is the binding constant of the interaction, Kfree is the free analyte concentration, Lfree is
the free ligand concentration, KL is the concentration of associated K and L, Ktotal is the total
analyte concentration, and Ltotal is the total ligand concentration. Equation S13 is the practical
solution for KL using Equations S10, S11, and S12 with respect to Kd, Ktotal, and Ltotal. All right
hand side variables are experimentally determinable, but KL is not observed in a qFLISA
experiment. However, the fraction of analyte bound (/

/0
!"!#$

) can be easily reported using a qFLISA

assay, so both sides of Equation S13 are divided by Ktotal to obtain Equation S14.

Obtaining a representation of a homogenous ligand in solution binding to a non-homogenous
analyte (coated on plate with almost none in solution) requires a nontrivial system of differential
equations. As in the above equilibrium equations, the differential system will assume 1 to 1

26

A caveat of this model is that we are assuming a 1 to 1 binding model, which we know from previous BLI/SPR
experiments to be unlikely. However, for comparative quantification of MC54 variants, it is often preferred to
oversimplify the model when increased complexity cannot be otherwise justified.
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binding, but will do so in a split system for tracking two fractions of the total analyte (coated and
uncoated) which each account for a different percent of the total analyte and a different fraction of
the volume. As such the respective concentrations of the two analyte fractions can be distinct in
this system, but the ligand concentration remains constant throughout the experimental volume.
𝜕𝐾𝐿1
= 𝑘2 ∗ 𝐾1 ∗ 𝐿 − 𝑘32 ∗ 𝐾𝐿1
𝜕𝑡

(S15)

𝜕𝐾1
= −𝑘2 ∗ 𝐾1 ∗ 𝐿 + 𝑘32 ∗ 𝐾𝐿1
𝜕𝑡
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𝜕𝐾𝐿4
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Where k1 and k-1 are the association and dissociation rate constants, Kc and Ku are the coated and
uncoated free analyte concentrations, L is the free ligand concentration, KL is the concentration of
analyte-bound ligand, v is the fraction of volume occupied by the coated analyte [0 to 1], and w is
the fraction of analyte that is biotinylated (associated with neutravidin on the plate) [0 to 1].
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Figure S4-4: Analyte heterogeneity does not impact equilibrium in a FLISA system. (A) Plotting the fraction bound for a
standard 1 to 1 equilibrium (Equation S14) and the numerical solution to the system of differential equations for the heterogeneous
analyte (Equations S15-S23). (Left panel) Plot of the equilibrium symbolic solution for a system with a Kd of 1nM, varying [Ktotal]
and [Ltotal]. (Middle panel) Plot of the numerical solution to the system of differential equations for the heterogeneous analyte
system with a Kd of 1nM, varying [Ktotal] and [Ltotal] equivalently to the left panel. (Right panel) Residuals of the simulated
curves for the symbolic equilibrium system and numerical solution to the heterogeneous analyte system. (B) Numerical solutions
to the heterogeneous analyte 1 to 1 model keeping the [Ktotal] and [Ltotal] dilutions constant and changing the Kd (left panel:
1nM, right panel: 0.1nM).

Interestingly, we observe no residuals when comparing the symbolic solution for a canonical 1 to
1 equilibrium fraction bound and the numerical solution to the system of differential equations
representing heterogeneous analyte distribution (coated and uncoated) (Figure S4-4A). This lack
of residuals was maintained irrespective of the w and v values, indicating that the high density
analyte in a small region of the solution (near the plate surface) does not impact the fraction of
analyte bound by ligand.
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4.2.5 Non-homogenous ligand concentrations would alter equilibrium

Figure S4-5: Fast on rates may locally increase ligand concentrations near high concentrations of analyte. (A) Under
conditions where the association rate between ligand and analyte are relatively slow, passive diffusion will likely maintain ligand
homogeneity throughout the sample volume. (B) Under conditions where the system’s association rate outpaced passive diffusion,
high concentrations of ligand may accumulate near high analyte concentrations. Relatively higher ligand concentrations near the
plate surface would lead to an incorrectly increased fraction of analyte being bound at a tested ligand concentration.

As a caveat to Appendix 4.2.4, heterogeneity of macromolecule concentrations within a sample do
not always maintain bulk equilibrium binding. This is particularly true when the concentrations of
both analyte and ligand are heterogeneous. Considering Equation S14 and Figure S4-4, an
increased ligand concentration (even just locally) will result in a greater fraction of analyte being
bound. Protein-protein interactions with fast association rates may lead to ligand heterogeneity in
a qFLISA experiment if the on-rate outpaces passive diffusion of the ligand in solution. If this
occurs, the observed fraction-bound of coated analyte would deviate higher than true equilibrium.
Additional experiments are warranted to determine if this is a valid concern within expected
physiological limits.
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4.2.6 qFLISA in practice

Figure S4-6: qFLISA assays of two MC54 variants. (A) Specifically biotinylated MC54-1vb1 was added to neutravidin coated
Maxisorp plates at four concentrations with serially diluted concentrations of hIL18-FITC. Following three washes in PBS and
reading, the data was simultaneously fit to a 1 to 1 model. (B) Specifically-biotinylated MC54-4 was added to neutravidin-coated
Maxisorp plates at four concentrations along with serially diluted hIL18-FITC. Following the wash and reading steps, the four
datasets were simultaneously fit to a 1 to 1 model.

The fraction of analyte bound is a function of the concentration of ligand and analyte (Equation
S14). If the concentration of macromolecules is higher than the Kd, the curve begins to report on
the concentrations of macromolecules more so than the intrinsic Kd (Figure S4-4). Therefore, the
concentration of analyte should be as low as feasible. Using FITC-conjugated hIL-18 and a
Synergy H1 plate reader, the apparent limit of detection is near 1.5nM of MC54 in a black 96 well
Maxisorp plate. This is somewhat unfortunate, as the Kdapp for MC54 determined by 1 to 1
competitive SPR binding is at least an order of magnitude lower (Figure S4-3C). Even so, the
simultaneous fit of the four curves resulted in sub-nanomolar Kdapp estimates. The similarity
between SPR-based and qFLISA-based MC54 affinities is quite remarkable, given their
methodologic dissimilarity. However, the sensitivity of the assay may be enhanced in future work
through advances in plate-reader technology and/or by using brighter fluorophore conjugates.
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